Macrocyclic heterocyclic rings and their applications

Compounds targeting GEFs like SOS proteins address the limitations of existing Ras pathway inhibitors by effectively inhibiting Ras signaling, enhancing treatment options for diseases such as cancer.

JP2026539035APending Publication Date: 2026-11-19KUMQUAT BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2026524026
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-25
Filing Date
2024-10-24
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Current therapeutic agents targeting Ras pathway signaling, particularly those inhibiting GEFs like SOS proteins, are limited due to the 'undruggable' nature of Ras proteins and issues with drug resistance and durability, especially for G12C mutations, which have a lower incidence compared to other Ras mutations.

Method used

Development of compounds of specific formulae that inhibit Ras pathway signaling by targeting GEFs such as SOS proteins, including (R)-2,2-difluoro-6,4-dimethyl-6,7-morpholino-7-oxa-5-aza-6(1,5)-pyrido[3,4-d]pyridadina-1(4,1)-piperidina-3(1,3)-benzenacyclotridecaphane and related structures, which can be used for treating various diseases including cancer.

Benefits of technology

These compounds effectively inhibit Ras pathway signaling, providing therapeutic benefits for diseases like cancer by targeting GEFs, offering potential for improved treatment efficacy and durability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026539035000001
    Figure 2026539035000001
  • Figure 2026539035000002
    Figure 2026539035000002
  • Figure 2026539035000003
    Figure 2026539035000003
Patent Text Reader

Abstract

This disclosure provides compounds, pharmaceutically acceptable salts thereof, and methods of use thereof. The compounds and methods have a wide range of applications as therapeutic agents, diagnostic tools, and research tools. In particular, the compositions and methods of the subject matter are useful for reducing the output of signaling of oncogenic proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Cross-reference of related applications This application claims the interests of U.S. Provisional Patent Application No. 63 / 593,007, filed on 25 October 2023, which is incorporated herein by reference in its entirety. Sequence List

[0002] This application includes a sequence listing submitted electronically in XML format, the entirety of which is incorporated herein by reference. The XML copy, created on October 22, 2024, is named 56690_780_601_SL.xml and has a size of 6,281 bytes.

[0003] Cancer (e.g., tumors, neoplasms, metastases) is the second leading cause of death worldwide, estimated to be responsible for approximately 10 million deaths each year. Many types of cancer involve mutations in one or more proteins involved in various signaling pathways that lead to the uncontrolled growth of cancer cells. In some cases, rat sarcoma (Ras) mutations are known to be present in approximately 25–30 percent of tumors.

[0004] Activated by guanine nucleotide exchange factors (GEFs), Ras in its GTP-bound state interacts with numerous effectors. Reversion to an inactive state is driven by GTPase-activating proteins (GAPs), which downregulate active Ras by accelerating weak endogenous GTPase activity. However, in oncogenic Ras mutants, GAP activity is impaired or significantly reduced, leading to persistent activation that drives oncogenic Ras signaling via pathways such as the RAS-RAF-MEK-ERK and RAS-PI3K-PDK1-AKT pathways, both essential for cell survival and proliferation.

[0005] The most studied GEF of Ras is the Son of Sevenless (SOS) protein, of which two human isoforms, SOS1 and SOS2, are known. SOS1 is the human homolog of the Drosophila protein Son of Sevenless, which was the first to be identified. SOS1 has two binding sites to the Ras protein: a catalytic site that binds to GDP-bound Ras protein to promote guanine nucleotide exchange, and an allosteric site that binds to GTP-bound Ras to further promote the activation of the Ras protein. Son of Sevenless 2 (SOS2) is the homolog of SOS1 in mammalian cells. Double knockout of SOS1 and SOS2 leads to rapid lethality in adult mice (Baltanas et al., Mol. Cell. Biol., 2013, 33(22):4562-78).

[0006] The Ras protein has long been considered "undruggable," partly due to its high affinity for its substrate, guanosine-5'-triphosphate (GTP), and / or its smooth surface lacking a clear target region. Certain G12C Ras gene mutations have been identified as drug targets, and numerous G12C-specific inhibitors have been developed. However, because G12C mutations in Ras exhibit a much lower incidence compared to other known Ras mutations, including G12D and G12V, the application of such therapeutics remains limited. Drug resistance and lack of durability further restrict such therapeutics. [Overview of the Initiative]

[0007] In view of the foregoing, there remains a considerable need for new designs of therapeutic agents and diagnostic methods that can specifically inhibit Ras pathway signaling by inhibiting GEFs such as, for example, SOS proteins. Such compositions and methods may be particularly useful for treating a variety of diseases, including but not limited to cancer and neoplastic conditions. The present disclosure addresses these needs and provides additional advantages applicable to the diagnosis, prognosis, and treatment of a wide variety of diseases.

[0008] In certain aspects, the present disclosure provides a compound of Formula (I): [Chemical Formula] or a pharmaceutically acceptable salt or solvate thereof, wherein: [Chemical Formula] is C 3~12 carbocycle, and 3-12 membered heterocycle, each of which is optionally substituted with one or more R 11 groups, [Chemical Formula] is absent, or selected from C 3~12 carbocycle, and 3-12 membered heterocycle, each of which is optionally substituted with one or more R 11a groups, [Chemical Formula] is [Chemical Formula] L 1 is selected from a bond, -O-, -N(R 12 )-, C 1~6 alkylene, C 1~6 haloalkylene, and 2-6 membered heteroalkyl, L 2However, C 5~25 Alkylene, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, or L 2 However, -L 3 -DL 4 -and, L 3 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, R 1 However, one or more R 11c C, which is optionally replaced by 1~3 It is alkyl, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R13 ), -C(O)OR 12 , -OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 , -S(O)2R 15 , -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 , -CH2S(O)2R 15 , -CH2S(O)2N(R 12 )(R 13 ), and -P(O)(R 17 )(R 17a ), wherein each C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C 3~10 carbocycle, and 3 to 10-membered heterocycle are, independently, optionally substituted with one, two, or three R 20 , and optionally, R 5 and R 6 , R 6 and R 7 , or R 6 and R 7b form a C 5~10 carbocycle, or a 5 to 10-membered heterocycle, each of which is optionally substituted with one, two, or three R20 is substituted with, R 5b , and R 7b are each independently hydrogen, -CN, C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C 3~10 carbocycle, 3- to 10-membered heterocycle, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 )(R 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 , -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 , -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ), each C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C 3~10 carbocycle, and 3- to 10-membered heterocycle are each independently optionally substituted with one, two, or three R 20 , R 11 , R 11a , and R 11d are, at each occurrence, each independently halogen, -CN, C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C 3~10 carbocycle, 3- to 10-membered heterocycle, -OR 12 , -SR12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR12 , and -N(R 12 )(R 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyls, or R 12 and R 13 However, together with the nitrogen atom to which they bond, they can optionally form one, two, or three R atoms. 20 Substituted with, it forms a 3- to 10-membered heterocycle, R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6Selected from cycloalkyl, C 1~6 Alkyl, and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups. 20 Replaced with, or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C are independently identified. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. The compound is (R)-2,2-difluoro-6 4 ,4-dimethyl-6 7 The present invention provides compounds, salts, or solvates that are not -morpholino-7-oxa-5-aza-6(1,5)-pyrido[3,4-d]pyridadina-1(4,1)-piperidina-3(1,3)-benzenacyclotridecaphane.

[0009] In some embodiments, for the compound of formula (I), [ka] teeth, [ka] Selected from: In some embodiments, [ka] teeth, [ka] Selected from.

[0010] In certain embodiments, this disclosure relates to compounds of formula (II): [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein in the formula, [ka] However, C 5~7 A selection of carbon rings and 5- to 7-membered heterocycles, each of which can optionally contain one or more R 11 Replaced by, [ka] However, it does not exist, or C 3~8 A selection of carbon rings and 3- to 8-membered heterocycles, each of which can optionally contain one or more R 11a Replaced by, L 1 However, bond, C 1~6 Alkylene and C 1~6 Selected from haloalkylenes, L 2 However, C 5~25 Alkylene, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced with L 2 However, W 3 , W 4 , or W 5 Covalently bonded to one of the following, or L 2 However, -L3 -DL 4 - and L 4 However, W 3 , W 4 , or W 5 Covalently bonded to one of them, L 3 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, L 5 However, the bond and -C(O)- are selected, W 2 However, N(R 2b ), N, C(R 2 ), C(R 2 )(R 2a ), and C(O) are selected, W 3 However, N(R 3b ), N, C(R 3 ), C(R 3 )(R 3a ), and C(O) are selected, W 4 However, N(R 4b ), N, C(R 4 ), C(R 4 )(R 4a ), and C(O) are selected, W 5 However, N(R 5b ), N, C(R5 ), C(R 5 )(R 5a ), and C(O) are selected, W 7 However, N(R 7b ), N, C(R 7 ), C(R 7 )(R 7a ), and C(O) are selected, R 1 However, one or more R 11c C, which is optionally replaced by 1~3 It is alkyl, R 2 , R 2a , R 3a , R 4a , R 5a , R 7a , and R 7 However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, C3-10 carbon ring, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyls, C3-10 carbon rings, and 3-10 membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 3 , R 4 , and R 5 However, each is independent, L 2 Bonding with hydrogen, halogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, C3-10 carbon ring, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyls, C3-10 carbon rings, and 3-10 membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 2b , and R7 b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon rings and 3- to 10-membered heterocycles independently and selectively form one, two, or three R groups. 20 Replaced by, R 3b , R 4b , and R 5b However, each is independent, L 2 Bonding with hydrogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11dHowever, in each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyls, or R 12 , and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl, and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups. 20 Replaced with, or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C are independently identified. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. [ka] The present invention provides compounds, salts, or solvates exhibiting single or double bonds such that all valencies are satisfied.

[0011] In some embodiments, the compound of formula (II) is the compound of formula (II-A): [ka] Alternatively, a pharmaceutically acceptable salt or solvate thereof, wherein W 3 However, it is a compound, salt, or solvate selected from N and C.

[0012] In certain embodiments, this disclosure relates to compounds of formula (III): [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein in the formula, [ka] However, C 5~7 A selection of carbon rings and 5- to 7-membered heterocycles, each of which can optionally contain one or more R 11 Replaced by, [ka] However, it does not exist, or C 3~8 A selection of carbon rings and 3- to 8-membered heterocycles, each of which can optionally contain one or more R 11a Replaced by, L 1 However, bond, C 1~6 Alkylene and C 1~6 Selected from haloalkylenes, L 2 However, C 5~25 Alkylene, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced with L 2 However, W 3 , W 4 , W 5 , or W 7 Covalently bonded to one of the following, or L 2 However, -L 3 -DL 4- and L 4 However, W 3 , W 4 , W 5 , or W 7 Covalently bonded to one of them, L 3 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, W 2 However, N(R 2b ), N, C(R 2 ), C(R 2 )(R 2a ), and C(O) are selected, W 3 However, N(R 3b ), N, C(R 3 ), C(R 3 )(R 3a ), and C(O) are selected, W 4 However, N(R 4b ), N, C(R 4 ), C(R 4 )(R 4a ), and C(O) are selected, W 5 However, N(R 5b ), N, O, S, C(R 5 ), C(R 5 )(R 5a ), and C(O) are selected, W 7 is selected from N(R 7b ), N, O, S, C(R 7 ), C(R 7 )(R 7a ), and C(O), W 8 is selected from N(R 8b ), N, O, S, C(R 8 ), C(R 8 )(R 8a ), and C(O), R 1 is C 11c alkyl optionally substituted with one or more R 1~3 , R 2 , R 2a , R 3a , R 4a , R 5a , R 7a , R 8 , and R 8a are each independently hydrogen, halogen, -CN, C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C3~10 carbocycle, 3~10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 , -S(O)2R15 , -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 , -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ), and each C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C3~10 carbocycle, and 3~10 membered heterocycle are independently optionally substituted with one, two, or three R 20 , R 3 , R 4 , R 5 , and R 7 are each independently a bond to L 2 , hydrogen, halogen, -CN, C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C 3~10 carbocycle, 3~10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 2b , and R 8b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15-CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon rings and 3- to 10-membered heterocycles independently and selectively form one, two, or three R groups. 20 Replaced by, R 3b , R 4b , R 5b , and R 7b However, each is independent, L 2 Bonding with hydrogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )( R13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11d However, in each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyls, or R 12 , and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl, and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups. 20 Replaced with, or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C are independently identified. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25, -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. [ka] However, compounds, salts, or solvates are provided that exhibit single or double bonds such that all valencies are satisfied.

[0013] In some embodiments, the compound of formula (III) is the compound of formula (III-A): [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein W 5 However, it is a compound, salt, or solvate selected from N and C.

[0014] In some embodiments, L is used for the compounds described herein. 2 C 5~25 Alkylene, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b It is replaced by. In some embodiments, [ka] However, C 5~7 Selected from cycloalkyl, 5-7 member heterocycloalkyl, 5-7 member heteroaryl, and phenyl, each of which can optionally be one or more R 11 Replaced with L 1 However, bond, C 1~2 Alkylene and C 1~2 Selected from haloalkylenes, R 1 However, one or more R 11c C, which is optionally replaced by 1~2 It is alkyl. In some embodiments, R 7 However, halogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally contain one, two, or three R groups. 20 It is replaced by, and also, R 7b However, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 It will be replaced with.

[0015] In some embodiments, for compounds of formula (II), (II-A), (III), or (III-A), W 2 However, N, or C(R 2 ) is. In some embodiments, W 3 However, N(R 3b ), and C(R 3 ) is selected from. In some embodiments, W 4 However, N, C(R 4 ), and C(O) are selected. In some embodiments, W 5 However, N(R 5b ), and C(R 5 ) is selected from. In some embodiments, W 7 However, N(R 7b ), and C(R 7 ) are selected from. In some embodiments, for a compound of formula (III) or (III-A), W 8 However, N(R 8b ), O, S, and C(R8 ) will be selected from.

[0016] In some embodiments, the compound of formula (I) is the compound of formula (I-A1) or (I-A2): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0017] In some embodiments, the compound of formula (I) is the compound of formula (I-B1) or (I-B2): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0018] In some embodiments, the compound of formula (I) is a compound of formula (I-C1), (I-C2), (I-C3), or (I-C4): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0019] In some embodiments, the compound of formula (I) is a compound of formula (I-E1), (I-E2), (I-E3), or (I-E4): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0020] In some embodiments, for the compounds described herein, R 1 is unsubstituted C 1~2 It is alkyl. In some embodiments, R 1 However, it is -CH3. In some embodiments, R 3 However, hydrogen, halogen, -CN, -OR 12 , and one, two, or three R 20C is optionally replaced by 1~6 Selected from alkyl groups. In some embodiments, R 3 However, one, two, or three R 20 C, which is optionally replaced by 1~6 It is alkyl. In some embodiments, R 3 However, it is hydrogen or -CH3. In some embodiments, R 3b However, it is -CH3. In some embodiments, R 5 However, hydrogen, -OR 12 , and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl groups. In some embodiments, R 5 However, it is hydrogen. In some embodiments, R 5b However, hydrogen and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl groups. In some embodiments, R 5b However, it is -CH3. In some embodiments, R 6 However, hydrogen, -OR 12 , and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl, R 12 However, C 1~6 Selected from alkyl groups. In some embodiments, R 6 However, it is selected from hydrogen and -OCH3.

[0021] In some embodiments, R is used for the compounds described herein. 7 However, C 1~6 Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 It is replaced by R. In some embodiments, 7 However, C 1~6 Alkyl, C 3~10 Cycloalkyl, 3-10 member heterocycloalkyl, and -N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Cycloalkyls and 3- to 10-membered heterocycloalkyls are optionally associated with one, two, or three R groups. 20 It is replaced by R. In some embodiments, 7 is one, two, or three R 20 It is a 3- to 10-membered heterocycloalkyl group that is optionally substituted with R. In some embodiments, 7 is one, two, or three R 20 C, which is optionally replaced by 3~10 It is cycloalkyl. In some embodiments, R 7 is one R 20 C, which is optionally replaced by 3~4 It is cycloalkyl. In some embodiments, R 7 is replaced with -CN. In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 is one, two, or three R 20 C, which is optionally replaced by 1~6 It is alkyl. In some embodiments, R 7 is -N(R 12 )(R 13 ) is. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 8 These are hydrogen, halogens, and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl groups. In some embodiments, R 8 It is hydrogen.

[0022] In some embodiments, the compounds described herein are used as follows: [ka] These are selected from phenyl and 5- to 7-membered heteroaryls, each of which can be optionally selected from one or more R 11 It is replaced by. In some embodiments, [ka] The compounds are selected from phenyl, pyridyl, and thiophenyl, and each of them is optionally selected from one or more R compounds. 11 It is replaced by. In some embodiments, [ka] teeth, [ka] Selected from. In some embodiments, R 11 If present, it is independently selected from fluorine and -CH3 in each occurrence.

[0023] In some embodiments, L is used for the compounds described herein. 1 is a bond, and C 1~3 Selected from haloalkylenes. In some embodiments, L 1 C 1~3 In some embodiments, L 1The following are selected: -CF2-, -CF2CH2-, and -CF2CH2CH2-.

[0024] In some embodiments, the compounds described herein are used as follows: [ka] The R is selected from the absence of, phenyl, and 4- to 8-membered heterocycles, and the phenyl and 4- to 8-membered heterocycles are optionally selected from one or more R 11a It is replaced by. In some embodiments, [ka] R is selected from the following: absent, phenyl, azetidine, pyrrolidine, and piperidine, and phenyl, azetidine, pyrrolidine, and piperidine are optionally selected as one or more R 11a It is replaced by. In some embodiments, [ka] The compounds are selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups.

[0025] In some embodiments, L is used for the compounds described herein. 2 It, together with the atoms to which it is bonded, forms a 16-36 membered macrocyclic ring. In some embodiments, L 2 It, together with the atoms to which it is bonded, forms a 16-24 membered macrocyclic ring. In some embodiments, L 2 C 6~15 Alkylene, C 6~15 Alkenylene, C 6~15 Selected from alkynylenes, 6-15 member heteroalkylenes, and 6-15 member heteroalkynylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 C 5~10 Alkylene, C 5~10Alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkylenes are selected, and each of them is optionally selected for one or more R 11b It is substituted with. In some embodiments, the alkenylene, or heteroalkenylene, contains one carbon-carbon double bond. In some embodiments, the heteroalkylene, or heteroalkenylene, contains at least one oxygen atom or nitrogen atom. In some embodiments, R 11b In each occurrence, halogen, oxo, and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 Selected from alkyl)-OH and -OH. In some embodiments, R 11b In each occurrence, it is independently selected from -F, =O, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH.

[0026] In some embodiments, R is used for the compounds described herein. 3 is selected from hydrogen or -CH3, R 7 C 1~6 Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced with R 8 is hydrogen. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 1It is -CH3, [ka] These are selected from phenyl and 5- to 7-membered heteroaryls, each of which can be optionally selected from one or more R 11 Replaced with L 1 is a bond, and C 1~3 Selected from haloalkylenes, [ka] is selected from absent, phenyl, and 4- to 8-membered heterocycles, and phenyl and 4- to 8-membered heterocycles are optionally present in one or more R groups. 11a Replaced with L 2 C 5~10 Alkylene, C 5~10 Alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkylenes are selected, and each of them is optionally selected for one or more R 11b It is replaced by R. In some embodiments, 11 If present, it is fluorine, and R 11a If present, it is -CH3, and R 11b If present, each occurrence independently involves halogen, oxo, and C. 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 Selected from alkyl)-OH and -OH.

[0027] In some embodiments, the compounds described herein are used as follows: [ka] In some embodiments, [ka] teeth, [ka] [ka] It is selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups, L 1 C 1~3 It is a haloalkylene, L 2 is one or more R 11b C, which is optionally replaced by 5~10 It is an alkenylene, R 1 It is -CH3, and R 3 is hydrogen, or -CH3, and R 7 teeth, [ka] Selected from, R 8 is hydrogen, and R 11 is selected from fluorine and -CH3, R 11b These are halogen, oxo, and C 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 Selected from alkyl)-OH and -OH. In some embodiments, [ka] teeth, [ka] [ka] It is selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups, L 1 C 1~3 It is a haloalkylene, L 2 is one or more R 11b Selected from 5-10 member heteroalkylenes that are optionally substituted with R 1 It is -CH3, and R 3 is hydrogen, or -CH3, and R 7 teeth, [ka] Selected from, R 8 is hydrogen, and R 11 is selected from fluorine and -CH3, R 11b These are halogen, oxo, and C 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 Selected from alkyl)-OH and -OH.

[0028] In certain embodiments, the Disclosure provides compounds selected from Table 1, or pharmaceutically acceptable salts or solvates thereof. In certain embodiments, the Disclosure provides pharmaceutical compositions comprising a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0029] In certain embodiments, the Disclosure provides a method for treating cancer in a subject requiring treatment, comprising administering to the subject a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof. In some embodiments, the cancer is a solid tumor or a hematological cancer. In some embodiments, the subject is administered in conjunction with additional drugs or additional therapies.

[0030] In certain embodiments, the Disclosure provides a method for reducing Ras signaling output, comprising contacting the SOS1 protein with an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, thereby reducing the Ras signaling output. In some embodiments, the compound disrupts the interaction between the Ras protein and SOS1. In some embodiments, the Ras protein is wild-type K-Ras or mutant K-Ras.

[0031] In certain embodiments, the present disclosure provides a method for inhibiting cell proliferation, comprising administering an effective amount of one of the compounds described herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, to cells expressing SOS1, thereby inhibiting the proliferation of said cells.

[0032] In certain embodiments, the Disclosure relates to a method for reducing the Ras signaling output of cells, the method comprising contacting cells with an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, in combination with an additional agent, the additional agent being a chemotherapeutic agent, a radiopharmaceutical, or an immunomodulator (immune) agent. (modulator), or one or more targets selected from the following: MEK, epidermal growth factor receptor (EGFR), FGFR1, FGFR2, FGFR3, FGFR4, mitotic kinase, topoisomerase, ALK, c-MET, ErbB2, AXL, NTRK1, RET, A-Raf, B-Raf, C-Raf, ERK, MDM2, mTOR, BET, IGF1 / 2, IGF1-R, CDK9, SHC, GAB, GRB, PI3 kinase, MAPK, SHIP1, SHIP2, SHP1, SHP2, SRC, JAK, PARP, BTK, FLT3, HDAC, VEGFR, PDGFR, LCK, Bcr-Abl, AKT, wild-type KRas, KRas variants (e.g., KrasG12C, KRasG12D, KRasG12S, KRasG12V, KRasG13D, KRas These are inhibitors against G13C (or KRas G13V), ROS1, CDK4 / 6, and variants of one or more of their targets. In some embodiments, additional agents are inhibitors against one or more targets selected from MEK, epidermal growth factor receptor (EGFR), A-Raf, B-Raf, C-Raf, SHP2, wild-type KRas, KRas variants, and CDK4 / 6. In some embodiments, additional agents are chemotherapeutic agents, radiopharmaceuticals, or immunomodulators.

[0033] In certain embodiments, the Disclosure provides an SOS1 protein conjugated with a compound described herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the interaction between the SOS1 protein and the Ras protein is reduced compared to an SOS1 protein not conjugated with the compound.

[0034] Reference All publications, patents, and patent applications referenced herein are incorporated by reference to the same extent as any individual publication, patent, or patent application is specifically and individually indicated to be incorporated by reference. [Modes for carrying out the invention]

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to whom this disclosure belongs. If there are multiple definitions of a term herein, the definition in this section shall prevail. All patents, patent applications, publications, and published nucleotide and amino acid sequences (e.g., sequences available in GenBank or other databases) referenced herein are incorporated by reference. Chemical structures are named herein in accordance with the IUPAC agreement as implemented in the ChemDraw® software (Perkin Elmer, Inc., Cambridge, MA). Section headings used herein are merely structural and should not be construed as limiting the subject matter described. Where used herein and in the claims, the singular forms “a,” “an,” and “the” also include plural references unless the context clearly indicates otherwise. Furthermore, the use of the term “including,” as with other forms such as “include,” “includes,” and “included,” is not limited to these. The section headings used in this specification are for structural purposes only and should not be interpreted as limiting the subject matter described herein.

[0036] When used in conjunction with chemical parts such as alkyl, alkenyl, or alkynyl, "C x~y " or "C x ~C y The term "C" means a group containing x to y carbon atoms in the chain. For example, "C x~yThe term "alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including linear alkyl groups and branched alkyl groups, that contain x to y carbon atoms in the chain.

[0037] "Alkyl" refers to substituted or unsubstituted saturated hydrocarbon groups, including linear and branched alkyl groups. Alkyl groups consist of 1 to 12 carbon atoms (for example, C 1~12 Alkyl), for example, 1 to 8 carbon atoms (C 1~8 Alkyl, or 1 to 6 carbon atoms (C 1~6 Alkyl groups may be present. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, septyl, octyl, nonyl, and decyl. Alkyl groups are bonded to the rest of the molecule by single bonds. Unless otherwise expressly stated herein, alkyl groups may be optionally substituted with one or more substituents, such as those described herein.

[0038] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens. Examples of haloalkyl groups include trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, and 1,2-dibromoethyl.

[0039] "Alkenyl" refers to a substituted or unsubstituted hydrocarbon group containing a linear or branched alkenyl group that has at least one double bond. An alkenyl group has 2 to 12 carbon atoms (for example, C 2~12 Alkenyls), for example, 2 to 8 carbon atoms (C 2~8 Alkenyl) or 2-6 carbon atoms (C) 2~6The material may contain an alkenyl group. Examples of alkenyl groups include ethenyl (i.e., vinyl), propa-1-enyl, buta-1-enyl, penta-1-enyl, and penta-1,4-dienyl. Unless otherwise specified herein, the alkenyl group may be optionally substituted with one or more substituents, such as those described herein.

[0040] "Alkynyl" refers to a substituted or unsubstituted hydrocarbon group containing a linear or branched alkynyl group that has at least one triple bond. An alkynyl group has 2 to 12 carbon atoms (e.g., C 2~12 Alkynyl), for example, 2 to 8 carbon atoms (C 2~8 Alkynyl) or 2-6 carbon atoms (C) 2~6 It may contain an alkynyl group. Exemplary alkynyl groups include ethynyl, propynyl, butynyl, pentynyl, and hexynyl. Unless otherwise specified herein, the alkynyl group may be optionally substituted with one or more substituents, such as those described herein.

[0041] "Alkylene" or "alkylene chain" consists of 1 to 12 carbon atoms (for example, C 1~12 Alkylenes), for example, 1 to 8 carbon atoms (C) 1~8 Alkylene, or 1 to 6 carbon atoms (C 1~6 This refers to substituted or unsubstituted divalent saturated hydrocarbon groups, including linear alkylene groups and branched alkylene groups. Exemplary alkylene groups include methylene, ethylene, propylene, and n-butylene. Similarly, "alkenylene" and "alkynylene" refer to the alkylene groups defined above, each containing one or more carbon-carbon double or triple bonds. Bonding sites of alkylene, alkenylene, or alkynylene chains to the rest of a molecule may be located on one carbon or any two carbons of the chain. Unless otherwise specified herein, alkylene, alkenylene, or alkynylene groups are optionally substituted with one or more substituents, such as those described herein.

[0042] "Heteroalkyl," "heteroalkenyl," and "heteroalkynyl" refer to substituted or unsubstituted alkyl, alkenyl, and alkynyl groups, respectively, in which one or more of the carbon atoms, e.g., one, two, or three, are substituted with heteroatoms such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may be optionally oxidized, and any nitrogen heteroatom may be optionally quaternized. Where a numerical range is specified, it refers to the total chain length. For example, a 3- to 8-membered heteroalkyl group has a chain length of 3 to 8 atoms. Connection to the rest of the molecule may occur via any heteroatoms or carbons in the heteroalkyl chain, heteroalkenyl chain, or heteroalkynyl chain. Unless otherwise specified herein, heteroalkyl groups, heteroalkenyl groups, or heteroalkynyl groups are optionally substituted with one or more substituents, such as the substituents described herein.

[0043] "Heteroalkylene," "heteroalkenylene," and "heteroalkylynylene" refer to substituted or unsubstituted alkylene, alkenylene, and alkylynylene groups, respectively, in which one or more carbon atoms, for example, one, two, or three, are substituted with heteroatoms such as O, N, P, Si, S, or combinations thereof. Any nitrogen, phosphorus, and sulfur heteroatoms present in the chain may be optionally oxidized, and any nitrogen heteroatom may be optionally quaternized. If a numerical range is specified, it refers to the total chain length. For example, a 3- to 8-membered heteroalkylene group has a chain length of 3 to 8 atoms. Bonding sites of a heteroalkylene, heteroalkenylene, or heteroalkylynylene chain to the rest of the molecule may be via one heteroatom or one carbon in the heteroalkylene, heteroalkenylene, or heteroalkylynylene chain, or via any two heteroatoms, any two carbons, or any one heteroatom and any one carbon. Unless otherwise specified herein, heteroalkylene, heteroalkenylene, or heteroalkylynylene groups are optionally substituted with one or more substituents, such as those described herein.

[0044] A "carbon ring" refers to a saturated, unsaturated, or aromatic ring in which each atom of the ring is a carbon atom. 3~10 Monocyclic ring, C 5~12 Bicyclic ring, C 5~18 polycyclic ring, C 5~12 Spirocyclic rings, and C 5~12 It may include a bridging ring. Each ring in a bicyclic or polycyclic carbocyclic ring may be selected from saturated, unsaturated, and aromatic rings. A polycyclic carbocyclic ring contains a number of rings equal to the minimum number of cleavage required to convert the carbocyclic ring into an acyclic skeleton (e.g., bicyclic, tricyclic, tetracyclic, etc.). In some embodiments, the carbocyclic ring is C 6~10 C, such as aryl 6~12 It is an aryl group. In some embodiments, the carbon ring is C 3~12 It is a cycloalkyl group. In some embodiments, the carbon ring is C 5~12This refers to a cycloalkenyl group. In exemplary embodiments, an aromatic ring, such as phenyl, may be condensed with a saturated or unsaturated ring, such as cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated, and aromatic rings is included in the definition of a carbocyclic ring, as long as the valence allows. A carbocyclic ring may include a fused ring, a bridging ring, a spirocyclic ring, a saturated ring, an unsaturated ring, an aromatic ring, or any combination thereof. Exemplary carbocyclic rings include cyclopentyl, cyclohexyl, cyclohexenyl, adamantly, phenyl, indanyl, and naphthyl. Unless otherwise specified herein, a carbocyclic ring may be optionally substituted with one or more substituents, such as those described herein.

[0045] A "heterocycle" refers to a saturated, unsaturated, or aromatic ring containing one or more heteroatoms, e.g., 1, 2, 3, or 4 heteroatoms selected from O, S, P, and N. Heterocycles include 3- to 10-membered monocyclic rings, 5- to 12-membered bicyclic rings, 5- to 18-membered polycyclic rings, 5- to 12-membered spirocyclic rings, and 5- to 12-membered bridging rings. Each ring in bicyclic and polycyclic heterocycles can be selected from saturated, unsaturated, and aromatic rings. Polycyclic heterocycles contain a number of rings equal to the minimum number of cleavage required to convert the heterocycle into an acyclic skeleton (e.g., bicyclic, tricyclic, tetracyclic, etc.). Heterocycles can be bonded to the rest of the molecule via any atom of the heterocycle, such as the carbon or nitrogen atom of the heterocycle, as long as the valence allows. In some embodiments, the heterocycle is a 5- to 10-membered heteroaryl group, e.g., a 5 or 6-membered heteroaryl. In some embodiments, the heterocycle is a 3- to 12-membered heterocycloalkyl group. The heterocycle may include a fused ring, a bridging ring, a spirocyclic ring, a saturated ring, an unsaturated ring, an aromatic ring, or any combination thereof. In exemplary embodiments, a heterocycle, for example, pyridyl, may be fused to a saturated or unsaturated ring, for example, cyclohexane, cyclopentane, or cyclohexene. Exemplary heterocycles include pyrrolidinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyridadinyl, pyrazinyl, thiophenyl, oxazolyl, thiazolyl, morpholinyl, indazolyl, indolyl, benzothienyl, benzoxazolyl, and quinolinyl. Unless otherwise specified herein, the heterocycle may be optionally substituted with one or more substituents, such as those described herein.

[0046] A "heteroaryl" refers to an aromatic ring containing one, two, three, or four heteroatoms, selected from at least one heteroatom, e.g., O, S, and N. Heteroaryls may include 5-10 membered monocyclic rings, 6-12 membered bicyclic rings, 6-18 membered polycyclic rings, 5-12 membered spirocyclic rings, and 6-12 membered bridging rings. As used herein, heteroaryl rings may be selected from monocyclic, bicyclic, or polycyclic ring systems, including fused rings, spirocyclic rings, and bridging ring systems, in which case at least one of the rings in the ring system is aromatic and contains at least one heteroatom. Polycyclic heteroaryls contain a number of rings equal to the minimum number of cleavage required to convert the heteroaryl to an acyclic skeleton (e.g., bicyclic, tricyclic, tetracyclic, etc.). Heteroatoms in a heteroaryl can be optionally oxidized. If one or more nitrogen atoms are present, they can be optionally quaternized. Heteroaryl groups can be bonded to the rest of the molecule via any atom of the heteroaryl, such as the carbon or nitrogen atom of the heteroaryl, as long as the valence allows. Examples of heteroaryl groups, but not limited to, include azepinyl, benzimidazolyl, benzisothiazolyl, benzisoxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, furanyl, imidazolyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, purinyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridadinyl, pyridazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydroquinolinyl, thiadiazolyl, thiazolyl, and thienyl groups. Unless otherwise specified herein, heteroaryl groups may be optionally substituted with one or more substituents, such as those described herein.

[0047] Unless otherwise stated, hydrogen atoms are implied to be necessary to satisfy the valence requirements in the structures depicted herein.

[0048] Joining, or dashed line joining [ka] A wavy line drawn across it [ka] The terms are used interchangeably herein to indicate the location of bond breakage or bond formation. For example, structure [ka] So, R 7 but, [ka] If it is 1-cyclopropyl-1-carbonitride, then R 7 teeth, [ka] It can be described as such.

[0049] The term “substitution” refers to a substituted moiety that substitutes one or more carbon atoms or hydrogen atoms on a heteroatom in a structure. It will be understood that “substitution” or “substituted with” implicitly implies that such substitution conforms to the acceptable valencies of the substituted atom and substituent, and that the substitution results in a stable compound that does not undergo spontaneous transformation, such as rearrangement, cyclization, or elimination. As used herein, the term “substitution” is intended to include all acceptable substituents of an organic compound. In broad embodiments, acceptable substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. There may be one or more acceptable substituents for a given organic compound, and these may be the same or different. For the purposes of this disclosure, a heteroatom, such as nitrogen, may have any of the acceptable substituents of the organic compounds described herein that satisfy the valency of the heteroatom.

[0050] The compounds disclosed herein, for example, the compound of formula (I), are optionally substituted with one or more substituents selected from the following, for example, one, two, or three substituents: Halogen, Oxo, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, 2-6 member heteroalkyl, 3-6 member heteroalkenyl, 3-6 member heteroalkynyl, -C 0~6 Alkyl-(C 3~12 (Carbon ring), -(2-6 member heteroalkyl)-(C 3~12 carbocycle), -C 0~6 Alkyl-(3-12 member heterocycle), -(2-6 member heteroalkyl)-(3-12 member heterocycle), -OR 22 , -SR 22 , -N(R 22 )(R 23 ), =NR 22 , =C(R 21 )2, -C(O)OR 22 ,-OC(O)N(R 22 )(R 23 ), -N(R 22 )C(O)N(R 22 )(R 23 ), -N(R 22 )C(O)OR 22 , -N(R 22 )S(O)2R 22 , -C(O)R 22 ,-S(O)R 22 -OC(O)R 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -N(R 22 )C(O)R 22 -S(O)2R 22 -S(O)(NR 22 )R 22 -S(O)2N(R 22 )(R 23 )-, and -S(=O)(=NR 22 )N(R 22 )(R 23) are optionally substituted by one or more substituents selected from ), and two substituents bonded to the same or adjacent atoms optionally join to form a C3-12 carbon ring, or 3~12 It forms a complex ring of members, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, 2-6 member heteroalkyl, 3-6 member heteroalkenyl, 3-6 member heteroalkynyl, -C 0~6 Alkyl-(C 3~12 (Carbon ring), -(2-6 member heteroalkyl)-(C 3~12 carbocycle), -C 0~6 Alkyl-(3-12 member heterocycle),-(2-6 member heteroalkyl)-(3-12 member heterocycle), C 3~12 Carbon rings and 3- to 12-membered heterocycles can be optionally halogenated, oxo, -CN, or C. 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 22 , -SR 22 , -N(R 22 )(R 23 ), =NR 22 , =C(R 21 )2, -C(O)OR 22 ,-OC(O)N(R 22 )(R 23 ), -N(R 22 )C(O)N(R 22 )(R 23 ), -N(R 22 )C(O)OR 22 , -N(R 22 )S(O)2R 22 , -C(O)R 22 ,-S(O)R 22 -OC(O)R 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -N(R 22 )C(O)R 22 -S(O)2R 22 -S(O)(NR 22 )R 22-S(O)2N(R 22 )(R 23 ), and -S(=O)(=NR 22 )N(R 22 )(R 23 ) is substituted with one or more substituents independently selected from, R 21 However, in each appearance, hydrogen, halogen, and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, -C 0~6 Alkyl-(C 3~12 (Carbon ring), and -C 0~6 Selected from alkyl-(3-12 membered heterocycle), or two R 21 However, together with the carbon atoms to which they are bonded, C 3~12 A carbon ring, or a 3- to 12-membered heterocycle, each of which can optionally contain a halogen, C 1~3 Alkyl, C~ 1-3 Substituted with one, two, or three substituents independently selected from haloalkyl and -OH groups, R 22 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, -C 0~6 Alkyl-(C 3~12 (Carbon ring), and -C 0~6 Selected from alkyl-(3-12 member heterocycle), -C 0~6 Alkyl-(C 3~12 (Carbon ring) and -C 0~6 Alkyl-(3-12 member heterocycle) is a halogen, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each appearance, hydrogen and C appear independently. 1~6 R selected from alkyl groups or bonded to the same nitrogen atom 22 , and R 23 However, it forms a 3- to 10-membered heterocyclic ring.

[0051] In some embodiments, the compounds disclosed herein, for example, the compounds of formula (I), are optionally substituted with one or more substituents, for example, one, two, or three, selected from the following: Halogen, Oxo, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, 2-6 member heteroalkyl, 3-6 member heteroalkenyl, 3-6 member heteroalkynyl, -C 0~6 Alkyl-(C 3~12 (Carbon ring), -(2-6 member heteroalkyl)-(C 3~12 carbocycle), -C 0~6 Alkyl-(3-12 member heterocycle), -(2-6 member heteroalkyl)-(3-12 member heterocycle), -OR 22 , -SR 22 , -N(R 22 )(R 23 ), =NR 22 , =C(R 21 )2, -C(O)OR 22 ,-OC(O)N(R 22 )(R 23 ), -N(R 22 )C(O)N(R 22 )(R 23 ), -N(R 22 )C(O)OR 22 , -N(R 22 )S(O)2R 22 , -C(O)R 22 -OC(O)R 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -N(R 22 )C(O)R 22 -S(O)2R 22 -S(O)(NR 22 )R 22 , and -S(O)2N(R 22 )(R 23 )- is replaced with C 1~6 Alkyl, C 2~6 Alkenil, C 2~6Alkynyl, 2-6 member heteroalkyl, 3-6 member heteroalkenyl, 3-6 member heteroalkynyl, -C 0~6 Alkyl-(C 3~12 (Carbon ring), -(2-6 member heteroalkyl)-(C 3~12 carbocycle), -C 0~6 Alkyl-(3-12 member heterocycle),-(2-6 member heteroalkyl)-(3-12 member heterocycle), C 3~12 Carbon rings and 3- to 12-membered heterocycles can be optionally halogenated, oxo, -CN, or C. 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 22 , -SR 22 , -N(R 22 )(R 23 ), =NR 22 , and =C(R 21 ) Substituted with one or more substituents independently selected from 2, R 21 However, in each appearance, hydrogen, halogen, and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyl groups, R 22 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, -C 0~6 Alkyl-(C 3~12 (Carbon ring), and -C 0~6 Selected from alkyl-(3-12 member heterocycle), -C 0~6 Alkyl-(C 3~12 (Carbon ring), and -C 0~6 Alkyl-(3-12 member heterocycle) is a halogen, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each appearance, hydrogen and C appear independently. 1~6 R selected from alkyl groups or bonded to the same nitrogen atom 22 , and R 23However, it forms a 3- to 10-membered heterocyclic ring.

[0052] In some embodiments, the compounds disclosed herein, for example, the compound of formula (I), are optionally substituted with one or more substituents selected from the following, for example, one, two, or three substituents: halogen, oxo, =NH, -CN, -NO2, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Substituted by a carbon ring, a 3- to 10-membered heterocycle, -CH2-(3- to 10-membered heterocycle), -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, -CH2- (3- to 10-membered heterocycles) are halogens, oxo compounds, =NH, -CN, -NO2, -CH3, -CH2CH3, -CH(CH -3 It is optionally substituted with one, two, or three groups independently selected from )2, -C(CH3)3, -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3.

[0053] It will be understood by those skilled in the art that, where appropriate, the substituents themselves may be substituted. Unless specifically stated as “unsubstituted,” references to chemical parts herein should be understood to include substituted variants. For example, references to “heteroaryl” groups or parts implicitly include both substituted and unsubstituted variants.

[0054] Where divalent substituents are specified herein by their conventional chemical formulas written from left to right, they are intended to encompass isomers resulting from writing the structure from right to left; for example, -CH2O- is intended to also encompass -OCH2-.

[0055] "Optional" or "optionally" means that the event or situation described afterward may or may not occur, and the description includes both cases where the event or situation occurs and cases where it does not. For example, an "optionally substituted" base may be either non-substituted or substituted.

[0056] The compounds of this disclosure also include crystalline and amorphous forms of those compounds, pharmaceutically acceptable salts, and active metabolites having the same type of activity, which include, for example, polymorphs, pseudopolymorphs, solvates, hydrates, non-solvated polymorphs (including anhydrous forms), conformal polymorphs, amorphous forms of the compounds, and mixtures thereof.

[0057] The compounds described herein may exhibit their natural isotopic abundance, or one or more atoms may be artificially enriched into specific isotopes having the same atomic number but atomic masses or mass numbers different from those primarily found in nature. All isotopic variations of the compounds disclosed herein, whether radioactive or not, are included within the scope of this disclosure. For example, hydrogen, 1 H (protium), 2 H (deuterium), and 3 It has three naturally occurring isotopes, represented by H (tritium). Protium is the most abundant isotope of hydrogen in nature. Deuterium enrichment may result in certain therapeutic benefits, such as increased in vivo half-life and / or exposure, or may provide compounds useful for investigating in vivo drug elimination and metabolic pathways. Examples of isotopes that may be incorporated into the compounds of this disclosure include, but are not limited to, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 35 S, 36 Cl, and 18F is one example. Of particular note are the compounds of formula (I) that are tritium or carbon-14 rich, which can be used in tissue distribution studies, and especially the compounds of this disclosure that are deuterium rich at the metabolic site, for example, which result in compounds with higher metabolic stability, and which can be used in positron emission topography (PET) studies, for example. 11 C, 18 F, 15 O, and 13 This is a compound of formula (I) that is rich in positron-emitting isotopes such as N. Isotopic-enriched compounds can be prepared by conventional techniques known to those skilled in the art.

[0058] As used herein, the terms “having the formula,” “having the formula,” or “having the structure” are not intended to be limiting, but are used in the same manner as the term “including.” For example, when a structure is illustrated, it is understood that all stereoisomers and tautomers are included unless otherwise stated.

[0059] Certain compounds described herein contain one or more chiral centers, and thus can give rise to enantiomers, diastereomers, and other stereoisomeric forms, the chiral centers of which may be defined as (R)- or (S)- from the viewpoint of absolute stereochemistry. In some embodiments, in order to optimize the therapeutic activity of the compounds of this disclosure, for example to treat fibrosis, it may be desirable for the carbon atoms to have a specific configuration (e.g., (R,R), (S,S), (S,R), or (R,S)) or to be enriched with stereoisomeric forms having such configurations. The compounds of this disclosure may be provided as racemic mixtures. Accordingly, this disclosure relates to racemic mixtures, pure stereoisomers (e.g., enantiomers and diastereomers), stereoisomer-enriched mixtures, etc., unless otherwise indicated. When a chemical structure is illustrated herein without any stereochemistry, it is understood that all possible stereoisomers are encompassed by such structure. Similarly, where a particular stereoisomer is shown or named herein, a person skilled in the art will understand, unless otherwise suggested, that small amounts of other stereoisomers may be present in the compositions of this disclosure, provided that the usefulness of the composition as a whole is not diminished by the presence of such other isomers. Individual stereoisomers can be obtained by a number of methods known in the art, including preparations using chiral synthons or chiral reagents, resolution using chiral chromatography using a suitable chiral stationary phase or support, or chemically converting them to diastereomers and separating the diastereoisomers by conventional means such as chromatography or recrystallization, and then regenerating the original stereoisomers.

[0060] Furthermore, where applicable, all cis-trans, or E / Z isomers (geometric isomers), tautomers, and topoisomers of the compounds described herein are included in the scope of this disclosure unless otherwise specified.

[0061] The term “pharmaceutically acceptable” refers to a substance that, when used in the composition and method of the subject, is not biologically or otherwise unacceptable. For example, the term “pharmaceutically acceptable carrier” refers to a substance such as an adjuvant, excipient, lubricant, sweetener, diluent, preservative, dye, colorant, flavor enhancer, surfactant, humectant, dispersant, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier that can be incorporated into a composition and administered to a patient without causing unacceptable biological effects or interacting with other components of the composition in an unacceptable manner. Such pharmaceutically acceptable substances typically include substances that meet the necessary standards of toxicological and manufacturing testing and have been identified as appropriate inactive ingredients by the U.S. Food and Drug Administration.

[0062] The terms “salt” and “pharmaceutically acceptable salt” refer to salts prepared from a base or acid. Pharmaceutically acceptable salts are suitable for administration to patients, such as mammals (e.g., a mammalian-safe salt that is acceptable for a given administration regimen). Salts can be formed from inorganic bases, organic bases, inorganic acids, and organic acids. Furthermore, if a compound contains both a basic moiety, such as an amine, pyridine, or imidazole, and an acidic moiety, such as a carboxylic acid or tetrazole, a zwitterion may be formed, which, as used herein, is included in the term “salt.” Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0063] A "pharmaceutically acceptable acid addition salt" refers to a salt formed with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, or phosphorous acid, which retains the biological effects and properties of the free base and is not biologically or otherwise undesirable. It also includes salts formed with organic acids such as aliphatic mono and dicarboxylic acids, phenyl-substituted alkanes, hydroxyalkanoates, alkanedioates, aromatic acids, aliphatic, and aromatic sulfonic acids, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Therefore, exemplary salts include sulfates, disulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinates, suberates, sebacinates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, and methanesulfonates. Amino acid salts such as alginates, glucons, and galacturons are also considered (see, for example, Berge SM et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared in some embodiments by contacting the free base form with a sufficient amount of the desired acid to produce the salt, according to methods and techniques familiar to those skilled in the art.

[0064] A "pharmaceutically acceptable base addition salt" refers to a salt that retains the biological efficacy and properties of a free acid and is not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to a free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed from metals or amines such as alkali metals and alkaline earth metals, or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Examples of salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as salts of isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydravamin, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, and polyamine resins. See the book by Berge et al. cited above.

[0065] The term “effective dose” or “therapeutic effective dose” refers to the amount of agent sufficient to produce a beneficial or desired outcome. The therapeutic effective dose may vary depending on one or more of the following: the subject being treated and the disease state, the subject’s weight and age, the severity of the disease state, the mode of administration, etc., which can be readily determined by those skilled in the art. An effective dose of the activator may be administered in single or multiple doses. Components may be described herein as having at least an effective dose, or having at least an effective dose, such as those related to a specific target or purpose, such as any of those described herein. The term “effective dose” also applies to doses that will provide an image for detection by appropriate imaging methods. Specific doses may vary depending on the particular agent selected, the administration regimen to be followed, whether or not other compounds are used in combination, the timing of administration, the tissue being imaged, and one or more physical delivery systems to which the agent is carried.

[0066] As used herein, “to treat” or “to treat” means an approach to obtain a beneficial or desirable outcome with respect to a disease, disorder, or medical condition (such as cancer) in a subject, including, but not limited to, (a) preventing the onset of the disease or medical condition, e.g., preventing recurrence of the disease or medical condition, or prophylactic treatment in a subject susceptible to the disease or medical condition; (b) improving the disease or medical condition, e.g., eliminating or causing regression of the disease or medical condition in a subject; (c) suppressing the disease or medical condition, e.g., slowing or halting its progression in a subject; or (d) reducing the symptoms of the disease or medical condition in a subject. For example, “to treat cancer” includes preventing the onset of cancer, improving cancer, suppressing cancer, and reducing the symptoms of cancer. The therapeutic benefit is achieved by the elimination or improvement of one or more physiological symptoms associated with the underlying disorder, even though the subject may still have the underlying disorder, so that improvement is observed in the subject.

[0067] When the term “therapeutic effect” is used herein, it encompasses the therapeutic and / or preventive benefits described above. Preventive effects include delaying or eliminating the onset of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, delaying, halting, or reversing the progression of a disease or condition, or any combination thereof.

[0068] The terms “antagonist” and “inhibitor” are used interchangeably and refer to compounds that have the ability to inhibit the biological function (e.g., activity, expression, binding, protein-protein interactions) of a target protein (e.g., K-Ras). Therefore, the terms “antagonist” and “inhibitor” are defined in relation to the biological role of the target protein. Preferred antagonists as used herein are compounds that specifically interact with the target (e.g., bind), but also specifically inhibit the biological activity of the target protein by interacting with other members of the signaling pathway to which the target protein is a member.

[0069] The term "selective inhibition" or "selectively inhibiting" refers to the ability of a bioactive agent to preferentially reduce target signaling activity compared to extratarget signaling activity, either through direct or indirect interaction with the target.

[0070] The terms “subject” and “patient” refer to mammals, such as humans and other animals. The methods described herein may be useful for both human therapeutics and veterinary applications. In some embodiments, the subject is a mammal, such as a human. “Mammals” include humans, as well as domesticated animals, both laboratory animals and pets (such as cats, dogs, pigs, cows, sheep, goats, horses, and rabbits), and non-domesticated animals such as wildlife.

[0071] The terms “therapeutic agent,” “therapeutic drug,” or “treatment agent” are used interchangeably and refer to a molecule or compound that, when administered to a subject, produces some beneficial effect. Beneficial effects include enabling diagnostic determination, improving a disease, symptom, disorder, or pathological condition, reducing or preventing the onset of a disease, symptom, disorder, or condition, and substantially counteracting a disease, symptom, disorder, or pathological condition.

[0072] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymers may be linear or branched, may contain modified amino acids, and may be interrupted by non-amino acids. These terms also encompass any other operations on modified amino acid polymers, such as the formation of disulfide bonds, glycosylation, lipidation, acetylation, phosphorylation, or binding with labeling components. As used herein, the term “amino acid” refers to any amino acid, whether natural, and / or unnatural, or synthetic, including glycine and both D and L optical isomers, as well as amino acid analogs and peptide mimetic compounds.

[0073] The terms “polynucleotide,” “nucleotide sequence,” “nucleic acid,” and “oligonucleotide” are interchangeable. They refer to polymeric forms of nucleotides of any length, which are either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. Non-limiting examples of polynucleotides include: coding or non-coding regions of genes or gene fragments, loci (groups of loci) defined from linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, small interfering RNA (siRNA), small hairpin RNA (shRNA), microRNA (miRNA), ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. Polynucleotides may contain one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs, e.g., peptide nucleic acids (PNA), morpholino, and locked nucleic acids (LNA), glycol nucleic acids (GNA), threose nucleic acids (TNA), 2'-fluoro, 2'-OMe, and phosphorothiolated DNA. If present, modifications to the nucleotide structure may be made before or after polymer construction. The nucleotide sequence may be interrupted by non-nucleotide components. Polynucleotides may be further modified after polymerization, such as by binding to labeling components or other binding targets.

[0074] As used herein, “expression” refers to the process by which polynucleotides are transcribed from a DNA template (to mRNA or other RNA transcripts, etc.), and / or the process by which the transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. The transcripts and the encoded polypeptides may collectively be referred to as “gene products.” If the polynucleotides originate from genomic DNA, expression may include the splicing of mRNA in eukaryotic cells.

[0075] An "antigen" is a portion or molecule containing an epitope that also specifically binds to an antibody. An "antigen-binding unit" can be the entire full-length antibody, a fragment (or group of fragments), its structural variant, its functional variant, or a combination thereof. Full-length antibodies can be, for example, monoclonal antibodies, recombinant antibodies, chimeric antibodies, deimmunized antibodies, humanized antibodies, and human antibodies. Examples of full-length antibody fragments include, but are not limited to, variable heavy chains (VH), variable light chains (VL), and heavy chains (VHH or V) found in camelids such as camels, llamas, and alpacas. H H) Examples include single-domain antibodies (sdAb, e.g., "nanobody") containing a heavy chain (V-NAR domain) found in sharks, a single antigen-binding domain, Fv, Fd, Fab, Fab', F(ab')2, and "r IgG" (or semi-antibody). Examples of modified antibody fragments include, but are not limited to, scFv, di-scFv, or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single-chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, minibodies (e.g., (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3), or (scFv-CH3-scFv)2), and multibodies (e.g., triabodies or tetrabodies).

[0076] The terms “antibody” and “antibody group” include, but are not limited to, monoclonal antibodies, human antibodies, humanized antibodies, camelized antibodies, chimeric antibodies, and other epitope-binding fragments, but encompass any antigen-binding unit.

[0077] The term "prodrug" refers to a compound that, under physiological conditions, can be converted by solvolysis to a biologically active compound described herein (e.g., the compound of formula (I)). Therefore, the term "prodrug" refers to a precursor of a pharmaceutically acceptable biologically active compound. In some embodiments, a prodrug is inactive when administered to a subject but is converted in vivo to an active compound, for example, by hydrolysis. Prodrug compounds often offer advantages in mammalian organisms, such as solubility, histocompatibility, or delayed release (see, for example, Bundgard, H., Design of Prodrugs (1985), pp. 7-9, 21-24 (Elsevier, Amsterdam), Higuchi, T., et al., “Pro-drugs as Novel Delivery Systems,” (1987) ACSSymposium Series, Vol. 14, and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, each of which is fully incorporated herein by reference). The term “prodrug” also means that such a prodrug includes any covalent carrier that releases the active compound in vivo when administered to a mammalian subject. Prodrugs of active compounds described herein are typically prepared by modifying a functional group present in the active compound such that the modification is cleaved into the parent active compound either in a routine operation or in vivo. Examples of prodrugs include compounds in which a hydroxyl group, an amino group, or a mercapto group is cleaved when the prodrug of the active compound is administered to a mammalian subject to form a free hydroxyl group, a free amino group, or a free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetic acid, formic acid, and benzoic acid derivatives of the hydroxyl functional group in the active compound, or acetamide, formamide, and benzamide derivatives of the amine functional group.

[0078] The term "in vivo" refers to events that occur within the body of the subject. The term "ex vivo" refers to events that initially occur outside the body of the subject in order to later apply them in vivo within the body of the subject. For example, ex vivo preparation may include preparing cells outside the body of the subject for the purpose of introducing the prepared cells into the body of the same or different subject. The term "in vitro" refers to events that occur outside the body of the subject. For example, an in vitro assay encompasses any assay performed outside the body of the subject. In vitro assays include cell-based assays in which living or dead cells are used. In vitro assays also include cell-free assays that do not use intact cells.

[0079] This disclosure also means that it encompasses in vivo metabolites of the disclosed compounds. Such products may arise, for example, from oxidation, reduction, hydrolysis, amidation, esterification, etc., of the administered compound, primarily due to enzymatic processes. Thus, this disclosure includes compounds produced by processes, which involve administering the compounds disclosed herein to mammals for a period of time sufficient to obtain their metabolites. Such products are typically identified by administering the radiolabeled compounds of this disclosure to animals such as rats, mice, guinea pigs, monkeys, or humans in a detectable dose, allowing sufficient time for metabolism to occur, and then isolating the converted products from urine, blood, or other biological samples.

[0080] The term "Ras," or "RAS," refers to proteins of the rat sarcoma (Ras) superfamily of low molecular weight GTPases, such as the Ras subfamily. The Ras superfamily includes, but is not limited to, the Ras subfamily, Rho subfamily, Rab subfamily, Rap subfamily, Arf subfamily, Ran subfamily, Rheb subfamily, RGK subfamily, Rit subfamily, Miro subfamily, and unclassified subfamilies. In some embodiments, the Ras protein is selected from the group consisting of KRAS (which is also used interchangeably herein as K-Ras, K-ras, and Kras), HRAS (or H-Ras), NRAS (or N-Ras), MRAS (or M-Ras), ERAS (or E-Ras), RRAS2 (or R-Ras2), RALA (or RalA), RALB (or RalB), RIT1, and any combination thereof, for example, KRAS, HRAS, NRAS, RALA, RALB, and any combination thereof.

[0081] As used interchangeably herein, the terms “mutant Ras” and “Ras variant” refer to a Ras protein having one or more amino acid mutations relative to a common reference sequence such as the wild-type (WT) sequence. In some embodiments, the mutant Ras is selected from mutant KRAS, mutant HRAS, mutant NRAS, mutant MRAS, mutant ERAS, mutant RRAS2, mutant RALA, mutant RALB, mutant RIT1, and any combination thereof, for example, from mutant KRAS, mutant HRAS, mutant NRAS, mutant RALA, mutant RALB, and any combination thereof. In some embodiments, the mutation may be an introduced mutation, a naturally occurring mutation, or a mutation that does not exist naturally. In some embodiments, the mutation may be a substitution (e.g., a substituted amino acid), an insertion (e.g., the addition of one or more amino acids), or a deletion (e.g., the removal of one or more amino acids). In some embodiments, two or more mutations may be consecutive, discontinuous, or a combination thereof. In some embodiments, the mutation may be located at any position in Ras. In some embodiments, when optimally aligned, mutations may be located at positions 12, 13, 62, 92, 95, and 96 of Ras relative to SEQ ID NO: 1 (e.g., Y96D), or any combination thereof. In some embodiments, a mutant Ras may contain approximately or at least approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 mutations. In some embodiments, a mutant Ras may contain up to approximately 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, or 50 mutations.In some embodiments, the mutant Ras has a length of approximately or up to approximately 500, 400, 300, 250, 240, 233, 230, 220, 219, 210, 208, 206, 204, 200, 195, 190, 189, 188, 187, 186, 185, 180, 175, 174, 173, 172, 171, 170, 169, 168, 167, 166, 165, 160, 155, 150, 125, 100, 90, 80, 70, 60, 50 amino acids, or fewer than 50 amino acids. In some embodiments, the mutant amino acids are proteolytic amino acids, native amino acids, standard amino acids, non-standard amino acids, non-canonical amino acids, essential amino acids, non-essential amino acids, or non-native amino acids. In some embodiments, the mutant amino acid has a positively charged side chain, a negatively charged side chain, a polar uncharged side chain, a nonpolar side chain, a hydrophobic side chain, a hydrophilic side chain, an aliphatic side chain, an aromatic side chain, a cyclic side chain, an acyclic side chain, a basic side chain, or an acidic side chain. In some embodiments, the mutation includes a reactive moiety. In some embodiments, the substituted amino acid includes a reactive moiety. In some embodiments, the mutant Ras can be further modified, such as by binding to a detectable label. In some embodiments, the mutant Ras is a full-length polypeptide or a cleaved polypeptide. For example, the mutant Ras may be a truncated polypeptide containing residues 1-169, or residues 11-183 (e.g., residues 11-183 of mutant RALA or mutant RALB).

[0082] compound The compounds of formulas (I), (II), and (III) disclosed herein, including compounds of formulas (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II-A), and (III-A), or their pharmaceutically acceptable salts or solvates, are SOS regulators and have a wide range of applications in therapeutic, diagnostic, and other biomedical research.

[0083] In certain embodiments, this disclosure relates to compounds of formula (I): [ka] or a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] However, C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11 Replaced by, [ka] However, it does not exist, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11a Replaced by, [ka] but, [ka] L 1 However, bond, -O-, -N(R 12 )-, C 1~6 Alkilen, C 1~6 Selected from haloalkylenes and 2-6 membered heteroalkyls, L 2 However, C 5~25 Alkilen, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, or L 2 However, -L 3 -DL 4 -and, L 3 However, C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, R 1 However, one or more R 11c C, which is optionally replaced by 1~3 It is alkyl, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), and -P(O)(R 17 )(R 17a ) selected from, in the formula, each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally contain one, two, or three R groups. 20 Replaced by, and optionally, R 5 and R 6 , R 6 and R 7 , or R 6 and R 7b However, C 5~10 A carbon ring, or a 5-10 membered heterocycle, each of which optionally contains one, two, or three R groups. 20 Replaced by, R 5b , and R 7b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O) 2 R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH 2 C(O)N(R 12 )(R 13 ), -CH 2 N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O) 2 N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11d However, in each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15, -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14)C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyls, or R 12 , and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl, and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups. 20 Replaced with, or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C are independently identified. 1~6Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. The compound is (R)-2,2-difluoro-6 4 ,4-dimethyl-6 7 The present invention provides compounds, salts, or solvates that are not -morpholino-7-oxa-5-aza-6(1,5)-pyrido[3,4-d]pyridadina-1(4,1)-piperidina-3(1,3)-benzenacyclotridecaphane.

[0084] In certain embodiments, this disclosure relates to compounds of formula (I): [ka] or a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] However, C 5~7 A selection of carbon rings and 5- to 7-membered heterocycles, each of which can optionally contain one or more R 11 Replaced by, [ka] However, it does not exist, or C 3~8 A selection of carbon rings and 3- to 8-membered heterocycles, each of which can optionally contain one or more R11a Replaced by, [ka] but, [ka] L 1 However, bond, C 1~6 Alkylene and C 1~6 Selected from haloalkylenes, L 2 However, C 5~25 Alkilen, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, or L 2 However, -L 3 -DL 4 -and, L 3 However, C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, R 1 However, one or more R 11c C, which is optionally replaced by 1~3 It is alkyl, R2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6Alkynnyls, C3-10 carbon rings, and 3-10 membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 5b , and R 7b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O) 2 R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH 2 C(O)N(R 12 )(R 13 ), -CH 2 N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O) 2 N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11d However, in each occurrence, halogen, -CN, and C appear independently. 1~6Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyls, or R 12 , and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups.20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl, and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups. 20 Replaced with, or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C are independently identified. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. The compound is (R)-2,2-difluoro-6 4 ,4-dimethyl-6 7 The present invention provides compounds, salts, or solvates that are not -morpholino-7-oxa-5-aza-6(1,5)-pyrido[3,4-d]pyridadina-1(4,1)-piperidina-3(1,3)-benzenacyclotridecaphane.

[0085] In some embodiments, the compound of formula (I) is the compound of formula (I-A1) or (I-A2): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0086] In some embodiments, the compound of formula (I) is the compound of formula (I-B1) or (I-B2): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0087] In some embodiments, the compound of formula (I) is a compound of formula (I-C1), (I-C2), (I-C3), or (I-C4): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0088] In some embodiments, the compound of formula (I) is a compound of formula (I-E1), (I-E2), (I-E3), or (I-E4): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0089] In some embodiments, for the compound of formula (I), [ka] teeth, [ka] Selected from: In some embodiments, [ka] teeth, [ka] Selected from: In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] No. In some embodiments, [ka] teeth, [ka]

[0090] In certain embodiments, this disclosure relates to compounds of formula (II): [ka] or a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] However, C 5~7 Selected from carbon rings and 5- to 7-membered heterocycles, each of which contains one or more R 11 It is optionally replaced by, [ka] However, it does not exist, or C 3~8 A selection of carbon rings and 3- to 8-membered heterocycles, each of which can optionally contain one or more R 11a Replaced by, L 1 However, bond, C 1~6 Alkylene and C 1~6 Selected from haloalkylenes, L 2 However, C 5~25 Alkilen, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by L 2 However, W 3 , W 4 , or W 5 Covalently bonded to one of the following, or L 2 However, -L 3 -DL 4 - and L 4 However, W 3 , W 4 , or W 5 Covalently bonded to one of them, L 3 However, C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, L 5 However, the bond and -C(O)- are selected, W 2 However, N(R 2b ), N, C(R 2 ), C(R 2 )(R 2a ), and C(O) are selected, W 3 However, N(R 3b ), N, C(R 3 ), C(R 3 )(R 3a ), and C(O) are selected, W 4 However, N(R 4b ), N, C(R 4 ), C(R 4 )(R 4a ), and C(O) are selected, W 5 However, N(R 5b ), N, C(R 5 ), C(R 5 )(R 5a ), and C(O) are selected, W 7 However, N(R 7b ), N, C(R 7 ), C(R 7 )(R 7a ), and C(O) are selected, R 1However, one or more R 11c C, which is optionally replaced by 1~3 It is alkyl, R 2 , R 2a , R 3a , R 4a , R 5a , R 7a , and R 7 However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, C3-10 carbon ring, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C2~6 Alkenil, C 2~6 Alkynnyls, C3-10 carbon rings, and 3-10 membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 3 , R 4 , and R 5 However, each is independent, L 2 Bonding with hydrogen, halogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, C3-10 carbon ring, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyls, C3-10 carbon rings, and 3-10 membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 2b , and R7 b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon rings and 3- to 10-membered heterocycles independently and selectively form one, two, or three R groups. 20 Replaced by, R 3b , R 4b , and R 5b However, each is independent, L 2 Bonding with hydrogen, -CN, C1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11d However, in each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12)(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) are selected from, R 12However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyls, or R 12 , and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl, and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups.20 Replaced with, or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C are independently identified. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. [ka] However, compounds, salts, or solvates are provided that exhibit single or double bonds such that all valencies are satisfied.

[0091] In some embodiments, the compound of formula (II) is the compound of formula (II-A): [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein W 3 However, the compound is selected from N or C, or a pharmaceutically acceptable salt or solvate thereof.

[0092] In certain embodiments, this disclosure relates to compounds of formula (III): [ka] or a pharmaceutically acceptable salt or solvate thereof, in the formula, [ka] However, C 5~7 A selection of carbon rings and 5- to 7-membered heterocycles, each of which can optionally contain one or more R 11 Replaced by, [ka] However, it does not exist, or C 3~8 A selection of carbon rings and 3- to 8-membered heterocycles, each of which can optionally contain one or more R 11a Replaced by, L 1 However, bond, C 1~6 Alkylene and C 1~6 Selected from haloalkylenes, L 2 However, C 5~25 Alkilen, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by L 2 However, W 3 , W 4 , W 5 , or W 7 Covalently bonded to one of the following, or L 2 However, -L 3 -DL 4 - and L 4 However, W 3 , W 4 , W 5 , or W 7 Covalently bonded to one of them, L 3 However, C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, W 2 However, N(R 2b ), N, C(R 2 ), C(R 2 )(R 2a ), and C(O) are selected, W 3 However, N(R 3b ), N, C(R 3 ), C(R 3 )(R 3a ), and C(O) are selected, W 4 However, N(R 4b ), N, C(R 4 ), C(R 4 )(R 4a ), and C(O) are selected, W 5 However, N(R 5b ), N, O, S, C(R 5 ), C(R 5 )(R 5a ), and C(O) are selected, W 7が , N(R 7b ), N, O, S, C(R 7 ), C(R 7 )(R 7a ), and C(O) are selected, W 8 However, N(R 8b ), N, O, S, C(R8 ), C(R 8 )(R 8a ), and C(O) are selected, R 1 However, one or more R 11c C, which is optionally replaced by 1~3 It is alkyl, R 2 , R 2a , R 3a , R 4a , R 5a , R 7a , R 8 , and R 8a However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, C3-10 carbon ring, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyls, C3-10 carbon rings, and 3-10 membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 3 , R 4 , R 5 , and R 7 However, each is independent, L 2 Bonding with hydrogen, halogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 2b , and R 8b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10The carbon rings and 3- to 10-membered heterocycles independently and selectively form one, two, or three R groups. 20 Replaced by, R 3b , R 4b , R 5b , and R 7b However, each is independent, L 2 Bonding with hydrogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )( R13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11d However, in each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 ,-OC(O)N(R 12 )(R 13 ), -N(R 14 )C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)OR 15 , -N(R 14 )S(O)2R 15 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -C(O)C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -S(=O)(=NH)N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)2N(R 12 )(R 13 ), -CH2N(R 12 )S(O)2(R 13 ), and -P(O)(R 17 )(R 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 )(R 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyls, or R 12 , and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered complex rings are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups.20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl, and C 3~6 Cycloalkyl groups, one, two, or three R 20 It is optionally replaced by, or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C are independently identified. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. [ka] The present invention provides compounds, salts, or solvates exhibiting single or double bonds such that all valencies are satisfied.

[0093] In some embodiments, the compound of formula (III) is the compound of formula (III-A): [ka] or a pharmaceutically acceptable salt or solvate thereof, W 5 However, it is a compound, salt, or solvate selected from N or C.

[0094] In some embodiments, for compounds of formula (II), (II-A), (III), or (III-A), W 2 In some embodiments, W 3 N(R) 3b ), N, C(R 3 ), and C(O), for example, selected from NCH3, N, CH, CCH3, and C(O). In some embodiments, W 3 C(R 3 ) and C(O), for example, selected from CH, CCH3, and C(O). In some embodiments, W 3 is CH. In some embodiments, W 3 is CCH3. In some embodiments, W 4 N(R) 4b ), N, C(R 4 ), and C(O) are selected. In some embodiments, W 4 N(R) 4b ), and N, for example, N(R 4b ) is selected from. In some embodiments, W 4 In some embodiments, W 5 N(R) 5b ), N, C(R 5 ), and C(O), for example, N(R 5b ), NCH3, N, CH, C(R 5 ), and C(O) are selected. In some embodiments, W 5 N(R) 5b ), N, and C(R 5 ), for example, N(R 5b ), NCH3, N, CH, and C(R 5 ) is selected from. In some embodiments, W 5 N(R) 5b ), and C(R 5 ), for example, N(R 5b), selected from NCH3 and CH. In some embodiments, W 5 N(R) 5b ) is. In some embodiments, W 7 C(R 7 ) is. In some embodiments, W 7 R 7 However, it is not hydrogen, C(R) 7 ) and for example, R 7 C 3~10 Cycloalkyl, 3-10 member heterocycloalkyl, and -OR 12 Selected from 、 C 3~10 Cycloalkyls and 3- to 10-membered heterocycloalkyls can optionally have one, two, or three R groups. 20 It will be replaced by this.

[0095] In some embodiments, for a compound of formula (II) or (II-A), W 2 N, and C(R 2 ) is selected from, W 3 N(R) 3b ), and C(R 3 ) is selected from, W 4 C(R 4 ), and C(O) are selected, W 5 C(R 5 ) and W 7 N, and C(R 7 ) is selected from. In some embodiments, W 2 It is selected from N and CH, and W 3 N(R) 3b ), and selected from CH, W 4 It is selected from CH and C(O), W 5 C(R 5 ) and W 7 is selected from N and CH. In some embodiments, L 5 is -C(O)- and W 2 C(R 2 ) and W 3 N(R) 3b ) and in the formula, R 3b L2 It is a combination with W 4 C(O) and W 5 C(R 5 ) and W 7 C(R 7 ) is. In some embodiments, L 5 is -C(O)- and W 2 CH is W 3 N(R) 3b ) and in the formula, R 3b L 2 It is a combination with W 4 C(O) and W 5 C(R 5 ) and W 7 is CH. In some embodiments, L 5 is a bond, W 2 N is W 3 C(R 3 ) and W 4 C(R 4 ) and W 5 C(R 5 ) and W 7 It is N.

[0096] In some embodiments, for a compound of formula (III) or (III-A), W 5 N(R) 5b ) and in the formula, R 5b L 2 It is a combination with W 7 C(R 7 ) and W 8 C(R 8 ) is. In some embodiments, W 5 C(R 5 ) and in the formula, R 5 L 2 It is a combination with W 7 C(R 7 ) and W 8 is selected from O and S. In some embodiments, W 2 N is W 3 C(R 3 ) and W 4N is W 5 N(R) 5b ) and in the formula, R 5b L 2 It is a combination with W 7 C(R 7 ) and W 8 C(R 8 ) is. In some embodiments, W 2 N is W 3 C(R 3 ) and W 4 N is W 5 C(R 5 ) and in the formula, R 5 L 2 It is a combination with W 7 C(R 7 ) and W 8 is selected from O and S. In some embodiments, W 2 N is W 3 C(R 3 ) and W 4 N is W 5 C(R 5 ) and in the formula, R 5 L 2 It is a combination with W 7 C(R 7 ) and W 8 In some embodiments, W 2 N is W 3 C(R 3 ) and W 4 N is W 5 C(R 5 ) and in the formula, R 5 L 2 It is a combination with W 7 C(R 7 ) and W 8 In some embodiments, R 3 R is selected from hydrogen and CH3. In some embodiments, 7 C(O)R 15 For example, -C(O) (a 3- to 6-membered complex ring), where the 3- to 6-membered complex ring can be any one, two, or three R20 It is replaced by W 8 C(R 8 ) and for example, W 8 It is CH.

[0097] In some embodiments, for a compound of formula (I), R 2 , R 3 , R 4 , R 5 , R 6 , and R 8 These are, independently, hydrogen, halogen, -CN, and C. 1~3 Alkyl, C 1~3 Selected from haloalkyl, -OH, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 2 , R 3 , R 4 , R 5 , R 6 , and R 8 Each of these is independently selected from hydrogen and -CH3, for example, hydrogen.

[0098] In some embodiments, for a compound of formula (II) or (II-A), R 2 , R 2a , R 3a , R 4a , R 5a , and R 7a These are, independently, hydrogen, halogen, -CN, and C. 1~3 Alkyl, C 1~3 Selected from haloalkyl, -OH, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 2 , R 2a , R 3a , R 4a , R 5a , and R 7a Each is independently selected from hydrogen and -CH3, for example, hydrogen.

[0099] In some embodiments, for a compound of formula (III) or (III-A), R 2 , R 2a , R3a , R 4a , R 5a , R 7a , R 8 , and R 8a These are, independently, hydrogen, halogen, -CN, and C. 1~3 Alkyl, C 1~3 Selected from haloalkyl, -OH, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 2 , R 2a , R 3a , R 4a , R 5a , R 7a , R 8 , and R 8a Each of these is independently selected from hydrogen and -CH3, for example, hydrogen.

[0100] In some embodiments, for compounds of formula (II), (II-A), (III), or (III-A), R 3 , R 4 , and R 5 Each is independent of L 2 Bonding with hydrogen, halogen, -CN, C 1~6 Alkyl, C 3~6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 3~6 Carbon rings and 3- to 6-membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced with R 7 C 1~6 Alkyl, C3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 It is replaced by R 3 , R 4 , and R 5 Each is independent of L 2 Bonding with hydrogen, halogen, -CN, C 1~3 Alkyl, C 1~3 Selected from haloalkyl, -OH, -OCH3, -NH2, -NHCH3, -N(CH3)2, R 7 is hydrogen, C 1~6 Alkyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 The carbon rings and 3- to 10-membered heterocycles are optionally substituted with one, two, or three R20 groups. In some embodiments, R 3 , R 4 , and R 5 Each is independent of L 2 The bond is selected from hydrogen, -CH3, and -OCH3, R 7 is hydrogen, C 1~6 Alkyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12)(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C3-10 carbon rings, and 3-10 membered heterocycles can optionally have one, two, or three R groups. 20 It will be replaced by this.

[0101] In some embodiments, for a compound of formula (I), R 5b is hydrogen, and C 1~3 Alkyl, for example, selected from hydrogen and -CH3. In some embodiments, R 7b C 1~6 Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 It is replaced by R 7b is one, two, or three R 20 It is a 3- to 10-membered heterocycloalkyl group that is optionally substituted with R. In some embodiments, 7b is one, two, or three R 20 C, which is optionally replaced by 3~10 It is a cycloalkyl group.

[0102] In some embodiments, for a compound of formula (II) or (II-A), R 2b is hydrogen, and C 1~3 Alkyl, for example, selected from hydrogen and -CH3. In some embodiments, R 7b C 1~6Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 It is replaced by R 7b is one, two, or three R 20 It is a 3- to 10-membered heterocycloalkyl group that is optionally substituted with R. In some embodiments, 7b is one, two, or three R 20 C, which is optionally replaced by 3~10 It is cycloalkyl. In some embodiments, R 3b , R 4b , and R 5b Each is independent of L 2 Bonding with hydrogen, and C 1~3 Alkyl, for example, L 2 A bond with hydrogen and -CH3 is selected. In some embodiments, R 3b , R 4b , and R 5b Each is independent of L 2 Bonding with and selected from -CH3. In some embodiments, R 3b , R 4b , and R 5b Each is independent of L 2 It is selected from the combination with.

[0103] In some embodiments, for a compound of formula (III) or (III-A), R 2b , and R 8b These are, independently, hydrogen and C 1~3 Alkyl, for example, selected from hydrogen and -CH3. In some embodiments, R 3b , R 4b , R 5b, and R 7b Each is independent of L 2 Bonding with hydrogen, and C 1~3 Alkyl, for example, L 2 A bond with hydrogen and -CH3 is selected. In some embodiments, R 3b , R 4b , R 5b , and R 7b Each is independent of L 2 Bonding with and selected from -CH3. In some embodiments, R 3b , R 4b , R 5b , and R 7b Each is independent of L 2 It is selected from the combination with.

[0104] L 2 However, -L 3 -DL 4 - For compounds of formula (II) or (III), R 3 , R 4 , R 5 , R 7 , R 3b , R 4b , R 5b , or R 7b For one of them, "L 2 The choice of "combining with" is -L 3 -DL 4 -and, especially, L 4 It is understood that this essentially involves a union with L. To avoid any doubt, it should be added that "L 2 R 3 , R 4 , R 5 , R 7 , R 3b , R 4b , R 5b , and / or R 7b Any enumeration of is also "L 4 It can be considered to include "combination with".

[0105] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), R 1 C 1~3 Alkyl, and C- 1~3 Haloalkyls are selected from, for example, -CH3, -CH2CH3, -CH(CH3)2, -CH2F, -CHF2, -CF3, CH2CH2F, -CH2CHF2, and -CH2CF3. In some embodiments, R 1 C 1~3 Alkyl, for example, selected from -CH3 and -CH2CH3. In some embodiments, R 1 is -CH3. In some embodiments, R 1 is (R)-CH3. In some embodiments, R 1 This is (S)-CH3.

[0106] In some embodiments, for compounds of formula (I), (I-C1), (I-C2), (I-E1), (I-E2), (II), (III), or (III-A), R 3 Hydrogen, halogen, -CN, C 1~6 Alkyl, C 3~6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR 12 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 , and -S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 3~6Carbon rings and 3- to 6-membered heterocycles can independently and optionally have one, two, or three R groups. 20 It is replaced by R 3 Hydrogen, halogen, -CN, C 1~3 Alkyl, C 1~3 Selected from haloalkyl, -OH, -OCH3, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 3 These are hydrogen, halogen, -CN, -OR 12 , and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl groups. In some embodiments, R 3 is one, two, or three R 20 C, which is optionally replaced by 1~6 It is alkyl. In some embodiments, R 3 is hydrogen, or -CH3. In some embodiments, R 3 is hydrogen. In some embodiments, R 3 It is -CH3.

[0107] In some embodiments, for compounds of formula (II), (III), or (III-A), R 3b is hydrogen, and C 1~3 Alkyl, for example, selected from hydrogen and -CH3. In some embodiments, R 3b is -CH3. In some embodiments, R 3b It is hydrogen.

[0108] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-E1), (I-E2), (I-E3), (II), (II-A), or (III), R 5 Hydrogen, halogen, -CN, C 1~6 Alkyl, C 3~6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)OR12 , -C(O)R 15 ,-S(O)R 15 -OC(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 , and -S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 3~6 Carbon rings and 3- to 6-membered heterocycles can independently and optionally have one, two, or three R groups. 20 It is replaced by R 5 Hydrogen, halogen, -CN, C 1~3 Alkyl, C 1~3 Selected from haloalkyl, -OH, -OCH3, -NH2, -NHCH3, and -N(CH3)2. In some embodiments, R 5 is hydrogen, -OR 12 , and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl groups. In some embodiments, R 5 is hydrogen, or -CH3. In some embodiments, R 5 is hydrogen. In some embodiments, R 5 It is -CH3.

[0109] In some embodiments, for compounds of formula (I), (I-B2), (I-E4), (II), (II-A), or (III), R 5b is hydrogen, and C 1~3 Alkyl, for example, selected from hydrogen and -CH3. In some embodiments, R 5b It consists of hydrogen and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl groups. In some embodiments, R 5b is -CH3. In some embodiments, R 5bis hydrogen. In some embodiments, R 5b L 2 It is a combination of the two.

[0110] In some embodiments, for compounds of formula (I), (I-A1), (I-B1), (I-B2), (I-C1), (I-C3), (I-C4), (II), (II-A), (III), or (III-A), R 7 C 1~6 Alkyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)2N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally contain one, two, or three R groups. 20 It is replaced by R 7 C 1~6 Alkyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 It is replaced by R 7 C 1~6 Alkyl, C 3~10 Cycloalkyl, 3-10 member heterocycloalkyl, and -N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Cycloalkyls and 3- to 10-membered heterocycloalkyls can optionally have one, two, or three R groups. 20 It is replaced by R 7 is one, two, or three R 20 A 3- to 10-membered heterocycloalkyl group optionally substituted with R, for example, 7 is one, two, or three R 20 It is a 4- to 6-membered heterocycloalkyl group that is optionally substituted with R. In some embodiments, 7 is one, two, or three R 20 A 3- to 10-membered heterocycloalkyl group optionally substituted with, the heterocycloalkyl group comprising at least one O, N, or S atom, for example, one O atom, one or two N atoms, or one S atom. In some embodiments, R 7 is one, two, or three R 20 A 3- to 6-membered heterocycloalkyl group is optionally substituted with, and the heterocycloalkyl group contains S(O)2. In some embodiments, R 7 is one, two, or three R 20 C, which is optionally replaced by 3~10 It is a cycloalkyl, for example, R 7 is one, two, or three R 20 C, which is optionally replaced by 3~6 It is cycloalkyl. In some embodiments, R 7 is one R 20 C, which is optionally replaced by 3~4 It is a cycloalkyl, and optionally R20 is -CN. In some embodiments, R 7 is one, two, or three R 20 C, which is optionally replaced by 1~6 It is alkyl, for example, R 7 is one or two R 20 Replaced with, C 1~6 It is alkyl. In some embodiments, R 7 is -N(R 12 )(R 13 ) is. In some embodiments, R 7 is -OR 12 For example, -O (3-6 member heterocycloalkyl). In some embodiments, R 7 is replaced by at least one -CN. In some embodiments, R 7 is non-substitutable. In some embodiments, R 7 C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which can optionally contain one, two, or three R groups. 20 It is replaced by R 7 C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which is oxo, -CN, and C 1~6 It is optionally substituted with one, two, or three substituents selected from alkyl groups. In some embodiments, R 7 These are oxo, -CN, and C 1~3 A 4- to 6-membered heterocycloalkyl group substituted with one, two, or three substituents selected from alkyl groups. In some embodiments, R 7 These are oxo, -CN, and C 1~3 A C molecule substituted with one, two, or three substituents selected from alkyl groups. 3~4 It is a cycloalkyl group.

[0111] In some embodiments, for compounds of formula (I), (I-A1), (I-B1), (I-B2), (I-C1), (I-C3), (I-C4), (II), (II-A), (III), or (III-A), R 7 C 1~6 Alkyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -SR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 -S(O)(NR 12 )R 15 -S(O)2N(R 12 )(R 13 ), -CH2C(O)N(R 12 )(R 13 ), -CH2N(R 14 )C(O)R 15 -CH2S(O)2R 15 -CH2S(O)(NR 12 )R 15 , and -CH2S(O)2N(R 12 )(R 13 ) are selected from each C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can independently and optionally contain one, two, or three R groups. 20 It is replaced by R 7 C 1~6 Alkyl, C 3~10 Carbon rings, 3-10 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 -S(O)(NR 12 )R 15 , and -SO2N(R 12 )(R 13) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 It is replaced by R 7 is one, two, or three R 20 A 3-6 member heterocycloalkyl group is optionally substituted with S(O)(NR 12 ) includes.

[0112] In some embodiments, for compounds of formula (I), (I-A1), (I-B1), (I-B2), (I-C1), (I-C3), (I-C4), (II), (II-A), (III), or (III-A), R 7 teeth, [ka] And, During the ceremony, n1 is an integer between 1 and 3. n2 is an integer between 0 and 2. n3 is an integer between 0 and 2. n4 is either 0 or 1. X is -O-, -S(O2)-, -P(O)-, -CH2-, -CH(OH)-, -CH(OR 12 )-,-CH(R 20 )-,-C(R 20 )2-, -NR 12 -, -CH(N(R 12 )(R 13 ))-,-CH(C(O)N(R 12 )(R 13 ))-, and -CH(S(O)2N(R 12 )(R 13 )- Selected from, R 12 , R 13 , and R 20 This is defined elsewhere in this specification, Selectively, two R 20 Base, or R 20 , and R 12These atoms bond together with the atom(s) they are bonded to to form a ring. For example, R 7 teeth, [ka] It can be selected from the following. In some embodiments, X is -O-, -S(O)2-, -S(O)(NR 12 )-, -P(O)-, -CH2-, -CH(OH)-, -CH(OR 12 )-,-CH(R 20 )-,-C(R 20 )2-, -NR 12 -, -CH(N(R 12 )(R 13 ))-,-CH(C(O)N(R 12 )(R 13 ))-, and -CH(S(O)2N(R 12 )(R 13 )- Selected from.

[0113] In some embodiments, for compounds of formula (I), (I-A1), (I-B1), (I-B2), (I-C1), (I-C3), (I-C4), (II), (II-A), (III), or (III-A), R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] Selected from. In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] In some embodiments, R 7 teeth, [ka] That is the case.

[0114] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (III), or (III-A), R 8 These are hydrogen, halogens, and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl groups. In some embodiments, R 8 It is hydrogen.

[0115] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), [ka] C 3~10 Carbon rings, and 3- to 10-membered heterocycles, for example, C 5~7 A selection of carbon rings and 5- to 7-membered heterocycles, each of which can optionally contain one or more R 11 It is replaced by. In some embodiments, [ka] C 5~7 Selected from cycloalkyl, 5-7 member heterocycloalkyl, 5-7 member heteroaryl, and phenyl, each of which can optionally be one or more R 11 It is replaced by. In some embodiments, [ka] The compounds are selected from phenyl, pyridyl, and thiophenyl, and each of them is optionally selected from one or more R compounds. 11 It is replaced by. In some embodiments, [ka] teeth, [ka] Selected from. In some embodiments, R 11 If present, it is independently selected from fluorine and -CH3 in each occurrence. In some embodiments, [ka] teeth, [ka] Selected from: In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] teeth, [ka] That is the case.

[0116] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), L 1 C 1~6 Alkylene and C 1~6 Haloalkylenes, for example, C 1~3 Alkylene and C 1~3 Selected from haloalkylenes. In some embodiments, L 1 is a bond, and C 1~3 Selected from haloalkylenes. In some embodiments, L 1 C 1~3 Haloalkylenes, for example, -CF2-, -CF2CH2-, or -CF2CH2CH2-. In some embodiments, L 1 C 1~2Haloalkylenes, for example, -CF2- or -CF2CH2-. In some embodiments, L 1 is -CF2-. In some embodiments, L 1 is -CF2CH2-. In some embodiments, L 1 is -CF2CH2CH2-. In some embodiments, L 1 is a bond. In some embodiments, L 1 These are bonded, -O-, -NR 12 -, -S-, C 1~6 Alkilen, C 1~6 Selected from haloalkylenes and 2-6 member heteroalkylenes, C 1~6 Alkilen, C 1~6 Haloalkylenes and 2- to 6-membered heteroalkylenes are optionally combined with one or more R 11b It is replaced by L 1 -O-, -NR 12 -, -S-, and 2- to 6-membered heteroalkylenes are selected, and the 2- to 6-membered heteroalkylenes are optionally selected from one or more R 11b It is replaced by L 1 is one or more R 11b For example, one, two, or three R 11b C, which is optionally replaced by 1~6 It is an alkylene. 1 These are bonded, -O-, -NR 12 -, -S-, C 1-3 Alkilen, C 1-3 Selected from haloalkylenes and 2-3 member heteroalkylenes, C 1-3 Alkilen, C 1-3 Haloalkylenes and 2-3 member heteroalkylenes are optionally combined with one or more R 11b It is replaced by L 1 -O-, -NR 12 -, -S-, and 2- to 3-membered heteroalkylenes are selected, and the 2- to 3-membered heteroalkylenes are optionally given one or more R 11b It is replaced by L 1is one or more R 11b For example, one, two, or three R 11b Replaced with, C 1~3 It is alkylene.

[0117] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), [ka] is absent, or C 4~8 Selected from carbon rings and 4- to 8-membered heterocycles, each of which can optionally contain one or more R 11a It is replaced by. In some embodiments, [ka] is either absent, or selected from phenyl and 4- to 8-membered heterocycles, each of which is optionally one or more R 11a It is replaced by, in some embodiments, [ka] The compounds are selected from phenyl and 4- to 8-membered heterocycles, each of which can optionally contain one or more R groups. 11a It is replaced by. In some embodiments, [ka] is either absent, or selected from phenyl, azetidine, pyrrolidine, and piperidine, each of which is optionally one or more R 11a It is replaced by. In some embodiments, [ka] The compounds are selected from phenyl, azetidine, pyrrolidine, and piperidine, each of which is optionally selected from one or more R compounds. 11a It is replaced by. In some embodiments, [ka] The is selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups. In some embodiments, [ka] is one or more R 11a Phenyl is optionally substituted with phenyl. In some embodiments, [ka] is one or more R 11a substituted by any choice [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] is one or more R 11a Azetidine is optionally substituted with . In some embodiments, [ka] is one or more R 11a substituted by any choice [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] is one or more R 11a It is a pyrrolidine that is optionally substituted with. In some embodiments, [ka] is one or more R 11a It is a piperidine that is optionally substituted with. In some embodiments, [ka] is one or more R 11a substituted by any choice [ka] In some embodiments, [ka] teeth, [ka] In some embodiments, [ka] It is non-substitutable. In some embodiments, [ka] is one or more R 11a For example, one, two, or three R 11a It is replaced by R 11aIn each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C 3~6 Carbon rings, 3-6 membered heterocycles, -OR 12 , -N(R 12 )(R 13 ), -N(R 14 )S(O)2R 15 ,-C(O)N(R 12 )(R 13 ), -N(R 14 )C(O)R 15 -S(O)2R 15 , and -S(O)2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~6 Carbon rings and 3- to 6-membered heterocycles can optionally contain one, two, or three R groups. 20 It is replaced by R 11a In each occurrence, halogen and C are independently present. 1~6 Alkyl, and C 1~6 Selected from haloalkyls. In some embodiments, R 11a In each occurrence, C 1~6 Selected from alkyl groups. In some embodiments, R 11a It is -CH3.

[0118] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), L 2 C 5~25 Alkilen, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 C 5~25 Alkilen, C 5~25Selected from alkenylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 Together with the atoms to which it is bonded, it forms a 16-36 membered macrocyclic ring, for example, a 16-24 membered macrocyclic ring. In some embodiments, L 2 C 6~15 Alkilen, C 6~15 Alkenylene, C 6~15 Selected from alkynylenes, 6-15 member heteroalkylenes, and 6-15 member heteroalkynylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 C 5~10 Alkilen, C 5~10 Selected from alkenylenes, 5-10 member heteroalkylenes, and 5-10 member heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 Alkenylenes, or heteroalkenylenes, contain one carbon-carbon double bond. In some embodiments, L 2 The heteroalkylene, or heteroalkenylene, contains at least one oxygen atom or nitrogen atom. In some embodiments, L 2 The heteroalkylene, or heteroalkenylene, contains at least one basic nitrogen. In some embodiments, L 2 C 5~9 Alkilen, C 5~9 Selected from alkenylenes and 5- to 9-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 C 6~9 Alkilen, C 6~9 Selected from alkenylenes and 6- to 9-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 C 5~8 Alkilen, C5~8 Selected from alkenylenes and 5- to 8-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 C 6~8 Alkilen, C 6~8 Selected from alkenylenes and 6- to 8-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 C 6~8 Alkylene and C 6~8 Selected from alkenylenes, each of which can be optionally selected from one or more R 11b It is replaced by L 2 The compounds are selected from C6 alkylenes and C6 alkenylenes, each of which can be optionally selected from one or more R compounds. 11b It is replaced by L 2 The C7 alkylenes and C7 alkenylenes are selected, and each of them can be optionally selected from one or more R 11b It is replaced by L 2 The C8 alkylenes and C8 alkenylenes are selected, and each of them can be optionally selected from one or more R 11b It is replaced by L 2 is -CH2CHCH(CH2)4-. In some embodiments, L 2 is one or more R 11b It is a 6- to 8-membered heteroalkylene that is optionally substituted with L. In some embodiments, L 2 is one or more R 11b It is a 6-membered heteroalkylene that is optionally substituted with L. In some embodiments, L 2 is one or more R 11b It is a 7-membered heteroalkylene that is optionally substituted with L. In some embodiments, L 2 is one or more R 11b It is an 8-membered heteroalkylene that is optionally substituted with L. In some embodiments, L 2L is an 8-membered heteroalkylene, and the heteroalkylene contains one oxygen atom. In some embodiments, L 2 is, -(CH2) 2~5 O(CH2) 0~5 - and for example, L 2 is, -(CH2) 2~5 O(CH2) 2~5 - is. In some embodiments, L 2 is -(CH2)4O(CH2)3-. In some embodiments, R 11b In each occurrence, halogen, oxo, and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 Selected from alkyl)-OH and -OH. In some embodiments, R 11b In each occurrence, R is independently selected from -F, =O, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b In each occurrence, it is independently selected from -CH3, -CH2OH, -CH2F, -CHF2, and -CF3, or two R 11b They combine to form =O, or C 3~6 A cycloalkyl group, for example, a cyclopropyl group, is formed. In some embodiments, R 11b In each occurrence, it is independently selected from -CH3, -CH2OH, -CH2F, -CHF2, and -CF3, or two R 11b They combine, C 3~6 A cycloalkyl group, for example, a cyclopropyl group, is formed. In some embodiments, R 11b In each occurrence, is independently selected from -CH3, -F, -CN, and -OH. In some embodiments, L 2 is -C(O)N(R 14 )-, or -N(R 14 )C(O)- contains. In some embodiments, L 2 It contains -O-. In some embodiments, L 2It is substituted with at least one -CH3, -CH2OH, -CH2F, -CHF2, or -CF3, or two substituents are bonded to form a cyclopropyl. In some embodiments, L 2 is substituted with at least one -CH3, -F, -CN, or -OH. In some embodiments, L 2 This is a non-substitution.

[0119] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), L 2 is, -(C 1~5 Alkylene)-C(O)N(R) 14 )-(C 1~5 Alkylene)-, for example, -(C 1~5 Alkylene)-C(O)N(CH3)-(C 1~5 Alkylene)-, or -(C 1~5 Alkylene)-C(O)NH-(C 1~5 Alkylene)- and C -1~5 Alkylenes can optionally be one or more R 11b It is replaced by L 2 is, -(C 1~2 Alkylene)-C(O)N(R) 14 )-(C 3~4 Alkylene)-, for example, -(C 1~2 Alkylene)-C(O)N(CH3)-(C 3~4 Alkylene)-, or -(C 1~2 Alkylene)-C(O)NH-(C 3~4 Alkylene)- and C -1~2 Alkylene and C 3~4 Each alkylene independently and arbitrarily selects one or more R 11b It is replaced by R 11b In each occurrence, halogen and C are independently present. 1~6 Alkyl, C 1~6 Haloalkyl, (C1~6 Selected from alkyl)-OH and -OH. In some embodiments, R 11b In each occurrence, R is independently selected from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b In each occurrence, it is independently selected from -CH3, -CH2OH, -CH2F, -CHF2, and -CF3, or two R 11b They combine, C 3~6 A cycloalkyl group, for example, a cyclopropyl group, is formed. In some embodiments, R 11b In each occurrence, is independently selected from -CH3, -F, -CN, and -OH. In some embodiments, L 2 It is substituted with at least one -CH3, -F, -CN, or -OH group.

[0120] In some embodiments, L 2 -C(R 11b )(R 11b )-(C 3~10 Alkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3~10 Alkylene)-C(R 11b )(R 11b )-,-CH2-(C 3~10 Alkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3~10 Alkylene)-CH(R 11b )-,-CH2-(C 3~10 Alkylene)-CH(R 11b )-,-C(R 11b )(R 11b )-(C 3~10 Alkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3~10 Alkenylene)-C(R 11b )(R 11b )-,-CH2-(C3~10 Alkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3~10 Alkenylene)-CH(R 11b )-,-CH2-(C 3~10 Alkenylene)-CH(R 11b )-,-C(R 11b )(R 11b )-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH2-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkylene)-CH(R 11b )-,-CH2-(3-10 member heteroalkylene)-CH(R 11b )-,-C(R 11b )(R 11b )-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH2-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkenylene)-CH(R 11b )-, and -CH2-(3-10 member heteroalkenylene)-CH(R 11b )- Selected from. In some embodiments, L 2 -C(R 11b )(R 11b )-(C 3~10 Alkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3~10 Alkylene)-C(R 11b )(R 11b)-,-CH2-(C 3~10 Alkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3~10 Alkylene)-CH(R 11b )-, and -CH2-(C 3~10 Alkylene)-CH(R 11b )- Selected from. In some embodiments, L 2 -C(R 11b )(R 11b )-(C 3~10 Alkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3~10 Alkenylene)-C(R 11b )(R 11b )-,-CH2-(C 3~10 Alkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(C 3~10 Alkenylene)-CH(R 11b )-, and -CH2-(C 3~10 Alkenylene)-CH(R 11b )- Selected from. In some embodiments, L 2 -C(R 11b )(R 11b )-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH2-(3-10 member heteroalkylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkylene)-CH(R 11b )-, and -CH2-(3-10 member heteroalkylene)-CH(R 11b )- Selected from. In some embodiments, L 2 -C(R 11b )(R 11b )-(3-10 member heteroalkenylene)-C(R11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkenylene)-C(R 11b )-(R 11b )-,-CH2-(3-10 member heteroalkenylene)-C(R 11b )(R 11b )-,-CH(R 11b )-(3-10 member heteroalkenylene)-CH(R 11b )-, and -CH2-(3-10 member heteroalkelene)-CH(R 11b )- Selected from any C in this paragraph. 3~10 Alkilen, C 3~10 Alkenylenes, 3-10 membered heteroalkylenes, or 3-10 membered heteroalkylenes may be optionally combined with one or more R 11b It can be replaced by R. In some embodiments, 11b In each occurrence, halogen, oxo, and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 Selected from alkyl)-OH and -OH. In some embodiments, R 11b In each occurrence, R is independently selected from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b In each occurrence, it is independently selected from -CH3, -CH2OH, -CH2F, -CHF2, and -CF3, or two R 11b They combine to form =O, or C 3~6 It forms a cycloalkyl group, for example, a cyclopropyl group.

[0121] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), L 2 is, -L 3 -DL 4 - and in the formula, L3 C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which can be optionally selected from one or more R 11b It is replaced by D, and D is absent, or C 3~12 Selected from carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by L 4 C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which can be optionally selected from one or more R 11b It is substituted with. As described above, the alkenylene group and the alkynylene group each contain one or more carbon-carbon double or triple bonds (i.e., for example, C 2~10 Alkenylene, C 2~10 Alkinylene, C 2~8 Alkenylene, C 2~8 Alkinylene, C 5~25 Alkenylene, C 5~25 Alkinylene, C 6~15 Alkenylene, C 6~15 Alkinylene, C 5~10 Alkenylene and C 5~10 (Like alkynylenes, which contain two or more carbon atoms). Similarly, heteroalkenylene groups contain one or more carbon-carbon double bonds (i.e., two or more carbon atoms and one or more heteroatoms, such as 3-10 membered heteroalkenylenes, 3-8 membered heteroalkenylenes, 5-25 membered heteroalkenylenes, 6-15 membered heteroalkenylenes, and 5-10 membered heteroalkenylenes. In some embodiments, L 2 is, -L 3 -DL 4 - and in the formula, L 3 C 1~10 Alkilen, C 2~10 Alkenylene, C 2~10Selected from alkynylenes, 2-10 member heteroalkynylenes, and 3-10 member heteroalkynylenes, each of which can be optionally selected from one or more R 11b It is replaced by C 3~12 Selected from carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by L 4 L is absent. In some embodiments, L 2 is, -L 3 -DL 4 - and in the formula, L 3 C 1~8 Alkilen, C 2~8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by D, and D is absent, or C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which can optionally have one or more R 11d Replaced by L 4 C 1~8 Alkilen, C 2~8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by L 2 is, -L 3 -DL 4 - and in the formula, L 3 C 1~8 Alkilen, C 2~8 Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, each of which can optionally have one or more R 11d It is optionally replaced by L 4 C 1~8 Alkilen, C 2~8Selected from alkenylenes, 2- to 8-membered heteroalkylenes, and 3- to 8-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by R 11b In each occurrence, halogen, oxo, and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 Selected from alkyl)-OH and -OH. In some embodiments, R 11b In each occurrence, R is independently selected from -F, -CH3, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2OH, and -OH. In some embodiments, R 11b In each occurrence, it is independently selected from -CH3, -CH2OH, -CH2F, -CHF2, and -CF3, or two R 11b They combine to form =O, or C 3~6 A cycloalkyl group, for example, a cyclopropyl group, is formed. In some embodiments, D is selected from phenyl and 5-8 member heteroaryl groups, for example, triazole and imidazole. In some embodiments, D is unsubstituted. In some embodiments, D is one or more R groups. 11d For example, one, two, or three R 11d It will be replaced by this.

[0122] In some embodiments, for the compound of formula (II), L 2 is, W 3 , W 4 , or W 5 Covalently bonded to one of the following, or L 2 is, -L 3 -DL 4 - and L 4 is, W 3 , W 4 , or W 5 It forms a covalent bond with one of them. For example, L 2 is, W 3 It may also be covalently bonded to R 3b , or R 3 As shown in equation (II-A), L2 This is a bond with L. In some embodiments, for the compound of formula (III), L 2 is, W 3 , W 4 , W 5 , or W 7 Covalently bonded to one of the following, or L 2 is, -L 3 -DL 4 - and L 4 is, W 3 , W 4 , W 5 , or W 7 It is covalently bonded to one of them. For example, L 2 is, W 5 It may also be covalently bonded to R 5b、 or R 5 As shown in equation (III-A), L 2 It is a combination of the two.

[0123] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), R 20 In each occurrence, the following are independently represented: halogen, oxo, =NH, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24)C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , and -N(R 22 )(R 23 ) are independently selected and optionally substituted by one, two, or three bases, R 21 In each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 In each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 In each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 In each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 In each occurrence, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are optionally substituted with one, two, or three groups, independently selected.

[0124] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), R 20 In each occurrence, halogen, oxo, and =NR are independent. 22 ,-CN,C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)(NR 22 )R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, and =NR 22 ,-CN,C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , and -N(R 22 )(R 23 It is optionally substituted by one, two, or three elements, which are selected independently of the other elements.

[0125] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), R 20 In each occurrence, the following are independently identified: halogen, oxo, =NH, -CN, -NO2, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Selected from carbon rings, 3-10 membered heterocycles, -CH2-(3-10 membered heterocycles), -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, -CH2- (3- to 10-membered heterocycles) are halogens, oxo compounds, =NH, -CN, -NO2, -CH3, -CH2CH3, -CH(CH -3 )2, -C(CH3)3, -OH, -OCH3, -OCH2CH3, -NH2, -NHCH3, and -NHCH2CH3 are optionally substituted with one, two, or three groups independently selected from these groups.

[0126] In some embodiments, for the compound of formula (I-B1), R 5 is hydrogen, and R 7 C 1~6 Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced with R 8 is hydrogen. In some embodiments, for the compound of formula (I-B2), R 5b It is -CH3, and R 7 C 1~6 Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced with R 8 It is hydrogen.

[0127] In some embodiments, for the compound of formula (I-C1), R 3 is hydrogen, or -CH3, and R 7 C 1~6 Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced with R 8 is hydrogen. In some embodiments, for a compound of formula (I-C2), R 3 is hydrogen, or -CH3, and R 7b C 1~6 Alkyl, C3~10 Carbon ring, 3-10 membered heterocycle, -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced with R 8 is hydrogen. In some embodiments, for a compound of formula (I-C3), R 4 R is hydrogen, -CH3, or -OCH3, 7 C 1~6 Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced with R 8 is hydrogen. In some embodiments, for the compound of formula (I-C4), R 4 R is hydrogen, -CH3, or -OCH3, 7 C 1~6 Alkyl, C 3~10 Carbon ring, 3-10 membered heterocycle, -N(R 12 )(R 13 ), -C(O)R 15 ,-C(O)N(R 12 )(R 13 ), -S(O)2R 15 , and -SO2N(R 12 )(R 13 ) is selected from C 1~6 Alkyl, C 3~10Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced with R 8 It is hydrogen.

[0128] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), R 1 It is -CH3, [ka] These are selected from phenyl and 5- to 7-membered heteroaryls, each of which can optionally be one or more R 11 Replaced by L 1 is a bond, and C 1~3 Selected from haloalkylenes, [ka] The R is selected from the absence of, phenyl, and 4- to 8-membered heterocycles, and the phenyl and 4- to 8-membered heterocycles are optionally selected from one or more R 11a Replaced by L 2 C 5~10 Alkilen, C 5~10 Selected from alkenylenes, 5-10 member heteroalkylenes, and 5-10 member heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by R 11 If present, it is fluorine, and R 11a If present, it is -CH3, and R 11b If present, halogen, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 Selected from alkyl)-OH and -OH.

[0129] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), R 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1~2 It is a haloalkylene, [ka] teeth, One or more R 11a substituted by any choice [ka] And L 2 C 6~8 Alkilen, C 6~8 Selected from alkenylenes and 6- to 8-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by R 1 It is -CH3, [ka] teeth, [ka] And L 1 C 1~2 It is a haloalkylene, [ka] teeth, [ka] And L 2 is one or more R 11b It is a 6- to 8-membered heteroalkylene that is optionally substituted with R. In some embodiments, 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1~2 It is a haloalkylene, [ka] teeth, One or more R 11a substituted by any choice [ka] And L 2 C 6~8 Alkylene and C 6~8 Selected from alkenylenes, each of which can be optionally selected from one or more R 11b It is replaced by R 1 It is -CH3, [ka] teeth, [ka] And L 1 C 1~2 It is a haloalkylene, [ka] teeth, [ka] And L 2 is one or more R 11bC, which is optionally replaced by 6~8 It is an alkenylene. In some embodiments, R 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1~2 It is a haloalkylene, [ka] teeth, One or more R 11a substituted by any choice [ka] And L 2 is, -(C 1~2 Alkylene)-C(O)N(CH3)-(C 3~4 Alkylene)-, or -(C 1~2 Alkylene)-C(O)NH-(C 3~4 Alkylene)- and C -1~2 Alkylene and C 3~4 Each alkylene independently and arbitrarily selects one or more R 11b It is replaced by R 11a If present, it is -CH3, and R 11b If present, halogen, -CN, oxo, C 1~3 Alkyl, C 1~3 Haloalkyl, (C 1~3 Selected from alkyl)-OH and -OH.

[0130] In some embodiments, for compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), R1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1~2 It is a haloalkylene, [ka] teeth, [ka] And L 2 C 6~8 Alkilen, C 6~8 Selected from alkenylenes and 6- to 8-membered heteroalkylenes, each of which is optionally selected from one or more R 11b It is replaced by R 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1~2 It is a haloalkylene, [ka] teeth, [ka] And L 2 C 6~8 Alkylene and C 6~8 Selected from alkenylenes, each of which can be optionally selected from one or more R 11b It is replaced by R 1 It is -CH3, [ka] teeth, [ka] Selected from, L 1 C 1~2 It is a haloalkylene, [ka] teeth, [ka] And L 2 is, -(C 1~2 Alkylene)-C(O)N(CH3)-(C 3~4 Alkylene)-, or -(C 1~2 Alkylene)-C(O)NH-(C 3~4 Alkylene)- and C -1~2 Alkylene and C 3-4 Each alkylene independently and arbitrarily selects one or more R 11b It is replaced by R 11b If present, halogen, -CN, oxo, C 1~3 Alkyl, C 1~3 Haloalkyl, (C 1~3 Selected from alkyl)-OH and -OH.

[0131] In certain embodiments, the Disclosure relates to compounds of formula (I-C1), (I-C2), (I-C3), or (I-C4), or pharmaceutically acceptable salts or solvates thereof, wherein, [ka] teeth, [ka] Selected from, [ka] teeth, Selected from azetidine, pyrrolidine, and piperidine, each of which is optionally substituted with one or more -CH3 groups. L 1 C 1~3 It is a haloalkylene, L 2 C 5~10 Alkilen, C 5~10 Selected from alkenylenes, 5-10 member heteroalkylenes, and 5-10 member heteroalkylenes, each of which is optionally selected from one or more R 11b Replaced by, R 1 It is -CH3, R 3 , or R 4 is hydrogen, -CH3, or -OCH3, R 7 teeth, [ka] Selected from, R 8 It is hydrogen, R 11 It is selected from fluorine and -CH3, R 11b These are halogen, oxo, and C 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 The present invention provides compounds, salts, or solvates selected from alkyl)-OH and -OH groups.

[0132] In certain embodiments, the Disclosure relates to compounds of formula (I-C1), (I-C2), (I-C3), or (I-C4), or pharmaceutically acceptable salts or solvates thereof, wherein, [ka] teeth, [ka] Selected from, [ka] teeth, Selected from azetidine, pyrrolidine, and piperidine, L 1 It is selected from -CF2-, -CF2CH2-, and -CF2CH2CH2-, L 2 C 5~10 Alkilen, C 5~10 Selected from alkenylenes, 5-10 member heteroalkylenes, and 5-10 member heteroalkenylenes, R 1 It is -CH3, R 3 , or R 4 is hydrogen, -CH3, or -OCH3. R 7 teeth, [ka] Selected from, R 8 This provides a compound, salt, or solvate that is hydrogen.

[0133] In some embodiments, this disclosure is, [ka] [ka] [ka] The present invention provides compounds selected from, or pharmaceutically acceptable salts or solvates thereof.

[0134] In some embodiments, the compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A) are not compounds disclosed in U.S. Patent Application No. 18 / 328,109 or International Application No. PCT / US2023 / 065963, and each of them is incorporated as a whole by reference.

[0135] In some embodiments, compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A) are provided as substantially pure stereoisomers. In some embodiments, the stereoisomers are provided with at least 80% enantiomer excess, e.g., at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.9% enantiomer excess.

[0136] In some embodiments, the compounds described herein exist as pharmaceutically acceptable salts thereof. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods for treating a disease by administering such pharmaceutically acceptable salts as a pharmaceutical composition.

[0137] In some embodiments, the compounds described herein have an acidic group or a basic group and therefore react with a number of inorganic bases or organic bases, or inorganic acids or organic acids, to form pharmaceutically acceptable salts. In some embodiments, such salts are prepared in situ during the final isolation and purification of the compounds described herein, or by reacting the purified compound in its free form separately with a suitable acid or base and isolating the salt thus formed.

[0138] In some embodiments, the compounds described herein exist as solvates. In some embodiments, there are methods for treating diseases by administering such solvates. Furthermore, this specification describes methods for treating diseases by administering such solvates as pharmaceutical compositions.

[0139] Solvates contain a stoichiometric or non-stoichiometric amount of solvent and, in some embodiments, are formed during a crystallization process using a pharmaceutically acceptable solvent such as water or ethanol. When the solvent is water, a hydrate is formed; when the solvent is alcohol, an alcoholate is formed. Solvates of the compounds described herein are conveniently prepared or formed during the processes described herein. As just one example, hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous / organic solvent mixture using an organic solvent including, but not limited to, dioxane, tetrahydrofuran, or MeOH. In addition, the compounds provided herein exist in both non-solvated and solvated forms. Generally, the solvated form is considered equivalent to the non-solvated form for the purposes of the compounds and methods provided herein.

[0140] In certain aspects, this disclosure is related to formula AL AB -Provides a compound of B, in which, A is a monovalent form of the compound described herein, L ABThis is a covalent linker bonded to A and B, B is a monovalent form of the degradation enhancer.

[0141] A "degradation accelerator" is a compound that can bind to a ubiquitin ligase protein (e.g., E3 ubiquitin ligase protein), or a protein-binding compound that can form a protein complex capable of binding to a ubiquitin ligase protein and conjugating the ubiquitin protein to a target protein. In some embodiments, the degradation accelerator can bind to an E3 ubiquitin ligase protein or a protein complex containing an E3 ubiquitin ligase protein. In some embodiments, the degradation accelerator can bind to an E2 ubiquitin-conjugating enzyme. In some embodiments, the degradation accelerator can bind to a protein complex containing an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin ligase protein.

[0142] In some embodiments, the decomposition accelerator is E3A, mdm2, APC, EDD1, SOCS / BC-box / eloBC / CUL5 / RING, LNXp80, CBX4, CBLL1, HACE1, HECTD1, HECTD2, HECTD3, HECTD4, HECW1, HECW2, HERC1, HERC2, HERC3, HERC4, HER5, HERC6, HUWE1, ITCH, NEDD4, NEDD4L, PPIL2, PRPF19, PIAS1, PIAS 2, PIAS3, PIAS4, RANBP2, RNF4, RBX1, SMURF1, SMURF2, STUB1, TOPORS, TRIP12, UBE3A, UBE3B, UBE3C, UBE3D, UBE4A, UBE4B, UBOX5, UBR5, VHL (von-Hippel-Lindau ubiquitin ligase), WWP1, WWP2, Parkin, MKRN1, CMA (chaperone-mediated autophagy), SCFb-TRCP (Skip-Cullin-F box (beta-TRCP) ubiquitin complex), b-TRCP (b-transducing repeat-containing protein), cIAP1 (cell inhibitor of apoptosis protein 1), APC / C (late-stage acceleration complex / cyclosome), CRBN (cereblon), CUL4-RBX1-DDB1-CRBN (CRL4 CRBNIt can bind to proteins selected from ubiquitin ligase, XIAP, IAP, KEAP1, DCAF15, RNF114, DCAF16, AhR, SOCS2, KLHL12, UBR2, SPOP, KLHL3, KLHL20, KLHDC2, SPSB1, SPSB2, SPSB4, SOCS6, FBXO4, FBXO31, BTRC, FBW7, CDC20, PML, TRIM21, TRIM24, TRIM33, GID4, abadomide, iverdimide, and CC-885. In some embodiments, the degradation accelerator can bind to proteins selected from UBE2A, UBE2B, UBE2C, UBE2D1, UBE2D2, UBE2D3, UBE2DR, UBE2E1, UBE2E2, UBE2E3, UBE2F, UBE2G1, UBE2G2, UBE2H, UBE2I, UBE2J1, UBE2J2, UBE2K, UBE2L3, UBE2L6, UBE2L1, UBE2L2, UBE2L4, UBE2M, UBE2N, UBE2O, UBE2Q1, UBE2Q2, UBE2R1, UBE2R2, UBE2S, UBE2T, UBE2U, UBE2V1, UBE2V2, UBE2W, UBE2Z, ATG3, BIRC6, and UFC1. In some embodiments, the degradation accelerator is a compound described in Ishida and Ciulli, SLAS Discovery 2021, Vol.25(4)484-502, e.g., VH032, VH101, VH298, thalidomide, bestatin, methylbestatin, nutlin, idasanutlin, bardoxolone, bardoxolone methyl, indislam (E7070), E7820, chloroquinoxalinesulfonamide (CQS), nimbolid, KB02, ASTX660, lenalidomide, or pomalidomide, which is incorporated in whole by reference for all purposes.

[0143] In some embodiments, the decomposition accelerator is US2018 / 0050021, WO2016 / 146985, WO2018 / 189554, WO2018 / 119441, WO2018 / 140809, WO2018 / 119448, WO2018 / 119357, WO2018 / 118598, WO2018 / 102067, WO2018 / 98280, WO2018 / 89736, WO 2018 / 81530, WO2018 / 71606, WO2018 / 64589, WO2018 / 52949, WO2017 / 223452, WO2017 / 204445, WO2017 / 19 7055, WO2017 / 197046, WO2017 / 180417, WO2017 / 176958, WO2017 / 11371, WO2018 / 226542, WO2018 / 223909, WO2018 / 189554, WO2016 / 169989, WO2016 / 146985, CN105085620B, CN106543185B, US10040804, US993830 2, US10144745, US10145848, US9938264, US9632089, US9821068, US9758522, US9500653, US9765019, US8 Compounds listed in 507488, US8299057, US2018 / 0298027, US2018 / 0215731, US2017 / 0065719, US2017 / 0037004, US2016 / 0272639, US2015 / 0291562, or US2014 / 0356322, each of which is incorporated by reference in whole for any purpose.

[0144] In some embodiments, L AB is, -L AB1 -L AB2 -L AB3 -L AB4 -L AB5 -and, L AB1 , L AB2 , L AB3 , L AB4 , and L AB5 These are, independently, bonded, -O-, and -N(R). 100 )-, -C(O)-, -N(R 100)C(O)-, -C(O)N(R 100 )-, -S-, -S(O)2-, -S(O)-, -S(O)2N(R 100 )-,-S(O)N(R 100 )-,-N(R 100 )S(O)-, -N(R 100 )S(O)2-, C 1~6 Alkylene, -(O-C) 1~6 Alkyl) z -,-(C 1~6 Alkyl-O) z -, C 2~6 Alkenylene, C 2~6 Alkinylene, C 1~6 Haloalkylene, C 3~12 Selected from carbocyclene and 3-10 member heterocyclene, C 1~6 Alkilen, C 2~6 Alkenylene, C 2~6 Alkinylene, C 1~6 Haloalkylene, C 3~12 Carbocyclenes and 3- to 10-membered heterocyclenes can be optionally given one, two, or three R groups. 20 It is replaced by -(O-C 1~6 Alkyl) z - and - (C 1~6 Alkyl-O) z - Each C 1~6 Alkyl groups can optionally consist of one, two, or three R groups. 20 Replaced by, Each z is an independent integer between 0 and 10. R 100 In each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Selected from carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles), C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) can optionally have one, two, or three R groups. 20 Replaced by, R 20 In each occurrence, the following are independently represented: halogen, oxo, =NH, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 (Carbon ring), 3-10 membered heterocycle, -CH2- (3-10 membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), -OCH2C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH2-(C 3~10 Carbon rings, 3- to 10-membered heterocycles, and -CH2- (3- to 10-membered heterocycles) are halogens, oxo, =NH, -CN, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 ,-C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O)2R 25 , -C(O)R 25 -S(O)2R 25 -S(O)2N(R 22 )(R 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 In each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 In each occurrence, H and C are independent. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, and C 1~6The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 In each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 In each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 In each occurrence, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are optionally substituted with one, two, or three groups, independently selected.

[0145] In some embodiments, L AB is -(O-C2 alkyl) z - where z is an integer from 1 to 10. In some embodiments, L AB is -(C2alkyl-O-) z - where z is an integer from 1 to 10. In some embodiments, L AB is, -(CH2) zz1 L AB2 (CH2O) zz2 - and L AB2 It is a bond, 5-6 member heterocyclene, phenylene, -C 2-4 It is an alkynylene, -SO2-, or -NH-, and zz1 and zz2 are independently integers from 0 to 10. In some embodiments, L AB is, -(CH2) zz1 (CH2O) zz2 - and zz1 and zz2 are each an integer between 0 and 10, independently of each other. In some embodiments, L ABis a PEG linker (for example, a divalent linker of 1 to 10 ethylene glycol subunits). In some embodiments, B is [ka] It is a monovalent form of the compound selected from. In some embodiments, B is [ka] It is a monovalent form of the compound selected from the above.

[0146] The chemical substances described herein may be synthesized according to one or more exemplary schemes herein and / or techniques known in the art. The substances used herein are commercially available or prepared by synthetic methods commonly known in the art. These schemes are used for illustrative purposes and are not limited to the compounds listed in the Examples or compounds with any particular substituents. Various steps are described and illustrated in Schemes 1–4 and Example 1, but in some cases these steps may be carried out in an order different from the order shown in Schemes 1–4 and Example 1. Various modifications to these synthetic reaction schemes may be made and will be suggested to those skilled in the art who have referred to this disclosure. The numbering or R group in each scheme typically has the same meaning as defined elsewhere herein, unless otherwise indicated.

[0147] Unless otherwise specified, the reactions described herein are carried out at atmospheric pressure and generally within a temperature range of -10°C to 200°C. Furthermore, unless otherwise specified, reaction times and conditions are approximate values, intended to be carried out over a period of about 1 to 24 hours at near atmospheric pressure within a temperature range of about -10°C to about 110°C, with the reaction left to react overnight for an average period of about 16 hours.

[0148] In general, the compounds of this disclosure can be prepared by the following reaction scheme. Scheme 1 [ka]

[0149] In some embodiments, compounds of formula 1e can be prepared according to scheme 1. For example, when ring C is a heteroaryl, heteroarylamine 1b can be formed from chloride 1a via a nucleophilic aromatic substitution reaction. The amine substitution can proceed under basic conditions to obtain diene 1c, which can then be cross-metathesis, such as a Grubbs cross-metathesis reaction, to form a macrocyclic compound 1d. Optionally, 1d can be subjected to one or more subsequent reactions, such as hydrogenation reactions, to provide compounds of formula 1e. Scheme 2 [ka]

[0150] In some embodiments, compounds of formula 2e can be prepared according to scheme 2. For example, when ring C is heteroaryl, heteroarylamine 2b can be formed from chloride 2a via a substitution reaction. Nitrogen substitution can yield a protected amine 2c. Hydrolysis of the ester can form a carboxylic acid 2d, which can then be obtained to yield the macrocyclic compound of formula 2e via deprotection and peptide coupling reactions. Scheme 3 [ka]

[0151] In some embodiments, compounds of formula 3e can be prepared according to scheme 3. For example, if ring C is a heteroaryl, heteroarylamine 3b can be formed by coupling chloride 3a with a suitable amine. Substitution of the remaining aryl chloride with a suitable alcohol can be carried out to obtain aryl ether 3c. Ester hydrolysis and deprotection of the amine can yield 3d, which can then be used to form the macrocyclic compound of formula 3e via a peptide coupling reaction. Scheme 4 [ka]

[0152] In some embodiments, compounds of formula 4h can be prepared according to scheme 4. For example, if ring C is a heteroaryl, heteroarylamine 4c can be obtained by nucleophilic aromatic substitution with amine 4b. Following the conversion of the bromide to the alcohol of 4d, substitution with a suitable bromodioxolane (4e) can be performed to obtain acetal 4f. The Boc protecting group can be removed by treatment with a suitable acid such as HCl, revealing the aldehyde (4g). Finally, cyclization of 4g can proceed via reductive amination conditions to obtain the macrocyclic compound of formula 4h.

[0153] In some embodiments, the compounds of this disclosure, for example, compounds of the formulas shown in Table 1, were synthesized according to one of the general routes outlined in Schemes 1 to 4, Example 1, or by methods known in the art. In some embodiments, exemplary compounds include, but are not limited to, compounds selected from Table 1, or salts or solvates thereof.

[0154] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5]

[0155] In some embodiments, the compounds of this disclosure exhibit one or more functional properties described herein. For example, the compounds of interest may reduce Ras signaling output. In some cases, the compounds of interest can disrupt Ras-SOS interactions, including disrupting interactions or binding between mutant Kras (e.g., Kras G12C) and SOS1, or between wild-type Kras and SOS1, thereby reducing Ras signaling output. In some embodiments, the compounds of interest specifically bind to SOS proteins, including SOS1. In some embodiments, the IC50 of the subject compounds (including those shown in Table 1) against SOS proteins is less than about 5 μM, less than about 1 μM, less than about 50 nM, less than about 10 nM, less than about 1 nM, less than about 0.5 nM, less than about 100 pM, or less than about 50 pM, as measured in in vitro assays known in the art or exemplified herein.

[0156] A reduction in Ras signaling output may be demonstrated by one or more of the following: (i) an increase in the steady-state level of GDP-bound Ras protein, (ii) a decrease in the steady-state level of GTP-bound Ras protein, (iii) a decrease in phosphorylated AKTs473, (iv) a decrease in phosphorylated ERKT202 / y204, (v) a decrease in phosphorylated S6S235 / 236, (vi) a decrease (e.g., inhibition) in the proliferation of Ras-driven tumor cells (e.g., those derived from the tumor cell lines disclosed herein), or (vii) interference with or disruption of the interaction or binding between SOS protein (e.g., SOS1) and Ras protein, e.g., wild-type or mutant Ras. In some cases, a reduction in Ras signaling output may be demonstrated by two, three, four, five, six, or all of the above (i) to (vii).

[0157] It should be understood that different aspects of the present invention may be evaluated individually, collectively, or in combination with one another. The various aspects of the present invention described herein may be applied to any of the specific uses disclosed herein. In the Compositions section of this disclosure, a composition of substances including a compound of any formula disclosed herein may be used in the Methods section, including the Use and Production Methods disclosed herein, and vice versa.

[0158] method In certain embodiments, the Disclosure provides a method for treating cancer in a subject requiring treatment, comprising administering to the subject a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof. In some embodiments, the cancer is a solid tumor or a hematological cancer. In some embodiments, the subject is administered additional drugs or additional therapies.

[0159] In certain embodiments, the Disclosure provides a method for reducing Ras signal output, comprising contacting the SOS1 protein with an effective amount of a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, thereby reducing the Ras signal output. In some embodiments, the compound disrupts the interaction between the Ras protein and SOS1. In some embodiments, the Ras protein is wild-type K-Ras or mutant K-Ras.

[0160] In certain embodiments, the present disclosure provides a method for inhibiting cell proliferation, comprising administering an effective amount of one of the compounds described herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, to cells expressing SOS1, thereby inhibiting the proliferation of said cells.

[0161] In certain embodiments, the present disclosure provides a method for reducing the Ras signaling output of cells, the method comprising contacting cells with an effective amount of compound formula (I), or a pharmaceutically acceptable salt or solvate thereof, in combination with an additional agent, the additional agent being a chemotherapeutic agent, a radiopharmaceutical, an immunomodulator, or one or more targets selected from the following groups: MEK, epidermal growth factor receptor (EGFR), FGFR1, FGFR2, FGFR3, FGFR4, mitotic kinase, topoisomerase These include ALK, c-MET, ErbB2, AXL, NTRK1, RET, A-Raf, B-Raf, C-Raf, ERK, MDM2, mTOR, BET, IGF1 / 2, IGF1-R, CDK9, SHC, GAB, GRB, PI3 kinase, MAPK, SHIP1, SHIP2, SHP1, SHP2, SRC, JAK, PARP, BTK, FLT3, HDAC, VEGFR, PDGFR, LCK, Bcr-Abl, AKT, wild-type KRas, KRas variants (e.g., KrasG12C, KRas G12D, KRas G12S, KRas G12V, KRas G13D, KRas G13C, or KRas G13V), ROS1, CDK4 / 6, and inhibitors of one or more of their targets.

[0162] In some embodiments, the additional agent is an inhibitor of one or more targets selected from MEK, epidermal growth factor receptor (EGFR), A-Raf, B-Raf, C-Raf, ErbB2 (Her2), SHP2, wild-type KRas, KRas variants, and CDK4 / 6. In some embodiments, the additional agent is a chemotherapeutic agent, a radiopharmaceutical, or an immunomodulator.

[0163] In certain embodiments, the Disclosure provides an SOS1 protein conjugated with a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, wherein the interaction between the SOS1 protein and the Ras protein is reduced compared to an SOS1 protein not conjugated with the compound.

[0164] In certain embodiments, the Disclosure provides a method for treating cancer in a subject requiring treatment, the method comprising administering a therapeutically effective amount of a compound of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), or a pharmaceutically acceptable salt or solvate thereof, to the subject. In some embodiments, the cancer is a solid tumor, or a hematological cancer, e.g., a solid tumor. In some embodiments, cancer includes prostate cancer, brain tumors, colon cancer, rectal cancer, renal cell carcinoma, liver cancer, lung cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin lymphoma, and endocrine system cancer. The following are selected from cancers of the thyroid gland, parathyroid gland, adrenal gland, soft tissue sarcoma, urethral cancer, penile cancer, solid tumors in childhood, bladder cancer, kidney or ureteral cancer, renal pelvis cancer, neoplasms of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axial tumor, brainstem glioma, pituitary adenoma, Kaposi's sarcoma, epidermal carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancer, combinations of the said cancers, and metastatic lesions of the said cancers. In some embodiments, cancer is a hematological cancer such as chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphoblastic leukemia (ALL), B-cell acute lymphoblastic leukemia (B-ALL), T-cell acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), B-cell prelymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell follicular lymphoma or large cell follicular lymphoma, malignant lymphoproliferative state, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenström macroglobulinemia, or preleukemia.In some embodiments, the cancer is one or more cancers selected from chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (T-ALL), B-cell acute lymphoblastic leukemia (B-ALL), and acute lymphoblastic leukemia (ALL).

[0165] Any of the therapies disclosed herein may be administered alone, in combination with another therapy or another agent, or in combination with another agent. "Combination" means (a) formulating a subject composition containing the subject compound together with another agent, and (b) using the subject composition separately from the other agent as an overall therapeutic regimen. "In combination" means that another therapy or agent is administered with the subject composition containing the compound disclosed herein, either concurrently, in parallel, or sequentially, without any specific time limitation, and such combination administration results in a therapeutic effect.

[0166] In some embodiments, the treatment method of the subject is combined with surgery, cell therapy, chemotherapy, radiation, and / or immunosuppressants. Furthermore, the compositions of the present disclosure may be combined with other therapeutic agents, such as other anticancer agents, anti-allergic agents, anti-nausea agents (or antiemetic agents), analgesics, cytoprotective agents, immunostimulants, and combinations thereof. In some embodiments, the treatment method of the subject is combined with chemotherapeutic agents.

[0167] Examples of chemotherapeutic agents include anthracyclines (e.g., doxorubicin (e.g., liposomal doxorubicin)), vinca alkaloids (e.g., vinblastine, vincristine, vindesine, vinorelbine), alkylating agents (e.g., cyclophosphamide, decarbazine, melphalan, ifosfamide, temozolomide), immune cell antibodies (e.g., alemtuzamab, gemtuzumab, rituximab, ofatumumab, tositumomab, brentuximab), and antimetabolites. Examples of immunomodulators include substances (e.g., folate antagonists, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors (e.g., fludarabine)), TNFR glucocorticoid-inducible TNFR-related protein (GITR) agonists, proteasome inhibitors (e.g., acrasinomycin A, gliotoxin, or bortezomib), thalidomide, or thalidomide derivatives (e.g., lenalidomide). Additional chemotherapeutic agents intended for use in combination include busulfan (Myleran®), busulfan injection (Busulfex®), cladribine (Leustatin®), cyclophosphamide (Cytoxan® or Neosar®), cytarabine, cytosine arabinoside (Cytosar-U®), cytarabine liposomal injection (DepoCyt®), daunorubicin hydrochloride (Cerubidine®), daunorubicin crate liposomal injection (DaunoXome®), dexamethasone, and doxorubicin hydrochloride. Salts (Adriamycin®, Rubex®), etoposide (Vepesid®), fludarabine phosphate (Fludara®), hydroxyurea (Hydrea®), idarubicin (Idamycin®), mitoxantrone (Novantrone®), gemtuzumab ozogamicin (Mylotarg®), anastrozole (Arimidex®), bicalutamide (Casodex®), bleomycin sulfate (Blenoxane®), busulfan injection (Busulfex®),Capecitabine (Xeloda®), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (Paraplatin®), carmustine (BiCNU®), chlorambucil (Leukeran®), cisplatin (Platinol®), dacarbazine (DTIC-Dome®), dactinomycin (Actinomycin) D, Cosmegan), Dexamethasone, Docetaxel (Taxotere®), 5-Fluorouracil (Adrucil®, Efudex®), Flutamide (Eulexin®), Tezacitibin, Gemcitabine (Difluorodeoxycytidine), Ifosfamide (IFEX®), Irinotecan (Camptosar®), L-Asparaginase (ELSPAR®), Leucovorin Calcium, Melphalan (Alkeran®), 6-Mercaptopurine (Purinethol®), Methotrexate (Folex®), Mitoxantrone (Novantro Examples include ne(registered trademark), Mylotarg, paclitaxel (Taxol(registered trademark)), Phoenix (Yttrium90 / MX-DTPA), pentostatin, polyfeprosan 20 and carmustine implant (Gliadel(registered trademark)), tamoxifen citrate (Nolvadex(registered trademark)), teniposide (Vumon(registered trademark)), 6-thioguanine, thiotepa, tirapazamine (Tirazone(registered trademark)), topotecan hydrochloride for injection (Hycamptin(registered trademark)), vinblastine (Velban(registered trademark)), vincristine (Oncovin(registered trademark)), and vinorelbine (Navelbine(registered trademark)).

[0168] Anticancer agents of particular interest in combination with the compounds of this disclosure include anthracyclines; alkylating agents; antimetabolites; drugs that inhibit either the calcium-dependent phosphatase calcineurin or the p70S6 kinase FK506, or drugs that inhibit p70S6 kinase; mTOR inhibitors; immunomodulators; vinca alkaloids; proteosome inhibitors; GITR agonists; protein tyrosine phosphatase inhibitors; CDK4 kinase inhibitors; BTK inhibitors; MKN kinase inhibitors; DGK kinase inhibitors; or oncolytic viruses.

[0169] Examples of antimetabolites include, but are not limited to, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors: methotrexate (Rheumatrex®, Trexall®), 5-fluorouracil (Adrucil®, Efudex®, Fluoroplex®), phloxuridine (FUDF®), cytarabine (Cytosar-U®, Tarabine PFS), 6-mercaptopurine (Puri-Nethol®), and 6-thioguanine. Examples include Tabloid®, fludarabine phosphate (Fludara®), pentostatin (Nipent®), pemetrexed (Alimta®), larcitrexed (Tomudex®), cladribine (Leustatin®), clofarex®, Clolar®, azacitidine (Vidaza®), decitabine, and gemcitabine (Gemzar®). Preferred antimetabolites include cytarabine, clofarex, and fludarabine.

[0170] Examples of alkylating agents include, but are not limited to, nitrogen mustards, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas, and triazenes: uracil mustard (aminouracil Mustard®, Chlorethaminacil®, Demethyldopan®, Desmethyldopan®, Haemanthamine®, Nordopan®), and uracil nitrogen mustard (Uracil nitrogen). Mustard (registered trademark), Uracillost (registered trademark), Uracilmostaza (registered trademark), Uramustin (registered trademark), Uramustine (registered trademark), Chlormetine (Mustargen (registered trademark)), Cyclophosphamide (Cytoxan (registered trademark), Neosar (registered trademark), Clafen (registered trademark), Endoxan (registered trademark), Procytox (registered trademark), Revimmune (trademark)), Ifosfamide (Mitoxana (registered trademark)), Melphalan (Alkeran (registered trademark)), Chlorambucil (Leukeran (registered trademark)), Pipobroman (Amedel (Am edel(registered trademark)), Vercyte(registered trademark)), triethylenemelamine (Hemel(registered trademark), Hexalen(registered trademark), Hexastat(registered trademark)), triethylenethiophosphoramine, temozolomide (Temodar(registered trademark)), thiotepa (Thioplex(registered trademark)), busulfan (Busilvex(registered trademark), Myleran(registered trademark)), carmustine (BiCNU(registered trademark)), lomustine (CeeNU(registered trademark)), streptozosin (Zanosar(registered trademark)), and dacarbazine (DTIC-Dome(registered trademark)).Further exemplary alkylating agents include, but are not limited to, oxaliplatin (Eloxatin®); temozolomide (Temodar® and Temodal®); dactinomycin (also known as actinomycin-D, Cosmegen®); melphalan (also known as L-PAM, L-sarcolicin, and phenylalanine mustard, Alkeran®); altoretamine (also known as hexamethylmelamine (HMM), Hexalen®); carmustine (BiCNU®); bendamustine (Treanda®); busulfan (Busulfex® and Myleran®); carboplatin (Paraplatin®); lomustine (also known as CCNU, CeeNU®); cisplatin (also known as CDDP, Platinol® and Platinol®-AQ); and chlorambucil (Leukeran®). (Registered Trademark)); Cyclophosphamide (Cytoxan® and Neosar®); Dacarbazine (also known as DTIC, DIC and imidazole carboxamide, DTIC-Dome®); Altretamine (also known as hexamethylmelamine (HMM), Hexalen®); Ifosfamide (Ifex®); Prednummustine; Procarbazine (Matulane®); Mechloretamine (Nitrogen Mustard, Mustine and Examples include Mustargen® (also known as mechloroetamine hydrochloride); streptozocin (Zanosar®); thiotepa (also known as thiophosphoamide, TESPA and TSPA, Thioplex®); cyclophosphamide (Endoxan®, Cytoxan®, Neosar®, Procytox®, Revimmune®); and bendamustine HCl (Treanda®).

[0171] In some embodiments, the compositions provided herein may be administered in combination with radiotherapy, such as radiation. Whole-body irradiation may be administered at 12 Gy. The radiation dose may include a cumulative dose of 12 Gy to the whole body, including healthy tissue. The radiation dose may include 5 Gy to 20 Gy. The radiation dose may be 5 Gy, 6 Gy, 7 Gy, 8 Gy, 9 Gy, 10 Gy, 11 Gy, 12 Gy, 13 Gy, 14 Gy, 15 Gy, 16 Gy, 17 Gy, 18 Gy, 19 Gy, or up to 20 Gy. The radiation may be whole-body radiation or partial radiation. If the radiation is whole-body radiation, the radiation may be uniform or non-uniform. For example, if the radiation is non-uniform, a small area of ​​the body, such as the neck, may receive a higher dose than a larger area, such as the waist.

[0172] Where desired, immunosuppressants may be used in combination with the treatment methods of the subject matter. Exemplary immunosuppressants include, but are not limited to, cyclosporine, azathioprine, methotrexate, mycophenolate, and FK506, antibodies such as CAMPATH, anti-CD3 antibodies (e.g., muromonab, otelixizumab), or other immunoablative agents, or other antibody therapies, cytoxin, fludarabine, cyclosporine, FK506, rapamycin, mycophenolic acid, steroids, FR901228, cytokines, and radiation, peptide vaccines, and any combination thereof. In accordance with the subject matter of this disclosure, the various methods described above may include the administration of at least one immunomodulatory agent. In certain embodiments, at least one immunomodulator is selected from the group consisting of immunostimulants, checkpoint immunoblockers (e.g., blockers or inhibitors of immune checkpoint genes such as PD-1, PD-L1, CTLA-4, IDO, TIM3, LAG3, TIGIT, BTLA, VISTA, ICOS, KIRs, and CD39), radiotherapy agents, chemotherapeutic agents, and combinations thereof. In some embodiments, the immunostimulant is selected from the group consisting of IL-12, agonist-costimulated monoclonal antibodies, and combinations thereof. In one embodiment, the immunostimulant is IL-12. In some embodiments, the agonist-costimulatory monoclonal antibody is selected from the group consisting of anti-4-1BB antibodies (e.g., urelumab, PF-05082566), anti-OX40 antibodies (pogalizumab, tavorixizumab, PF-04518600), anti-ICOS antibodies (BMS986226, MEDI-570, GSK3359609, JTX-2011), and combinations thereof. In one embodiment, the agonist-costimulatory monoclonal antibody is an anti-4-1BB antibody.In some embodiments, the checkpoint immunoblocker is selected from the group consisting of anti-PD-L1 antibodies (atezolizumab, avelumab, durvalumab, BMS-936559), anti-CTLA-4 antibodies (e.g., tremelimumab, ipilimumab), anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab), anti-LAG3 antibodies (e.g., C9B7W, 410C9), anti-B7-H3 antibodies (e.g., DS-5573a), anti-TIM3 antibodies (e.g., F38-2E2), and combinations thereof. In one embodiment, the checkpoint immunoblocker is an anti-PD-L1 antibody. In some cases, the compounds of this disclosure may be administered to a subject in combination with (e.g., before, concurrently with, or after) bone marrow transplantation, chemotherapeutic agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide, or T-cell depletion therapy using antibodies such as OKT3 or CAMPATH. In some cases, the proliferated cells may be administered before or after surgery. Alternatively, a composition containing the compounds described herein may be administered together with an immunostimulant. The immunostimulant may be a vaccine, colony stimulant, interferon, interleukin, virus, antigen, costimulator, immunogenicity agent, immunomodulator, or immunotherapy agent. The immunostimulant may be a cytokine, such as an interleukin. One or more cytokines may even be introduced using the modified cells provided herein. Cytokines can be used to enhance the function of modified T lymphocytes (including adoptively transferred tumor-specific cytotoxic T lymphocytes) and enable them to proliferate within the tumor microenvironment. In some cases, IL-2 may be used to promote the proliferation of the modified cells described herein. Cytokines such as IL-15 may also be employed. Other relevant cytokines in the field of immunotherapy, such as IL-2, IL-7, IL-12, IL-15, IL-21, or combinations thereof, may also be utilized. The interleukin may be IL-2 or aldesleukin. Aldesleukin can be administered in low or high doses. High-dose aldesleukin regimens may involve intravenous administration of aldesleukin at approximately 0.037 mg / kg (600,000 IU / kg) every 8 hours for up to approximately 14 doses, depending on tolerability.Immunostimulants (e.g., aldesleukin) may be administered within 24 hours of cell administration. Immunostimulants (e.g., aldesleukin) may be administered approximately every 8 hours as an infusion lasting approximately 15 minutes for up to approximately 4 days after cell infusion. Immunostimulants (e.g., aldesleukin) may be administered in doses of approximately 100,000 IU / kg, 200,000 IU / kg, 300,000 IU / kg, 400,000 IU / kg, 500,000 IU / kg, 600,000 IU / kg, 700,000 IU / kg, 800,000 IU / kg, 900,000 IU / kg, or up to approximately 1,000,000 IU / kg. In some cases, aldesleukin may be administered in doses of approximately 100,000 IU / kg to 300,000 IU / kg, 300,000 IU / kg to 500,000 IU / kg, 500,000 IU / kg to 700,000 IU / kg, and 700,000 IU / kg to approximately 1,000,000 IU / kg.

[0173] In some embodiments, compounds disclosed herein that can modulate the SOS protein (e.g., SOS1) to reduce Ras signaling output may be administered in combination with, or in conjunction with, one or more pharmacological agents, including, but not limited to, the following: (1) MEK inhibitors (e.g., MEK1, MEK2) or their variants (e.g., trametinib, cobimetinib, binimetinib, selumetinib, refametinib, AZD6244); (2) Epidermal growth factor receptor (EGFR) inhibitors and / or their variants (e.g., afatinib, erlotinib, gefitinib, lapatinib, cetuk (1) Simab panitumumab, osimertinib, olmutinib, EGF-816; (2) Immunotherapy agents (e.g., checkpoint immunoblockers as disclosed herein); (3) Taxanes (e.g., paclitaxel, docetaxel); (4) Antimetabolites (e.g., antifolates such as methotrexate, pyrimidine analogs such as larcitrexed, 5-fluorouracil (5-FU), ribonucleosides, and deoxyribonucleoside analogs, capecitabine, and gemcitabine, purines such as mercaptopurine, and adenosine analogs, thioguanine, cladribine, and pentostatin, cytarabine (ara) C) Fludarabine); (6) Inhibitors of FGFR1 and / or FGFR2 and / or FGFR3, and / or their variants (e.g., nintedanib); (7) Mitotic kinase inhibitors (e.g., CDK4 / 6 inhibitors, e.g., palbociclib, ribociclib, abemaciclib); (8) Anti-angiogenic drugs (e.g., anti-VEGF antibodies, e.g., bevacizumab); (9) Topoisomerase inhibitors (e.g., etoposide, etopophos, etc.); (10) Platinum-containing compounds (e.g., cisplatin, oxaliplatin, carboplatin); (11) Inhibitors of ALK and / or their variants (e.g., crizotinib, alectinib, entrectinib, brigatinib); (12) Inhibitors of c-MET and / or their variants (e.g., K252a, SU11274, PHA665752, PF2341066);(13) Inhibitors of BCR-ABL and / or their variants (e.g., imatinib, dasatinib, nilotinib); (14) Inhibitors of ErbB2 (Her2) and / or their variants (e.g., afatinib, lapatinib, trastuzumab, pertuzumab); (15) Inhibitors of AXL and / or their variants (e.g., R428, amvatinib, XL-880); (16) Inhibitors of NTRK1 and / or their variants (e.g., meresteinib); (17) Inhibitors of RET and / or their variants (e.g., BLU-667, lenvatinib); (18) Inhibitors of A-Raf and B-Raf (e.g., sorafenib, vemurafenib, debrafenib, encorafenib), and / or inhibitors of C-Raf, and / or their variants (RAF-709, LY-3009120); (19) Inhibitors of ERK, and / or their variants (e.g., urixertinib); (20) MDM2 inhibitors (e.g., HDM-201, NVP-CGM097, RG-71 12, MK-8242, RG-7388, SAR405838, AMG-232, DS-3032, RG-7775, APG-115); (21) Inhibitors of mTOR (e.g., rapamycin, temsirolimus, everolimus, ridafololimus); (22) Inhibitors of BET (e.g., I-BET 151, I-BET 762, OTX-015, TEN-010, CPI-203, CPI-0610, Olionon, RVX-208, ABBC-744, LY294002, AZD5153, MT-1, MS645); (23) Inhibitors of IGF1 / 2 and / or IGF1-R (e.g., Zentuzumab, MEDI-573); (24) Inhibitors of CDK9 (e.g., DRB, Flavopyridol, CR8, AZD 5438, Purvalanol B) B) AT7519, dinaciclib, SNS-032; (25) Farnesyltransferase inhibitors (e.g., tipifarnib); (26) SHIP pathway inhibitors, including SHIP2 inhibitors (e.g., 6-(4-amino-4-methylpiperidine-1-yl)-3-(2,3-dichlorophenyl)pyrazine-2-amine), and SHIP1 inhibitors; (27) SRC inhibitors (e.g., dasatinib);(28) JAK inhibitors (e.g., tofacitinib); (29) PARP inhibitors (e.g., olaparib, lucaparib, niraparib, talazoparib); (30) BTK inhibitors (e.g., ibrutinib, acalabrutinib, zanubrutinib); (31) ROS1 inhibitors (e.g., entrectinib); (32) FLT3 HDAC, VEGFR, PDGFR, LCK, Bcr-Abl or AKT inhibitors;(33) Inhibitors of Kras12C mutants (including, but not limited to, AMG510, MRTX849, and any covalent inhibitors that bind to cysteine ​​residue 12 of Kras; the structures of these compounds are publicly known) (e.g., US2018 / 0334454, US2019 / 0144444, US2015 / 0239900, US10246424, US2018 / 0086753, WO2018 / 143315, WO201 8 / 206539, WO2019 / 1107519, WO2019 / 141250, WO2019 / 150305, US9862701, US2017 / 0197945, US2018 / 0086753, US1014 4724, US2019 / 0055211, US2019 / 0092767, US2018 / 0127396, US2018 / 0273523, US10280172, US2018 / 0319775, US2018 / 0 273515, US2018 / 0282307, US2018 / 0282308, WO2019 / 051291, WO2019 / 213526, WO2019 / 213516, WO2019 / 217691, WO201 9 / 241157, WO2019 / 217307, WO2020 / 047192, WO2017 / 087528, WO2018 / 218070, WO2018 / 218069, WO2018 / 218071, WO2020 Ras as described in / 027083, WO2020 / 027084, WO2019 / 215203, WO2019 / 155399, WO2020 / 035031, WO2014 / 160200, WO2018 / 195349, WO2018 / 112240, WO2019 / 204442, WO2019 / 204449, WO2019 / 104505, WO2016 / 179558, WO2016 / 176338, or related patents and applications. G12C inhibitors; each of these is incorporated into the whole by reference; (34) SHC inhibitors (e.g., PP2, AID371185); (35) GAB inhibitors (e.g., GAB-0001); (36) GRB inhibitors; (37) PI-3 kinase inhibitors (e.g., idelalisib, copanlisib, duvelisib, alpelisib, taselicib, perifosin, buparlisib, umbralisib, NVP-BEZ235-AN); (38) MARPK inhibitors;(39) CDK4 / 6 (e.g., palbociclib, ribociclib, abemaciclib); (40) MAPK inhibitors (e.g., VX-745, VX-702, RO-4402257, SCIO-469, BIRB-796, SD-0006, PH-797804, AMG-548, LY2228820, SB-681323, GW-856553, RWJ67657, BCT-197); (41) SHP pathway inhibitors, SHP2 inhibitors (e.g., 6-(4-amino-4-methylpiperidine-1-yl)-3-(2,3-dichlorophenyl)pyrazine-2-amine, RMC-4630, ERAS-601, ; [ka] ), and SHP1 inhibitors; or (42) inhibitors of wild-type KRas or Kras variants (e.g., compounds described in WO2021 / 041671, including Kras G12D, KRas G12C, KRas G12D, KRas G12S, KRas G12V, KRas G13D, KRas G13C, or KRas G13V), e.g., LY3537982, JAB-21822, BBO-8520, D-1553, BI-1823911, RMC-9805, [ka] In some embodiments, KRAS, or mutant KRAS inhibitors, are compounds disclosed in WO2021 / 041671, WO2023 / 004102, WO2022 / 223037, WO2023 / 041059, WO2021 / 118877, WO2020 / 233592, WO2021 / 091967, WO2021 / 091982, WO2021 / 091956, WO2022 / 060836, or related patents and applications, each of which is incorporated in whole by reference. Inhibitors of any of the exemplary targets are applicable to the corresponding mutant targets having one or more mutations in them. In some embodiments, the compounds disclosed herein can inhibit the SOS protein (e.g., SOS1) to reduce Ras signaling output. These compounds may be administered in combination with, or in conjunction with, one or more checkpoint immunoblockers (e.g., anti-PD-1, and / or anti-PD-L1 antibodies, anti-CLTA-4 antibodies).

[0174] In combination therapy, the compounds provided herein and other anticancer agents may be administered simultaneously, in parallel, or sequentially without any specific time constraints, thereby delivering therapeutically effective levels of both compounds into the patient's body. In some embodiments, the compounds of this disclosure and other anticancer agents are generally administered sequentially by infusion or orally in any order. The administration regimen may vary depending on the stage of the disease, the patient's physical condition, the safety profiles of the individual agents, the tolerance of the individual agents, and other criteria known to the attending physician and physician(s) administering the combination therapy. The compounds of the present invention and other anticancer agents may be administered within minutes, hours, days, or weeks of each other, depending on the specific cycle used for treatment. In addition, this cycle may include administering one drug more frequently than the other during the treatment cycle, or administering different doses of the drugs with each administration.

[0175] Antibiotics may be administered to a patient as part of a treatment regimen. Antibiotics may be administered at a therapeutically effective dose. Antibiotics may kill bacteria or inhibit their growth. Antibiotics may be broad-spectrum antibiotics that can target a wide range of bacteria. Third-generation or fourth-generation broad-spectrum antibiotics may be cephalosporins or quinolones. Antibiotics may also be narrow-spectrum antibiotics that can target specific types of bacteria. Antibiotics such as penicillin and cephalosporins may target the bacterial cell wall. Antibiotics such as polymyxin may target the cell membrane. Antibiotics such as rifamycin, ripialmycin, quinolones, and sulfonamides may interfere with essential bacterial enzymes. Antibiotics may also be protein synthesis inhibitors, such as macrolides, lincosamides, and tetracyclines. Antibiotics can also be cyclic lipopeptides such as daptomycin, glycylcyclines such as tigecycline, oxazolidiones such as linezolid, and ripialmycins such as fidaxomicin. In some cases, antibiotics can be first-generation, second-generation, third-generation, fourth-generation, or fifth-generation. First-generation antibiotics can be narrow-spectrum. Examples of first-generation antibiotics may be penicillin (penicillin G or penicillin V) and cephalosporins (cefazolin, cephalothin, cefapillin, cephalethin, cefradin, or cephadroxin). In some cases, antibiotics can be second-generation. Second-generation antibiotics may include penicillins (amoxicillin or ampicillin) and cephalosporins (cefuroxime, cephamandol, cefoxitin, cefaclor, cefurosil, and loracalbef). In some cases, antibiotics may be third-generation. Third-generation antibiotics may include penicillins (carbenicillin and ticarcillin) or cephalosporins (cephixime, ceftriaxone, cefotaxime, ceftizoxime, and cephtazidime). Antibiotics may also be fourth-generation antibiotics.A fourth-generation antibiotic may be cephipime. Antibiotics may also be fifth-generation. A fifth-generation antibiotic may be cephtaroline or cephtobiprole.

[0176] In some cases, antiviral agents may be administered as part of a treatment regimen. In some cases, herpesvirus prophylaxis may be administered to patients as part of a treatment regimen. Herpesvirus prophylaxis may be valacyclovir (Valtrex). Valtrex may be used orally to prevent the development of herpesvirus infections in patients who test positive for HSV serologically. It may be supplied in 500 mg tablets. Valacyclovir may be administered in a therapeutically effective dose.

[0177] In some cases, treatment regimens may be administered according to the subject's weight. For subjects determined to be obese (BMI > 35), actual weight may need to be used. BMI is calculated as: BMI = weight (kg) / [height (m)] 2 It is calculated as follows: Weight can be calculated as 50 kg + 2.3 × (number of inches greater than 60 inches) for men, or 45.5 kg + 2.3 × (number of inches greater than 60 inches) for women. For subjects whose weight exceeds 20% of their ideal weight, an adjusted weight can be calculated. The adjusted weight can be the sum of ideal weight + (0.4 × (actual weight - ideal weight)). In some cases, body surface area can be used to calculate the dosage. Body surface area (BSA) can be calculated as BSA(m2) = √height(cm) × weight(kg) / 3600.

[0178] In some embodiments, the Disclosure provides a method for reducing Ras signaling output, comprising contacting an SOS protein (e.g., SOS1) with an effective amount of a compound of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), or a pharmaceutically acceptable salt or solvate thereof, thereby reducing Ras signaling output. In some embodiments, the compound inhibits SOS1 protein activity or disrupts the interaction or binding between the SOS1 protein and the Ras protein. In some embodiments, compounds of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A) inhibit SOS1 or disrupt the interaction or binding between SOS1 and one or more K-Ras proteins, including wild-type and any of its variants, such as the K-Ras G12D variant or the K-Ras G12V variant.

[0179] In some embodiments, the Disclosure provides a method for reducing Ras signaling output in cells by contacting the cells with the compounds described herein. Reduction of Ras signaling may be demonstrated by one or more of the following: (i) an increase in the steady-state level of GDP-bound Ras protein; (ii) a decrease in the steady-state level of GTP-bound Ras protein; (iii) a decrease in phosphorylated AKTs473; (iv) a decrease in phosphorylated ERKT202 / y204; (v) a decrease in phosphorylated S6S235 / 236; (vi) a decrease (e.g., inhibition) of cell proliferation of Ras-driven tumor cells (e.g., those derived from the tumor cell lines disclosed herein); (vii) interference with or disruption of the interaction or binding between SOS protein (e.g., SOS1) and Ras protein, e.g., wild-type or mutant Ras. In some cases, reduction of Ras signaling output may be demonstrated by two, three, four, five, six, or all of the above (i) to (vii). In some embodiments, one or more of (i) to (vii) represent a reduction of 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, and 0.0 compared to a control not treated with the subject compound.The increase can be 9x, 1x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 20x, 30x, 40x, 50x, 60x, 70x, 80x, 90x, 100x, 200x, 300x, 400x, 500x, 600x, 700x, 800x, 900x, 1000x, 2000x, 3000x, 4000x, 5000x, or more. Reduced cell proliferation can be demonstrated by the use of tumor cells or cell lines. Tumor cell lines may originate from tumors of one or more tissues, such as the pancreas, lungs, ovaries, biliary tract, intestines (e.g., small intestine, large intestine, colon), endometrium, stomach, hematopoietic tissue (e.g., lymphoid tissue). Examples of tumor cell lines containing K-Ras mutations include, but are not limited to, A549 (e.g., K-Ras G12S), AGS (e.g., K-Ras G12D), ASPC1 (e.g., K-Ras G12D), Calu-6 (e.g., K-Ras Q61K), CFPAC-1 (e.g., K-Ras G12V), CL40 (e.g., K-Ras G12D), COLO678 (e.g., K-Ras G12D), COR-L23 (e.g., K-Ras G12V), DAN-G (e.g., K-Ras G12V), GP2D (e.g., K-Ras G12D), GSU ​​(e.g., K-Ras G12F), HCT116 (e.g., K-Ras G13D), HEC1A (e.g., K-Ras G12D), HEC1B (e.g., K-Ras G12F), HEC50B (e.g., K-Ras G12F), HEYA8 (e.g., K-Ras G12D or G13D), HPAC (e.g., K-Ras G12D), HPAFII (e.g., K-Ras G12D), HUCCT1 (e.g., K-Ras G12D), KARPAS620 (e.g., K-Ras G13D), KOPN8 (e.g., K-Ras G13D), KP-3 (e.g., K-Ras G12V), KP-4 (e.g., K-Ras G12D), L3.3 (e.g., K-Ras G12D), LoVo (e.g., K-Ras G13D), LS180 (e.g., K-Ras G12D), LS513 (e.g., K-Ras G12D), MCAS (e.g., K-Ras G12D), NB4 (e.g., K-Ras A18D), NCI-H1355 (e.g., K-Ras G13C), NCI-H1573 (e.g., K-Ras G12A), NCI-H1944 (e.g., K-Ras G13D), NCI-H2009 (e.g., K-Ras G12A), NCI-H441 (e.g., K-Ras G12V), NCI-H747 (e.g., K-Ras G13D), NOMO-1 (e.g., K-Ras G12D), OV7 (e.g., K-Ras G12D), PANC0203 (e.g., K-Ras G12D), PANC0403 (e.g., K-Ras G12D), PANC0504 (e.g., K-Ras G12D), PANC0813 (e.g., K-Ras G12D), PANC1 (e.g., K-Ras G12D), Panc-10.05 (e.g., K-Ras G12D), PaTu-8902 (e.g., K-Ras G12V), PK1 (e.g., K-Ras G12D), PK45H (e.g., K-Ras G12D), PK59 (e.g., K-Ras G12D), SK-CO-1 (e.g., K-Ras G12V), SKLU1 (e.g., K-Ras G12D), SKM-1 (e.g., K-Ras K117N), SNU1 (e.g., K-Ras G12D), SNU1033 (e.g., K-Ras G12D), SNU1197 (e.g., K-Ras G12D), SNU407 (e.g., K-Ras G12D), SNU410 (e.g., K-Ras G12D), SNU601 (e.g., K-Ras G12D), SNU61 (e.g., K-Ras G12D), SNU8 (e.g., K-Ras G12D), SNU869 (e.g., K-Ras G12D), SNU-C2A (e.g., K-Ras G12D), SU.86.Examples include 86 (e.g., K-Ras G12D), SUIT2 (e.g., K-Ras G12D), SW1990 (e.g., K-Ras G12D), SW403 (e.g., K-Ras G12V), SW480 (e.g., K-Ras G12V), SW620 (e.g., K-Ras G12V), SW948 (e.g., K-Ras Q61L), T3M10 (e.g., K-Ras G12D), TCC-PAN2 (e.g., K-Ras G12R), TGBC11TKB (e.g., K-Ras G12D), and MIA Pa-Ca (e.g., MIA Pa-Ca 2 (e.g., K-Ras G12C)).

[0180] In some embodiments, the Disclosure provides an SOS protein (e.g., SOS1) conjugated with a compound of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the interaction between the SOS1 protein and the Ras protein is reduced compared to an SOS1 protein not conjugated with the compound.

[0181] Pharmaceutical composition and method of administration In certain embodiments, the Disclosure provides a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0182] Compounds of formulas (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), or their pharmaceutically acceptable salts or solvates, may be administered to subjects in a biocompatible form suitable for administration to treat or prevent a disease, disorder, or condition. The compounds described herein may be administered in any pharmacological form, comprising a therapeutically effective amount of a compound of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), or a pharmaceutically acceptable salt or solvate thereof, alone or in combination with a pharmaceutically acceptable carrier. In some embodiments, the Disclosure provides pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound of formula (I), (I-A1), (I-A2), (I-B1), (I-B2), (I-C1), (I-C2), (I-C3), (I-C4), (I-E1), (I-E2), (I-E3), (I-E4), (II), (II-A), (III), or (III-A), or a pharmaceutically acceptable salt or solvate thereof.

[0183] In some embodiments, the compounds described herein are administered as pure chemical substances. In some embodiments, the compounds described herein are combined with a pharmaceutically suitable or acceptable carrier (also referred to as a pharmaceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier) selected based on a selected route of administration and standard pharmaceutical practice as described, for example, Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)).

[0184] Accordingly, pharmaceutical compositions are provided herein, comprising at least one compound or pharmaceutically acceptable salt described herein, together with one or more pharmaceutically acceptable excipients. Excipients (or carriers) are acceptable or preferred if they are compatible with the other components of the composition and are not harmful to the recipient of the composition.

[0185] When practicing any of the subject methods, the compounds described herein may be administered alone or in combination with pharmaceutically acceptable carriers, excipients, or diluents in a pharmaceutical composition. The administration of the compounds and compositions described herein may be influenced by any method that enables the delivery of the compound to the site of action. These methods include, but are not limited to, enteral routes (including oral, gastric, or duodenal feeding tubes, rectal suppositories, and rectal enemas), parenteral routes (including intra-arterial, intracardiac, intradermal, intraduodenal, intramedullary, intramuscular, intraosseous, intraperitoneal, subarachnoid, intravascular, intravenous, intravitreous, epidural, and subcutaneous injections or infusions), inhalation, percutaneous, transmucosal, sublingual, buccal, and topical (including skin, cutaneous, enema, eye drops, ear drops, intranasal, and vaginal) administration, but the most preferred route may depend, for example, on the recipient's condition and impairments. As just one example, the compounds described herein may be administered topically to the site of treatment, for example, by local injection during surgery, topical application such as creams or ointments, injection, catheter, or implant. Administration may also be by direct injection into the site of diseased tissue or organ. In some embodiments, the compounds described herein are administered orally.

[0186] When practicing any of the methods of the subject, pharmaceutical compositions suitable for oral administration may be provided as individual units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient, as a powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion. In some embodiments, the active ingredient is provided as a bolus, electrolyte, or paste.

[0187] Pharmaceutical compositions for oral use may include tablets, gelatin push-fit capsules, and flexible encapsulated capsules made of gelatin and a plasticizer such as glycerin or sorbitol. Tablets may optionally be prepared by compression or molding with one or more adjuncts. Compressed tablets may optionally be prepared by compressing a free-flowing active ingredient, such as a powder or granules, mixed with a binder, inert diluent, or lubricant, surface-active, or dispersant, using a suitable machine. Molded tablets may be prepared by molding a mixture of powder compounds moistened with an inert liquid diluent using a suitable machine. In some embodiments, tablets are coated or divided to provide delayed or controlled release of the active ingredient. All formulations for oral administration should be in a dosage suitable for such administration. Push-fit capsules may contain the active ingredient mixed with a filler such as lactose, a binder such as starch, and / or a lubricant such as talc or magnesium stearate, and optionally a stabilizer. In soft capsules, the active compound may be dissolved or suspended in a suitable liquid such as fatty oil, liquid paraffin, or liquid polyethylene glycol. In some embodiments, a stabilizer is added. A suitable coating is provided for the core of the sugar-coated tablet. For this purpose, a concentrated sugar solution may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, Carbopol gel, polyethylene glycol, and / or titanium dioxide, a lacquer solution, and a suitable organic solvent or solvent mixture. Dyes and pigments may be added to the tablet or sugar-coated tablet coating for identification or to characterize different combinations of dosages of the active compound.

[0188] In some embodiments, pharmaceutical compositions are formulated for parenteral administration by injection, e.g., bolus injection or continuous infusion. Injectable formulations may be provided in unit dosage forms, e.g., ampoules or multi-dose containers, with preservatives added. Compositions may take the form of suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending agents, stabilizers, and / or dispersing agents. Compositions may be presented in single-dose or multi-dose containers, e.g., sealed ampoules and vials, and may be stored in powder form or freeze-dried state, requiring only the addition of a sterile liquid carrier, e.g., saline or sterile pyrogen-free water, immediately before use. Instantaneous injectable solutions and suspensions may be prepared from the aforementioned types of sterile powders, granules, and tablets.

[0189] Pharmaceutical compositions for parenteral administration include aqueous and non-aqueous (oil-based) sterile injection solutions of active compounds, which may contain antioxidants, buffers, bacteriostatic agents, and solutes that make the preparation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickeners. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, suspensions may also contain suitable stabilizers or agents that increase the solubility of the compound to enable the preparation of high-concentration solutions.

[0190] Pharmaceutical compositions can also be formulated as depot preparations. Such long-acting formulations can be administered by implantation (e.g., subcutaneous or intramuscular) or intramuscular injection. Therefore, for example, the compound may be formulated with a suitable polymer material, or a hydrophobic material (e.g., as an emulsion in an acceptable oil), or an ion exchange resin, or as a slightly insoluble derivative, for example, as a slightly insoluble salt. [Examples]

[0191] The following examples are provided for illustrative purposes only and are not intended to limit the scope of the claims provided herein.

[0192] As used herein, the following abbreviations shall have the following meanings unless otherwise specified: ACN, or MeCN acetonitrile Acetic acid (ACOH) Acetyl BINAP 2,2'-bis(diphenylphosphin)-1,1'-binaphthalene Bn Benzyl BOC, or Boc tert-butylcarbamate i-Bu isobutyl t-Butyl DCM Dichloromethane (CH2Cl2) DIBAL-H Diisobutylaluminum Hydrogenate DIPEA, or DIEA diisopropylethylamine DMAP 4-(N,N-dimethylamino)pyridine DME 1,2-Dimethoxyethane DMF (N,N-dimethylformamide) DMA N,N-dimethylacetamide DMSO (Dimethyl Sulfoxide) Dppf, or dppf 1,1'-bis(diphenylphosphino)ferrocene EDC, or EDCI, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride eq equivalent Et ethyl Et2O Diethyl ether EtOH Ethanol HCl ethyl acetate HPLC (High-Performance Liquid Chromatography) KHMDS (Potassium Bis(Trimethylsilyl)amide) NaHMDS (Sodium Bis(Trimethylsilyl)amide) LiHMDS (Lithium Bis(Trimethylsilyl)amide) LAH Lithium Aluminum Anhydrous LCMS (Liquid Chromatography Mass Spectrometry) Me methyl MeOH methanol MS mass spectrometry Ms Mesil NMR nuclear magnetic resonance Ph Phenyl iPr / i-Pr isopropyl RP-HPLC (Reverse-Phase High-Pressure Liquid Chromatography) rt room temperature TBS tert-butyldimethylsilyl TEA (Triethylamine) TFA (Trifluoroacetic Acid) THF (Tetrahydrofuran) TLC (Thin-Layer Chromatography) TMS (trimethylsilyl) TsOH / p-TsOH p-toluenesulfonic acid

[0193] Unless otherwise stated, all materials, including reagents, starting materials, and solvents, were purchased from commercial suppliers such as Sigma-Aldrich and VWR and used without further purification. Unless otherwise stated, reactions were carried out under a nitrogen atmosphere. The progress of the reactions was monitored by thin-layer chromatography (TLC), analytical high-performance liquid chromatography (HPLC), and mass spectrometry, details of which may be provided in specific examples.

[0194] The reactions proceeded as specifically described for each preparation, and in common, the reaction mixtures were purified by extraction, as well as by other purification methods such as temperature and solvent-dependent crystallization and precipitation. Furthermore, the reaction mixtures were purified by preparative HPLC using conventional procedures, e.g., Microsorb C18 or Microsorb BDS column packing and conventional eluents. The progress of the reactions was typically monitored by liquid chromatography-mass spectrometry (LCMS). Characterization of isomers was typically performed by nuclear Overhauser effect spectroscopy (NOE). Characterization of reaction products was performed by mass spectrometry, and / or 1 The procedure was carried out using conventional 1H-NMR spectroscopy. For NMR measurement, the sample was dissolved in a deuterated solvent (CD3OD, CDCl3, or DMSO-d6).

[0195] Example 1a: (4R)-6 3 -(1,1-dioxidetetrahydro-2H-thiopyran-4-yl)-3 2 ,2,2-trifluoro-6 8 -Methoxy-4-methyl-6 1 ,6 2 -Dihydro-5-aza-6(5,1)-pyrido[2,3-d]pyrimidina-1(4,1)-piperidina-3(1,3)-benzenacyclotridecaphane-6 2 - ON (101) synthesis. [ka]

[0196] Step A: In a stirred solution of 6-chloro-3-methoxypyridazine-4-amine (1-1) (13 g, 1.0 equivalent, 81.25 mmol) in acetonitrile (130 mL), N-iodosuccinimide (36.6 g, 2.0 equivalent, 162.5 mmol) was added, and the mixture was stirred at 80°C for 20 hours. The mixture was diluted with aqueous sodium thiosulfate (100 mL) and water (100 mL), and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were washed with brine, dried on anhydrous sodium sulfate, and concentrated. The residue was purified by silica gel flash chromatography (in petroleum ether, 0-40% ethyl acetate) to obtain the desired products 1-2 as pale yellow solids. ESI-MS m / z: 286.0 [M + H] + .

[0197] Step B: A mixture of 6-chloro-5-iodo-3-methoxypyridazine-4-amine (1-2) (10.0 g, 1.0 equivalent, 35.09 mmol), di-tert-butyl dicarbonate (15.3 g, 2.0 equivalent, 70.18 mmol), and 4-dimethylaminopyridine (2.1 g, 0.5 equivalent, 17.54 mmol) was stirred at room temperature for 16 hours in tetrahydrofuran (100 mL). The mixture was concentrated, the residue was dissolved in ethyl acetate, and diluted with water. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 × 200 mL). The organic layers were combined, dried on anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the residue. The residue was purified by silica gel flash chromatography (in dichloromethane, 0%~10% ethyl acetate) to obtain the desired products 1-3 as off-white solids. ESI-MS m / z: 486.1[M+H]+.

[0198] Step C: In 150 mL of 1,4-dioxane and 15 mL of water, di-tert-butyl(6-chloro-5-iodo-3-methoxypyridazin-4-yl)carbamate (1-3) (15.5 g, 1.0 equivalent, 31.89 mmol), potassium trifluoro(vinyl)borate (4.3 g, 1.0 equivalent, 31.89 mmol), and potassium carbonate (13.2 g, 3.0 equivalent, 95.68 mmol) were stirred together, to which Pd(dppf)Cl2 (1.2 g, 0.05 equivalent, 1.59 mmol) was added. The mixture was heated at 90°C under a nitrogen atmosphere. It was cooled to room temperature, diluted with water (200 mL), and extracted with ethyl acetate (3 × 300 mL). The combined organic layer was washed with brine, dried on anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel flash chromatography (in petroleum ether, 0%-30% ethyl acetate) to obtain the desired products 1-4 as off-white solids. ESI-MS m / z: 386.3 [M+H] + .

[0199] Step D: Di-tert-butyl(6-chloro-3-methoxy-5-vinylpyridazin-4-yl)carbamate (1-4) (9.2 g, 1.0 equivalent, 23.83 mmol) and sodium periodate (25.5 g, 5.0 equivalent, 119.17 mmol) were stirred in tetrahydrofuran (90 mL) and water (90 mL). Potassium osminate (VI) dihydrate (175 mg, 0.02 equivalent, 0.48 mmol) was added at 0°C, and the mixture was stirred at 0°C for 10 minutes, then stirred at room temperature for 16 hours. The mixture was filtered, and the filtrate was extracted with ethyl acetate (3 × 80 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the desired products 1-5 as brown oil, which were used directly in the next step without further purification. ESI-MS m / z:388.2[M+H] + .

[0200] Step E: In a 20 mL solution of DCM, a 10 g crude solution of di-tert-butyl(6-chloro-5-formyl-3-methoxypyridazine-4-yl)carbamate (1-5) was stirred. Trifluoroacetic acid (5.0 mL) was added, and the mixture was stirred at room temperature for 2 hours. Then, saturated aqueous solution of NaHCO3 was added, and the mixture was stirred for 15 minutes. The solution was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the residue. The residue was purified by silica gel flash chromatography (in petroleum ether, 0%~40% ethyl acetate) to obtain the desired product as an off-white solid. ESI-MS m / z: 188.2 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 10.16 (s, 1H), 8.74 (s, 1H), 8.18 (s, 1H), 4.03 (s, 3H).

[0201] Step F: In 20 mL of tetrahydrofuran at -78°C, a solution of methyl 2-(tetrahydro-2H-thiopyran-4-yl)acetate (1-6) (1.5 g, 2 equivalents, 7.97 mmol) was added to lithium bis(trimethylsilyl)amide (39.8 mL, 10 equivalents, 39.8 mmol, 1 M). The mixture was stirred at -78°C for 1 hour, and then a solution of 5-amino-3-chloro-6-methoxypyridazine-4-carbaldehyde (747 mg, 1 equivalent, 3.98 mmol) in 10 mL of tetrahydrofuran was added at the same temperature. The reaction mixture was heated to room temperature and stirred for 16 hours. The mixture was quenched with aqueous NH4Cl solution (60 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine (50 mL), dried on anhydrous sodium sulfate, filtered, and concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0% to 50% ethyl acetate) to obtain the desired products 1-7 as yellow solids. ESI-MS m / z: 312[M+H] + .

[0202] Step G: To a solution of 5-chloro-8-methoxy-3-(tetrahydro-2H-thiopyran-4-yl)pyrido[2,3-d]pyridazine-2(1H)-one(1-7) (600 mg, 1 equivalent, 1.92 mmol) in dichloromethane (12 mL), 3-chloroperoxybenzoic acid (828 mg, 2.5 equivalents, 4.8 mmol) was slowly added at 0°C. The reaction mixture was stirred at room temperature for 4 hours, quenched with saturated NaHCO3 aqueous solution (35 mL), and extracted with dichloromethane (3 × 60 mL). The organic phases were combined, then washed with saturated Na2SO3 (2 × 40 mL) and brine (40 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in petroleum ether, 0-60% ethyl acetate) to obtain the desired product as a white solid. ESI-MS m / z:344[M+H] + .

[0203] Step H: In dimethyl sulfoxide (5 mL), a solution of 5-chloro-3-(1,1-dioxidetetrahydro-2H-thiopyran-4-yl)-8-methoxypyrido[2,3-d]pyridazine-2(1H)-one (500 mg, 1 equivalent, 1.45 mmol) was added to 2-(6-bromohexyl)-1,3-dioxolane(1-8) (414 mg, 1.2 equivalents, 1.74 mmol) and potassium phosphate (922 mg, 3 equivalents, 4.35 mmol) at room temperature. The mixture was stirred at room temperature for 4 hours, poured into water (60 mL), and extracted with ethyl acetate (3 × 70 mL). The combined organic layer was washed with brine (3 × 250 mL) and dried on anhydrous sodium sulfate. It was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by preparative TLC (dichloromethane:methanol 25:1) to obtain the desired products 1-9 as brown solids. ESI-MS m / z:500[M+H] + .

[0204] Step I: In toluene (6 mL), a solution of 1-(6-(1,3-dioxolan-2-yl)hexyl)-5-chloro-3-(1,1-dioxidetetrahydro-2H-thiopyran-4-yl)-8-methoxypyrido[2,3-d]pyridazine-2(1H)-one(1-9) (200 mg, 1 equivalent, 0.4 mmol) is prepared by adding tert-butyl(R)-4-((3-(1-aminoethyl (-2-fluorophenyl)difluoromethyl)piperidine-1-carboxylate (1-10) (239 mg, 1.1 equivalents, 0.44 mmol), Cs2CO3 (326 mg, 2.5 equivalents, 1 mmol), BINAP (50 mg, 0.2 equivalents, 0.08 mmol), and Pd2(dba)3 (37 mg, 0.1 equivalents, 0.04 mmol) were added at room temperature under a nitrogen atmosphere. The mixture was stirred at 110°C for 12 hours and cooled to room temperature. The reaction mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0%-10% methanol) to obtain the desired product (1-11) as a white solid. ESI-MS m / z: 836 [M+H] + .

[0205] Step J: In tetrahydrofuran (3 mL), a solution of tert-butyl(R)-4-((3-(1-((1-(6-(1,3-dioxolan-2-yl)hexyl)-3-(1,1-dioxidetetrahydro-2H-thiopyran-4-yl)-8-methoxy-2-oxo-1,2-dihydropyrido[2,3-d]pyridazin-5-yl)amino)ethyl)-2-fluorophenyl)difluoromethyl)piperidine-1-carboxylate (1-11) (160 mg, 1 equivalent, 0.19 mmol) was added to HCl (2N aqueous solution, 6 mL). The mixture was stirred at room temperature for 16 hours and adjusted to pH = 7-8 with saturated NaHCO3 aqueous solution. It was then extracted with dichloromethane (3 x 40 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the desired products 1-12, which were used directly in the next step without further purification. ESI-MS m / z:692[M+H] + .

[0206] Step K: In 65 mL of 1,2-dichloroethane and 130 mL of methanol, a solution of (R)-7-(5-((1-(3-(difluoro(piperidine-4-yl)methyl)-2-fluorophenyl)ethyl)amino)-3-(1,1-dioxidetetrahydro-2H-thiopyran-4-yl)-8-methoxy-2-oxopyrido[2,3-d]pyridazine-1(2H)-yl)heptanal (1-12) (132 mg, 1.0 mmol, 0.19 equivalents) was prepared, to which acetic acid (10 drops) was added. The mixture was stirred at room temperature for 0.5 hours, then sodium borocyanohydride (30 mg, 2.5 equivalents, 0.475 mmol) was added, and the mixture was stirred at room temperature for 1 hour. It was concentrated to obtain a residue, which was dissolved in 30 mL of dichloromethane and washed with saturated aqueous NaHCO3. The aqueous phase was extracted with dichloromethane (3 × 50 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0% to 13% methanol) to obtain compound 101 as a white solid. ESI-MS m / z: 676 [M + H] + .

[0207] Example 1b: (R)-4-(3 2 ,2,2-trifluoro-6 4 ,4-dimethyl-7-oxa-5-aza-6(1,5)-pyrido[3,4-d]pyridadina-1(4,1)-piperidina-3(1,3)-benzenacyclotridekaphane-6 7 Synthesis of -yl)thiomorpholine 1,1-dioxide(103) [ka]

[0208] Step A: In a solution of methyl 2-chloro-6-(1,1-dioxide thiomorpholino) isonicotinate (2-1) (12.6 g, 1.0 equivalent, 41.35 mmol) in N,N-dimethylformamide (25 mL), N-bromosuccinimide (5.12 g, 1.05 equivalent, 43.20 mmol) was added. The mixture was stirred at room temperature for 16 hours. The mixture was diluted with water (150 mL x 1) and then extracted with ethyl acetate (80 mL x 4). The combined organic layer was washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by silica gel column chromatography (in petroleum ether, 0-60% ethyl acetate) to obtain the desired product 2-2 as a white solid. ESI-MS m / z: 384.9 [M+H] + .

[0209] Step B: In 600 mL of dioxane, a solution of methyl 3-bromo-2-chloro-6-(1,1-dioxidethiomorpholino)isonicotinate (2-2) (13.8 g, 1.0 equivalent, 36.12 mmol) was added to tributyl (1-ethoxyvinyl) stannan (2-3) (14.76 mL, 1.2 equivalents, 43.34 mmol) and Pd(PPh3)2Cl2 (2.53 mg, 0.1 equivalents, 3.61 mmol). The mixture was stirred at 80°C for 16 hours, then cooled to room temperature, diluted with a saturated solution of potassium fluoride (200 mL) and ethyl acetate (200 mL), and stirred for 2 hours. The mixture was filtered. The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (200 mL x 4). The organic compounds were combined, washed with brine (150 mL), dried over Na2SO4, filtered, and the filtrate was concentrated to obtain the desired products 2-4, which were used directly in the next step without further purification.

[0210] Step C: In 180 mL of THF, a solution of methyl 2-chloro-6-(1,1-dioxide thiomorpholino)-3-(1-ethoxyvinyl) isonicotinate (2-4) (6.2 g) was added to a solution containing 180 mL of 3 M HCl at room temperature. The mixture was stirred at room temperature for 1 hour and then diluted with 200 mL of water. This was extracted with ethyl acetate (100 mL x 4), the combined organic layer was washed with brine (100 mL x 1), dried over Na₂SO₄, filtered, and the filtrate was concentrated under reduced pressure to obtain the residue. The residue was purified by silica gel column chromatography (in petroleum ether, 0-60% ethyl acetate) to obtain the desired product 2-5 as a yellow solid. ESI-MS m / z: 347.0 [M+H] + .

[0211] Step D: In 30 mL of EtOH, a solution of methyl 3-acetyl-2-chloro-6-(1,1-dioxide thiomorpholino) isonicotinate (2-5) (2.5 g, 1.0 equivalent, 7.22 mmol) was added to hydrazine hydrate (470 mg, 1.3 equivalents, 9.39 mmol). The mixture was stirred at 95°C for 2 hours. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure to obtain the desired product 2-6 as a yellow solid, which was used directly in the next step without further purification. ESI-MS m / z: 329.1 [M+H] + .

[0212] Step E: In POCl3 (30 mL), a mixture of 4-(5-chloro-1-hydroxy-4-methylpyrido[3,4-d]pyridazin-7-yl)thiomorpholine 1,1-dioxide (2-6) (2.5 g, 1.0 equivalent, 7.22 mmol) was stirred at 110°C for 2 hours and then cooled to room temperature. The mixture was washed with saturated NaHCO3 (50 mL x 3) and dried on sodium sulfate. It was filtered, and the filtrate was concentrated to obtain the residue, which was purified by silica gel column chromatography (in petroleum ether, 0%~100% ethyl acetate) to obtain the desired product 2-7 as a yellow solid. ESI-MS m / z: 347.1 [M+H] + .

[0213] Step F: In DMSO (10 mL), a solution of 4-(1,5-dichloro-4-methylpyrido[3,4-d]pyridazin-7-yl)thiomorpholine 1,1-dioxide (2-7) (1 g, 1.0 equivalent, 2.89 mmol) was added to 5-(1,3-dioxolan-2-yl)pentan-1-ol (2-8) (694 mg, 1.5 equivalent, 4.33 mmol) and KF (1.08 g, 6 equivalents, 17.38 mmol). The mixture was stirred at 100 °C for 16 hours, then cooled to room temperature and diluted with ethyl acetate (20 mL x 3). The organic matter was washed with brine (150 mL) and dried over Na2SO4. It was filtered, and the filtrate was concentrated to obtain the residue, which was purified by silica gel column chromatography (in DCM, 0%~6% MeOH) to obtain the desired product as a white solid. ESI-MS m / z:471.1[M+H] + .

[0214] Step G: In toluene (6 mL), a solution of 4-(5-((5-(1,3-dioxolan-2-yl)pentyl)oxy)-1-chloro-4-methylpyrido[3,4-d]pyridazin-7-yl)thiomorpholine 1,1-dioxide (600 mg, 1.0 equivalent, 1.27 mmol) was added to tert-butyl(R)-4-((3-(1-aminoethyl)-2-fluorophenyl)difluoromethyl)piperidine-1-carboxylate (1-10) (712 mg, 1.5 equivalent, 1.91 mmol), Pd2(dba)3 (117 mg, 0.1 equivalent, 0.13 mmol), BINAP (159 mg, 0.2 equivalent, 0.26 mmol), and Cs2CO3 (2.489 g, 6 equivalents, 7.66 mmol). The mixture was stirred at 110°C for 16 hours and then cooled to room temperature. The reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM, 0%-10% MeOH) to obtain the desired products 2-9 as white solids. ESI-MS m / z: 807.3 [M+H] + .

[0215] Step H: In 5 mL of THF, a solution of tert-butyl(R)-4-((3-(1-((5-((5-(1,3-dioxolan-2-yl)pentyl)oxy)-7-(1,1-dioxidethiomorpholino)-4-methylpyrido[3,4-d]pyridazin-1-yl)amino)ethyl)-2-fluorophenyl)difluoromethyl)piperidine-1-carboxylate (2-9) (300 mg, 1.0 equivalent, 0.37 mmol) was added to HCl (2N, aqueous, 10 mL). The mixture was stirred at room temperature for 16 hours. The reaction mixture was then cooled to 0°C and treated with saturated NaHCO3 solution to adjust the pH to approximately 7-8. The solution was extracted with DCM (150 mL x 5), the combined organic layers were washed with brine, and dried over Na2SO4. The solution was filtered, and the filtrate was concentrated under reduced pressure to obtain the desired product, which was used directly in the next step without further purification. ESI-MS m / z:663.4[M+H] + .

[0216] Step I: In 100 mL of 1,2-dichloroethane and 300 mL of methanol, a solution of (R)-6-((1-((1-(3-(difluoro(piperidine-4-yl)methyl)-2-fluorophenyl)ethyl)amino)-7-(1,1-dioxidethiomorpholino)-4-methylpyrido[3,4-d]pyridazin-5-yl)oxy)hexanal (300 mg, 1.0 equivalent, 0.37 mmol) was prepared, to which HOAc (6 drops) was added. The mixture was stirred at room temperature for 0.5 hours, and NaBH3CN (66 mg, 2.5 equivalents, 0.93 mmol) was added. The mixture was stirred at room temperature for a further 0.5 hours, then concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (in DCM, 0%~10% MeOH) to obtain compound 103 of the title as a white solid. ESI-MS m / z:647.2[M+H] + .

[0217] Example 1c: 3,10-dimethyl-13-morpholino-1 1 ,1 2 -Dihydro-6-oxa-2,10-diaza-1(5,1)-naphthilidina-4(1,3)-benzenacyclohexadecaphane-12 - ON (108) composition [ka]

[0218] Step A: In a stirred solution of tert-butyl(3-hydroxypropyl)(methyl)carbamate (8.9 g, 1.0 equivalent, 47.2 mmol) in dry THF (100 mL), NaH (2.45 g, 1.3 equivalent, 61.36 mmol) was added under argon at 0°C. After 30 minutes, 1-(3-(bromomethyl)phenyl)ethane-1-one (3-1) (10 g, 1.0 equivalent, 47.2 mmol) was added, and the mixture was stirred for 1 hour. It was quenched with water and extracted with ethyl acetate (4 × 80 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. It was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by flash silica gel column chromatography (in petroleum, 0-10% ethyl acetate) to obtain the desired product as a pale yellow oil. ESI-MS m / z: 344.1 [M+H] + .

[0219] Step B: A mixture of tert-butyl(3-(3-acetylbenzyl)oxy)propyl)(methyl)carbamate (5.4 g, 1.0 equivalent, 16.8 mmol), 2-methylpropane-2-sulfinamide (2.04 g, 1.2 equivalents, 20.16 mmol), and tetraethyl titanate (11.51 g, 3.0 equivalents, 50.4 mmol) was heated under argon at 80°C for 16 hours and then cooled to room temperature. It was diluted with ethyl acetate (50 mL) and water (40 mL). The resulting solution was stirred at room temperature for 30 minutes and filtered through Celite. The filtered cake was washed with ethyl acetate, and the aqueous solution was extracted with ethyl acetate (3 × 40 mL). The combined organic layers were dried over Na₂SO₄, filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by combiflash column (in petroleum, 0%-20% ethyl acetate) to obtain the desired product 3-2 as a pale yellow oil. ESI-MS m / z: 425.2 [M+H] + .

[0220] Step C: In a stirred solution of tert-butyl(Z)-(3-((3-(1-((tert-butylsulfinyl)imino)ethyl)benzyl)oxy)propyl)(methyl)carbamate(3-2) (5.28 g, 1.0 equivalent, 12.45 mmol) in THF (50 mL), sodium borohydride (710 mg, 1.5 equivalent, 18.68 mmol) was added at 0°C, and the mixture was stirred for 1 hour. It was diluted with water and extracted with ethyl acetate (3 × 60 mL). The combined organic layers were then dried over Na₂SO₄, filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by combiflash column (in petroleum, 0%~50% ethyl acetate) to obtain the desired product 3-3 as a pale yellow oil. ESI-MS m / z: 427.1 [M+H] + .

[0221] Step D: In a stirred solution of tert-butyl(3-((3-(1-((tert-butylsulfinyl)amino)ethyl)benzyl)oxy)propyl)(methyl)carbamate (3-3) (4.86 g, 1.0 equivalent, 11.41 mmol) in MeOH (86.7 mL), HCl (21.68 mL, 1.9 equivalents, 21.68 mmol, 1 M) was added dropwise in dioxane at 0°C, and the mixture was stirred for 1 hour. This was treated with saturated NaHCO3 aqueous solution, diluted with saturated NaCl aqueous solution, and extracted with ethyl acetate (4 × 60 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by flash silica gel column chromatography (0%~5% MeOH in DCM) to obtain the desired product 3-4 as a yellow oil. ESI-MS m / z: 323.1 [M+H] + .

[0222] Step E: In 10 mL of THF, lithium bis(trimethylsilyl)amide (12.8 mL, 4 equivalents, 12.8 mmol, 1 M) was slowly added at -78°C to a solution of ethyl 2-morpholinoacetate (1108 mg, 2.0 equivalents, 6.41 mmol). The mixture was stirred at -78°C for 1 hour. Then, 2-amino-4-chloronicotinaldehyde (3-5) (500 mg, 1.0 equivalent, 3.2 mmol) was added at -78°C, and the resulting mixture was stirred overnight at room temperature. It was diluted with water (100 mL) and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were concentrated to obtain a residue, which was purified by silica gel column chromatography (in petroleum ether, 0%~40% ethyl acetate) to obtain the desired products 3-6 as yellow solids. ESI-MS m / z: 266.0 [M+H] + .

[0223] Step F: In dimethyl sulfoxide (10 mL), a solution of 5-chloro-3-morpholino-1,8-naphthyrizine-2(1H)-one (3-6) (800 mg, 1.0 equivalent, 3.02 mmol) was added to 2-(5-bromopentyl)-1,3-dioxolane (3-7) (1340 mg, 2.0 equivalent, 6.04 mmol) and tripotassium orthophosphate (1920 mg, 3.0 equivalent, 9.06 mmol). The mixture was stirred at 100°C for 12 hours under an argon atmosphere. The mixture was cooled to room temperature, diluted with water (200 mL), and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were washed with brine (3 × 300 mL) and dried over Na₂SO₄. The mixture was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0%-10% methanol) to obtain the desired products 3-8 as yellow solids. ESI-MS m / z: 408.1[M+H] + .

[0224] Step G: In 5 mL of dry toluene, a mixture of 1-(5-(1,3-dioxolan-2-yl)pentyl)-5-chloro-3-morpholino-1,8-naphthyrizine-2(1H)-one(3-8) (200 mg, 1.0 equivalent, 0.49 mmol), tert-butyl(3-((3-(1-aminoethyl)benzyl)oxy)propyl)(methyl)carbamate(3-4) (174 mg, 1.1 equivalent, 0.54 mmol), and cesium carbonate (400 mg, 2.5 equivalents, 1.225 mmol) was mixed with Pd2(dba)3 (45 mg, 0.1 equivalent, 0.049 mmol) and BINAP (61 mg, 0.2 equivalent, 0.098 mmol). The mixture was then stirred at 110°C for 16 hours. The mixture was cooled to room temperature and then diluted with water (50 mL) and ethyl acetate (50 mL). The organic layer was collected, and the aqueous layer was extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The mixture was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0%-8% methanol) to obtain the desired products 3-9 as brown solids. ESI-MS m / z: 694.3 [M+H] + .

[0225] Step H: In 8 mL of THF, a solution of tert-butyl(3-((3-(1-((8-(5-(1,3-dioxolan-2-yl)pentyl)-6-morpholino-7-oxo-7,8-dihydro-1,8-naphthyridine-4-yl)amino)ethyl)benzyl)oxy)propyl)(methyl)carbamate (3-9) (150 mg, 1.0 equivalent, 0.216 mmol) was added to 16 mL of HCl (3N aqueous solution). The mixture was then stirred at room temperature for 12 hours. The reaction mixture was adjusted to pH approximately 8 with saturated aqueous NaHCO3 at 0°C and extracted with dichloromethane (3 × 40 mL). The combined organic layers were washed with brine and dried over Na2SO4. It was filtered, and the filtrate was concentrated to obtain the desired product 3-10, which was used directly in the next step without further purification. ESI-MS m / z:550.3[M+H] + .

[0226] Step I: In methanol / 1,2-dichloroethane (144 mL / 72 mL, c=0.001 M), 6-(5-((1-(3-((3-(methylamino)propoxy)methyl)phenyl)ethyl)amino)-3-morpholino-2-oxo-1,8-naphthyridine-1(2H)-yl)hexanal (3-10) (150 mg, 1.0 equivalent, approximately 0.216 mmol) was dissolved, to which acetic acid (6 drops) was added, and the mixture was stirred at room temperature for 0.5 hours. Sodium cyanoborohydride (34 mg, 2.5 equivalents, 0.54 mmol) was added, and the reaction mixture was stirred at room temperature overnight. It was concentrated, diluted with dichloromethane (30 mL), and treated with saturated NaHCO3 (150 mL). The resulting mixture was stirred at room temperature for 0.5 hours. The organic layer was separated, and the aqueous layer was extracted with dichloromethane (3 × 80 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The filtrate was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by preparative HPLC (NH₄HCO₃ conditions) to obtain the desired product 108 as a white solid. ESI-MS m / z: 534.2 [M + H] + .

[0227] Example 1d: (3,10-dimethyl-6-oxa-2,10-diaza-1(4,7)-thieno[3,2-d]pyrimidina-4(1,3)-benzenacyclohexadecaphane-1 6 - Synthesis of (Il)(morpholino)methanone(109) [ka]

[0228] Step A: A solution of 7-bromo-4-chlorothieno[3,2-d]pyrimidine (4-1) (2 g, 1.0 equivalent, 8.01 mmol) in tetrahydrofuran (20 mL) was stirred under argon at -78°C for 15 minutes, and lithium diisopropylamide (1.029 g, 1.2 equivalent, 9.62 mmol) was added dropwise. The resulting mixture was stirred at -78°C for 1.5 hours, followed by the addition of methyl chloroformate (6.2 g, 6 equivalents, 48.06 mmol). The mixture was stirred from -78°C to room temperature for 4 hours. The mixture was adjusted to pH=3 with HCl (1N, aqueous solution) and extracted with ethyl acetate (3 × 300 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The mixture was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in petroleum ether, 0-15% ethyl acetate) to obtain the desired product 4-2 as a yellow solid. ESI-MS m / z: 308.8[M+2+H] + .

[0229] Step B: In dimethyl sulfoxide (10 mL), a solution of methyl 7-bromo-4-chlorothieno[3,2-d]pyrimidine-6-carboxylate (4-2) (600 mg, 1.0 equivalent, 1.95 mmol) was added to tert-butyl (3-((3-(1-aminoethyl)benzyl)oxy)propyl)(methyl)carbamate (3-4) (687 mg, 1.1 equivalent, 2.13 mmol) and potassium fluoride (678 mg, 6.0 equivalent, 11.7 mmol). The resulting mixture was stirred at 100°C for 12 hours under an argon atmosphere. It was cooled to room temperature, diluted with water (200 mL), and extracted with ethyl acetate (3 × 80 mL). The combined organic layers were washed with brine (3 × 300 mL) and dried over Na₂SO₄. It was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0%-10% methanol) to obtain the desired product 4-3 as a white solid. ESI-MS m / z: 595.1[M+2+H] + .

[0230] Step C: In a solution of methyl 7-bromo-4-((1-(3-((3-((tert-butoxycarbonyl)(methyl)amino)propoxy)methyl)phenyl)ethyl)amino)thieno[3,2-d]pyrimidine-6-carboxylate (4-3) (1005 mg, 1.0 equivalent, 1.69 mmol) in tetrahydrofuran (10 mL), methanol (2.5 mL), and water (2.5 mL), lithium hydroxide monohydrate (212 mg, 3.0 equivalent, 5.07 mmol) was added. The resulting mixture was stirred at room temperature for 4 hours. It was concentrated to obtain a residue, which was dissolved in dichloromethane (30 mL). This was acidified to pH=2-3 with HCl (1N, aqueous solution) and extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The solution was filtered, the filtrate concentrated to obtain the desired product, which was used directly in the next step without further purification. ESI-MS m / z: 581.0[M+2+H] + .

[0231] Step D: In 10 mL of dichloromethane, a solution of 7-bromo-4-((1-(3-((3-((tert-butoxycarbonyl)(methyl)amino)propoxy)methyl)phenyl)ethyl)amino)thieno[3,2-d]pyrimidine-6-carboxylic acid (970 mg, 1.0 equivalent, 1.67 mmol) and morpholine (290 mg, 2.0 equivalent, 3.34 mmol) was prepared. Triethylamine (506 mg, 3.0 equivalent, 5.01 mmol) and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.27 g, 2.0 equivalent, 3.34 mmol) were added at room temperature. The resulting mixture was stirred under nitrogen at room temperature for 3 hours. The solution was concentrated to obtain a residue, which was then purified by silica gel column chromatography (in petroleum ether, 0-30% ethyl acetate) to obtain the desired product 4-4 as a white solid. ESI-MS m / z: 594.0 [M+2-55] + .

[0232] Step E: In a solution of tert-butyl(3-((3-(1-((7-bromo-6-(morpholine-4-carbonyl)thieno[3,2-d]pyrimidine-4-yl)amino)ethyl)benzyl)oxy)propyl)(methyl)carbamate(4-4) (470 mg, 1.0 equivalent, 0.79 mmol), hexa-5-in-1-ol (142 mg, 2 equivalents, 1.448 mmol), dichlorotris(triphenylphosphine)palladium (201 mg, 0.4 equivalents, 0.288 mmol), and copper(I) iodide (41 mg, 0.3 equivalents, 0.216 mmol) were added at room temperature. The mixture was stirred under an argon atmosphere at 70°C for 12 hours. The mixture was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (3 × 200 mL). The combined organic layers were washed with brine (3 × 200 mL) and dried over Na₂SO₄. The mixture was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0%~10% methanol) to obtain the desired products 4-5 as yellow oil. ESI-MS m / z: 666.1 [M+H] + .

[0233] Step F: In a solution of tert-butyl(3-((3-(1-((7-(6-hydroxyhexa-1-in-1-yl)-6-(morpholine-4-carbonyl)thieno[3,2-d]pyrimidine-4-yl)amino)ethyl)benzyl)oxy)propyl)(methyl)carbamate (4-5) (200 mg, 1.0 equivalent, 0.30 mmol) in methanol (30 mL), Pd / C (200 mg) was added at room temperature. The mixture was stirred under a hydrogen atmosphere at room temperature for 12 hours. It was filtered, and the filtrate was concentrated to obtain the desired product, which was used directly in the next step without further purification. ESI-MS m / z: 670.3 [M+H] + .

[0234] Step G: Ethanesulfonyl chloride (76 mg, 4.0 equivalents, 0.588 mmol) was added dropwise at 0°C to a solution of tert-butyl(3-((3-(1-((7-(6-hydroxyhexyl)-6-(morpholine-4-carbonyl)thieno[3,2-d]pyrimidine-4-yl)amino)ethyl)benzyl)oxy)propyl)(methyl)carbamate (100 mg, 1.0 equivalent, 0.147 mmol) and triethylamine (74 mg, 5.0 equivalents, 0.736 mmol). The mixture was stirred at 0°C for 5 minutes under an argon atmosphere. The mixture was poured into water (40 mL) and extracted with dichloromethane (3 × 50 mL). The combined organic layer was washed with brine and dried over Na₂SO₄. It was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0%-10% methanol) to obtain the desired products 4-6 as white solids. ESI-MS m / z: 762.2 [M+H] + .

[0235] Step H: In a solution of 6-(4-((1-(3-((3-((tert-butoxycarbonyl)(methyl)amino)propoxy)methyl)phenyl)ethyl)amino)-6-(morpholine-4-carbonyl)thieno[3,2-d]pyrimidine-7-yl)hexylethanesulfonate (4-6) (90 mg, 1.0 equivalent, 0.12 mmol) in dichloromethane (5 mL), trifluoroacetic acid (1 mL) was added at room temperature. The mixture was stirred at room temperature for 1 hour. It was concentrated to obtain the desired product as a pale yellow oil, which was used in the next step without further purification. ESI-MS m / z: 662.0 [M+H] + .

[0236] Step I: In acetonitrile (24 mL, c=0.005 M), a solution of 6-(4-((1-(3-((3-(methylamino)propoxy)methyl)phenyl)ethyl)amino)-6-(morpholine-4-carbonyl)thieno[3,2-d]pyrimidine-7-yl)hexylethanesulfonate (90 mg, 1.0 equivalent, approximately 0.12 mmol) was added to N,N-diisopropylethylamine (310 mg, 20.0 equivalents, 2.4 mmol) at room temperature. The mixture was stirred at 70°C for 30 hours and then cooled to room temperature. It was concentrated, the residue was dissolved in DCM (30 mL), and treated with saturated NaHCO3 (150 mL). The mixture was stirred at room temperature for 1 hour. The organic layer was separated, and the aqueous layer was extracted with DCM (30 mL x 4). The combined organic layers were washed with brine and dried over Na2SO4. The solution was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by preparative HPLC (under formic acid conditions) to obtain the desired product 109 as a white solid. ESI-MS m / z: 552.3 [M+H] + .

[0237] Example 1e: 1 6 -(cyclopropylmethyl)-3,10-dimethyl-1 7 ,1 8 Synthesis of -dihydro-16H-6,16-dioxa-2,10-diaza-1(4,10)-[1,4]oxazino[3,2-g]quinazolina-4(1,3)-benzenacyclohexadecaphane(111) [ka]

[0238] Step A: In 25 mL of dry tetrahydrofuran, a solution of methyl 8-bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (5-1) (2.6 g, 1 equivalent, 9.6 mmol) was added to a solution of sodium hydride (595 mg, 1.55 equivalents, 14.88 mmol, 60% in oil) at 0°C. The mixture was stirred at 0°C for 1 hour, and then a solution of acetyl chloride (1.5 g, 2.0 equivalents, 19.2 mmol) was added to 4 mL of dry tetrahydrofuran. The mixture was stirred at room temperature for 2 hours, quenched with water (150 mL), and extracted with ethyl acetate (3 × 150 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. The layers were filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in petroleum ether, 0-20% ethyl acetate) to obtain the desired product as a white solid. ESI-MS m / z:315.9[M+H] + .

[0239] Step B: In a solution of methyl 4-acetyl-8-bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (2.7 g, 1.0 equivalent, 8.57 mmol) in H2SO4 (15 mL), HNO3 (1.5 mL) was added at 0°C, and the mixture was stirred under argon at 0°C for 0.5 hours. The mixture was slowly poured into water (100 mL), filtered, and the desired product 5-2 (2.5 g) was obtained as a yellow solid. ESI-MS m / z: 383.0[M+Na]+.

[0240] Step C: Methyl 4-acetyl-8-bromo-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (5-2) (2.5 g, 1.0 equivalent, 6.96 mmol) was treated with 3N HCl (100 mL) in methanol (50 mL), and the resulting mixture was stirred at 60°C for 16 hours. It was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (3 × 120 mL). The combined organic layers were washed with brine and dried over Na₂SO₄. It was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by flash silica gel column chromatography (in petroleum ether, 0%~30% ethyl acetate) to obtain the desired product as a yellow solid. ESI-MS m / z: 340.9 [M+H] + .

[0241] Step D: In acetonitrile (20 mL), a stirred solution of methyl 8-bromo-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (1.6 g, 1.0 equivalent, 4.70 mmol) was mixed with (bromomethyl)cyclopropane (1009 mg, 1.5 equivalent, 7.05 mmol), tetrabutylammonium iodide (173 mg, 0.1 equivalent, 0.47 mmol), and cesium carbonate (3.6 g, 2 equivalents, 9.4 mmol) at room temperature. The mixture was stirred at 80°C for 3 hours. It was cooled to room temperature, diluted with water (100 mL), extracted with ethyl acetate (3 × 120 mL), washed with brine, and dried over Na₂SO₄. It was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by flash silica gel column chromatography (in petroleum ether, 0-30% ethyl acetate) to obtain the desired product 5-3 as a yellow solid. ESI-MS m / z: 373.0 [M+H] + .

[0242] Step E: In 10 mL of N,N-dimethylformamide, a solution of methyl 8-bromo-4-(cyclopropylmethyl)-7-nitro-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (5-3) (1.2 g, 1.0 equivalent, 3.22 mmol) was slowly added to 4,4'-bipyridine (201 mg, 0.4 equivalent, 1.29 mmol) and diboronic acid (579 mg, 2 equivalents, 6.44 mmol) at 0°C. The mixture was stirred from 0°C to room temperature for 0.5 hours. The mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 120 mL). The extract was washed with brine (150 mL) and dried over Na₂SO₄. It was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by flash silica gel column chromatography (in petroleum ether, 0% to 30% ethyl acetate) to obtain the desired product as a white solid. ESI-MS m / z: 342.0 [M+H] + .

[0243] Step F: In tetrahydrofuran (10 mL), a solution of methyl 7-amino-8-bromo-4-(cyclopropylmethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (720 mg, 1.0 equivalent, 2.11 mmol) was added, to which methanol (2 mL), water (2 mL), and lithium hydroxide monohydrate (529 mg, 6.0 equivalent, 12.6 mmol). The mixture was stirred at 40°C for 12 hours, cooled to room temperature, adjusted to pH=3 with 1N HCl, and extracted with dichloromethane (3 × 100 mL). The combined organic layer was washed with brine and dried over Na₂SO₄. It was filtered, and the filtrate was concentrated to obtain the desired product 5-4, which was used directly in the next step without further purification. ESI-MS m / z: 327.9 [M+H] + .

[0244] Step G: To a solution of 7-amino-8-bromo-4-(cyclopropylmethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylic acid (5-4) (500 mg, 1.0 equivalent, 1.53 mmol) in 2-methoxyethanol (10 mL), formamidine acetate (797 mg, 5.0 equivalent, 7.7 mmol) was added at room temperature. The mixture was stirred at 130 °C for 4 hours. The reaction mixture was cooled to room temperature, concentrated, and the residue was poured into water (50 mL). It was filtered to obtain the solid as the desired product 5-5, which was used directly in the next step without further purification. ESI-MS m / z: 337.7 [M+H] + .

[0245] Step H: In a solution of 10-bromo-6-(cyclopropylmethyl)-3,6,7,8-tetrahydro-4H-[1,4]oxazino[3,2-g]quinazolin-4-one (5-5) (370 mg, 1.0 equivalent, 1.1 mmol) in phosphorus oxychloride (5 mL), N,N-diisopropylethylamine (710 mg, 4.0 equivalent, 4.4 mmol) was added at room temperature. The mixture was stirred at 90 °C for 4 hours. The reaction mixture was cooled to room temperature, concentrated, and the residue was diluted with ethyl acetate (40 mL). The above solution was slowly added at 0 °C to pre-cooled saturated NaHCO3 (150 mL). The organic layer was separated, and the aqueous layer was extracted with ethyl acetate (3 × 100 mL). The combined organic layers were concentrated. The residue was purified by silica gel column chromatography (in petroleum ether, 0%~20% ethyl acetate) to obtain the desired product as a pale green solid. ESI-MS m / z:355.7[M+H] + .

[0246] Step I: In a solution of 10-bromo-4-chloro-6-(cyclopropylmethyl)-7,8-dihydro-6H-[1,4]oxazino[3,2-g]quinazoline (230 mg, 1.0 equivalent, 0.65 mmol) in dimethyl sulfoxide (5 mL), tert-butyl(3-((3-(1-aminoethyl)benzyl)oxy)propyl)(methyl)carbamate (3-4) (315 mg, 1.5 equivalents, 0.976 mmol) and potassium fluoride (226 mg, 6.0 equivalents, 3.9 mmol) were added at 100°C for 4 hours under an argon atmosphere. The mixture was cooled to room temperature, diluted with water (100 mL), and extracted with ethyl acetate (3 × 80 mL). The combined organic layer was washed with brine (3 × 100 mL) and dried over Na₂SO₄. It was filtered, and the filtrate was concentrated to obtain the residue. The residue was purified by silica gel column chromatography (in dichloromethane, 0%-10% methanol) to obtain the desired products 5-6 as yellow oil. ESI-MS m / z: 641.8[M+2+H] + . ...

Claims

1. Compound of formula (I): 【Chemistry 1】 or a pharmaceutically acceptable salt or solvate thereof, wherein in the formula, 【Chemistry 2】 However, C 3~1 Two carbon rings, and 3~12 A complex ring is selected from the member complex rings, each of which can be arbitrarily selected from one or more R's. 11 Replaced by, 【Transformation 3】 However, it does not exist, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11a Replaced by, 【Chemistry 4】 but, 【Transformation 5】 Selected from, L 1 is selected from a bond, -O-, -N(R 12 )-, C 1~6 alkylene, C 1~6 haloalkylene, and 2- to 6-membered heteroalkyl, L 2 However, C 5~25 Alkylene, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b It is replaced by or L 2 However, -L 3 -D-L 4 - and L 3 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, R 1 However, one or more R 11c C, which is optionally substituted with 1~3 It is alkyl, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (R 13 ), and -P(O)(R 17 )(R 17a ), wherein each C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C 3~10 carbocycle, and 3-10 membered heterocycle are each independently optionally substituted with one, two, or three R 20 groups, and optionally, R 5 and R 6 , R 6 and R 7 , or R 6 and R 7b form a C 5~10 carbocycle, or a 5-10 membered heterocycle, each of which is optionally substituted with one, two, or three R 20 groups, R 5b , and R 7b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon ring and the 3- to 10-membered heterocycle independently and selectively have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11d However, in each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (Caution 13 ), -CH 2 N(R) 12 ) S(O) 2 (R 13 ), and -P(O)(R 17 ) (Caution 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (Caution 13 ), -CH 2 N(R) 12 ) S(O) 2 (R 13 ), and -P(O)(R 17 ) (Caution 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 ) (Caution 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl and C 1~6 Selected from haloalkyls, or R 12 , and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered heterocycles are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups. 20 It is replaced by or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH 2 - (C 3~10 Carbon rings), 3- to 10-membered heterocycles, -CH 2 - (3- to 10-membered complex ring), - OR 21 , -SR 21 , -N(R 22 ) (Caution 23 ), -C(O)OR 22 , -C(O)N(R 22 ) (Caution 23 ), -C(O)C(O)N(R 22 ) (Caution 23 ), -OC(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)OR 25 , -N(R 24 ) C(O)R 25 , -N(R 24 ) S(O) 2 R 25 , -C(O)R 25 , -S(O) 2 R 25 , -S(O) 2 N(R) 22 ) (Caution 23 ), -OCH 2 C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH 2 - (C 3~10 Carbon rings), 3- to 10-membered heterocycles, and -CH 2 - (3- to 10-membered heterocycles) are halogens, oxos, =NH, -CN, and C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 ) (Caution 23 ), -C(O)OR 22 , -C(O)N(R 22 ) (Caution 23 ), -C(O)C(O)N(R 22 ) (Caution 23 ), -OC(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)OR 25 , -N(R 24 ) C(O)R 25 , -N(R 24 ) S(O) 2 R 25 , -C(O)R 25 , -S(O) 2 R 25 , -S(O) 2 N(R) 22 ) (Caution 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. The aforementioned compound is (R)-2,2-difluoro-6 4 ,4-dimethyl-6 7 Compounds, salts, or solvates other than -morpholino-7-oxa-5-aza-6(1,5)-pyrido[3,4-d]pyridadina-1(4,1)-piperidina-3(1,3)-benzenacyclotridecaphane. 【Request Item 2】 【Chemistry 6】 but, 【Transformation 7】 A compound, salt, or solvate according to claim 1, selected from the above. 【Request Item 3】 【Transformation 8】 but, 【Chemistry 9】 A compound, salt, or solvate according to claim 1, selected from the above.

4. Compound of formula (II): 【Chemistry 10】 or a pharmaceutically acceptable salt or solvate thereof, wherein in the formula, 【Chemistry 11】 However, C 5~7 A selection of carbon rings and 5- to 7-membered heterocycles, each of which can optionally contain one or more R 11 Replaced by, 【Chemistry 12】 However, it does not exist, or C 3~8 A selection of carbon rings and 3- to 8-membered heterocycles, each of which can optionally contain one or more R 11a Replaced by, L 1 However, bond, C 1~6 Alkylene and C 1~6 Selected from haloalkylenes, L 2 However, C 5~25 Alkylene, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by L 2 However, W 3 , W 4 , or W 5 It is covalently bonded to one of the following, or L 2 However, -L 3 -D-L 4 - and L 4 However, W 3 , W 4 , or W 5 Covalently bonded to one of them, L 3 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, L 5 However, a bond and -C(O)- are selected, W 2 However, N(R 2b ), N, C (R 2 ), C (R 2 ) (Caution 2a Selected from C(O), W 3 However, N(R 3b ), N, C (R 3 ), C (R 3 ) (Caution 3a Selected from C(O), W 4 However, N(R 4b ), N, C (R 4 ), C (R 4 ) (Caution 4a Selected from C(O), W 5 However, N(R 5b ), N, C (R 5 ), C (R 5 ) (Caution 5a Selected from C(O), W 7 However, N(R 7b ), N, C (R 7 ), C (R 7 ) (Caution 7a Selected from C(O), R 1 However, one or more R 11c C, which is optionally substituted with 1~3 It is alkyl, R 2 , R 2a , R 3a , R 4a , R 5a , R 7a , and R 7 However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon ring and the 3- to 10-membered heterocycle independently and selectively have one, two, or three R groups. 20 Replaced by, R 3 , R 4 , and R 5 However, each is independent, L 2 Bonding with hydrogen, halogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, C3-10 carbon ring, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyls, C3-10 carbon rings, and 3-10 membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 2b , and R 7b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon ring and the 3- to 10-membered heterocycle independently and selectively have one, two, or three R groups. 20 Replaced by, R 3b , R 4b , and R 5b However, each is independent, L 2 Bonding with hydrogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon ring and the 3- to 10-membered heterocycle independently and selectively have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11d However, in each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (Caution 13 ), -CH 2 N(R) 12 ) S(O) 2 (R 13 ), and -P(O)(R 17 ) (Caution 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (Caution 13 ), -CH 2 N(R) 12 ) S(O) 2 (R 13 ), and -P(O)(R 17 ) (Caution 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 ) (Caution 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl and C 1~6 Selected from haloalkyls, or R 12、 and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered heterocycles are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups. 20 It is replaced by or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 is independently at each occurrence selected from halogen, oxo, =NH, -CN, C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C 3~10 carbocycle, -CH 2 -(C 3~10 carbocycle), 3- to 10-membered heterocycle, -CH 2 -(3- to 10-membered heterocycle), -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 , -C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O) 2 R 25 , -C(O)R 25 , -S(O) 2 R 25 , -S(O) 2 N(R 22 )(R 23 ), -OCH 2 C(O)OR 22 , and -OC(O)R 25 , and C 1~6 alkyl, C 2~6 alkenyl, C 2~6 alkynyl, C 3~10 carbocycle, -CH 2 -(C 3~10 carbocycle), 3- to 10-membered heterocycle, and -CH 2 -(3- to 10-membered heterocycle) are each optionally substituted with halogen, oxo, =NH, -CN, C 1~6 alkyl, C 1~6 haloalkyl, C 1~6 alkoxy, C 1~6 haloalkoxy, -OR 21 , -SR 21 , -N(R 22 )(R 23 ), -C(O)OR 22 , -C(O)N(R 22 )(R 23 ), -C(O)C(O)N(R 22 )(R 23 ), -OC(O)N(R 22 )(R 23 ), -N(R 24 )C(O)N(R 22 )(R 23 ), -N(R 24 )C(O)OR 25 , -N(R 24 )C(O)R 25 , -N(R 24 )S(O) 2 R 25 , -C(O)R 25 , -S(O) 2 R 25 , -S(O) 2 N(R 22 )(R 23 ), and -OC(O)R 25 is optionally substituted with one, two, or three groups independently selected from R 21 However, in each occurrence, H and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. 【Chemistry 13】 A compound, salt, or solvate exhibiting single or double bonds such that all valencies are satisfied.

5. Compounds having the structure of formula (II-A): 【Chemistry 14】 or a pharmaceutically acceptable salt or solvate thereof, wherein in the formula, W 3 The compound, salt, or solvate according to claim 4, wherein N and C are selected.

6. Compound of formula (III): 【Chemistry 15】 or a pharmaceutically acceptable salt or solvate thereof, wherein in the formula, 【Chemistry 16】 However, C 5~7 A selection of carbon rings and 5- to 7-membered heterocycles, each of which can optionally contain one or more R 11 Replaced by, 【Chemistry 17】 However, it does not exist, or C 3~8 A selection of carbon rings and 3- to 8-membered heterocycles, each of which can optionally contain one or more R 11a Replaced by, L 1 However, bond, C 1~6 Alkylene and C 1~6 Selected from haloalkylenes, L 2 is, C 5~25 alkylene, C 5~25 alkenylene, C 5~25 alkynylene, 5-25 membered heteroalkylene, and 5-25 membered heteroalkenylene, each of which is optionally substituted with one or more R 11b , and L 2 is covalently bonded to one of W 3 , W 4 , W 5 , or W 7 , or L 2 is -L 3 -D-L 4 -, and L 4 is covalently bonded to one of W 3 , W 4 , W 5 , or W 7 , L 3 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, D is absent, or C 3~12 A selection of carbon rings and 3- to 12-membered heterocycles, each of which can optionally contain one or more R 11d Replaced by, L 4 However, C 1~10 Alkylene, C 2~10 Alkenylene, C 2~10 Selected from alkynylenes, 2-10 member heteroalkylenes, and 3-10 member heteroalkynylenes, each of which is optionally selected from one or more R 11b Replaced by, W 2 However, N(R 2b ), N, C (R 2 ), C (R 2 ) (Caution 2a Selected from C(O), W 3 However, N(R 3b ), N, C (R 3 ), C (R 3 ) (Caution 3a Selected from C(O), W 4 However, N(R 4b ), N, C (R 4 ), C (R 4 ) (Caution 4a Selected from C(O), W 5 However, N(R 5b ), N, O, S, C (R 5 ), C (R 5 ) (Caution 5a Selected from C(O), W 7 However, N(R 7b ), N, O, S, C (R 7 ), C (R 7 ) (Caution 7a Selected from C(O), W 8 However, N(R 8b ), N, O, S, C (R 8 ), C (R 8 ) (Caution 8a Selected from C(O), R 1 However, one or more R 11c C, which is optionally substituted with 1~3 It is alkyl, R 2 , R 2a , R 3a , R 4a , R 5a , R 7a , R 8 , and R 8a However, each is independent of hydrogen, halogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, C3-10 carbon ring, 3-10 membered heterocycle, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynnyls, C3-10 carbon rings, and 3-10 membered heterocycles can independently and optionally have one, two, or three R groups. 20 Replaced by, R 3 , R 4 , R 5 , and R 7 However, each is independent, L 2 Bonding with hydrogen, halogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon ring and the 3- to 10-membered heterocycle independently and selectively have one, two, or three R groups. 20 Replaced by, R 2b , and R 8b However, each is independent of hydrogen, -CN, and C. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon rings and 3- to 10-membered heterocycles independently and selectively have one, two, or three R groups. 20 Replaced by, R 3b , R 4b , R 5b , and R 7b However, each is independent, L 2 Bonding with hydrogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) ( R13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon ring and the 3- to 10-membered heterocycle independently and selectively have one, two, or three R groups. 20 Replaced by, R 11 , R 11a , and R 11d However, in each occurrence, halogen, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (Caution 13 ), -CH 2 N(R) 12 ) S(O) 2 (R 13 ), and -P(O)(R 17 ) (Caution 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11b However, in each occurrence, halogen, oxo, -CN, and C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 ien-CH 2 S(O) 2 N(R) 12 ) (Caution 13 ), -CH 2 N(R) 12 ) S(O) 2 (R 13 ), and -P(O)(R 17 ) (Caution 17a ) is selected from C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 11c However, in each occurrence, halogen, -OR 12 , and -N(R 12 ) (Caution 13 ) are selected from, R 12 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 13 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl and C 1~6 Selected from haloalkyls, or R 12 , and R 13 However, together with the nitrogen atom they bond to, they form one, two, or three R atoms. 20 The 3- to 10-membered heterocycles are formed by the arbitrary substitutions of the following: R 14 However, in each appearance, hydrogen and C appear independently. 1~6 Alkyl and C 1~6 Selected from haloalkyl groups, R 15 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 17 , and R 17a However, in each occurrence, C 1~6 Alkyl and C 3~6 Selected from cycloalkyl, C 1~6 Alkyl and C 3~6 The cycloalkyl group can optionally have one, two, or three R groups. 20 It is replaced by or R 17 , and R 17a However, together with the phosphorus atoms to which they bond, they form a 3- to 10-membered heterocycle. R 20 However, in each occurrence, halogen, oxo, =NH, -CN, C appear independently. 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH 2 - (C 3~10 Carbon rings), 3- to 10-membered heterocycles, -CH 2 - (3- to 10-membered complex ring), - OR 21 , -SR 21 , -N(R 22 ) (Caution 23 ), -C(O)OR 22 , -C(O)N(R 22 ) (Caution 23 ), -C(O)C(O)N(R 22 ) (Caution 23 ), -OC(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)OR 25 , -N(R 24 ) C(O)R 25 , -N(R 24 ) S(O) 2 R 25 , -C(O)R 25 , -S(O) 2 R 25 , -S(O) 2 N(R) 22 ) (Caution 23 ), -OCH 2 C(O)OR 22 , and -OC(O)R 25 Selected from, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbocycle, -CH 2 - (C 3~10 Carbon rings), 3- to 10-membered heterocycles, and -CH 2 - (3- to 10-membered heterocycles) are halogens, oxos, =NH, -CN, and C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 1~6 Haloalkoxy, -OR 21 , -SR 21 , -N(R 22 ) (Caution 23 ), -C(O)OR 22 , -C(O)N(R 22 ) (Caution 23 ), -C(O)C(O)N(R 22 ) (Caution 23 ), -OC(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)N(R 22 ) (Caution 23 ), -N(R 24 ) C(O)OR 25 , -N(R 24 ) C(O)R 25 , -N(R 24 ) S(O) 2 R 25 , -C(O)R 25 , -S(O) 2 R 25 , -S(O) 2 N(R) 22 ) (Caution 23 ), and -OC(O)R 25 It is optionally substituted by one, two, or three elements, which are independently selected from the above. R 21 However, in each occurrence, H and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 22 However, in each occurrence, H and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens and C 1~6 The alkyl group is optionally substituted with one, two, or three groups independently selected. R 23 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 24 However, in each occurrence, H and C appear independently. 1~6 Selected from alkyl groups, R 25 However, in each occurrence, independently, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Selected from carbon rings and 3- to 10-membered heterocycles, C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles are halogens, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Alkoxy, C 3~10 The carbon ring and the 3- to 10-membered heterocycle are independently substituted with one, two, or three groups of any choice. [Chemistry 18] A compound, salt, or solvate exhibiting single or double bonds such that all valencies are satisfied.

7. Compounds having the structure of formula (III-A): 【Chemistry 19】 or a pharmaceutically acceptable salt or solvate thereof, wherein in the formula, W 5 The compound, salt, or solvate according to claim 6, wherein N and C are selected.

8. L 2 However, C 5~25 Alkylene, C 5~25 Alkenylene, C 5~25 Selected from alkynylenes, 5-25 member heteroalkylenes, and 5-25 member heteroalkynylenes, each of which is optionally selected from one or more R 11b A compound, salt, or solvate according to any one of claims 1 to 7, substituted with the compound, salt, or solvate. 【Request Item 9】 【Chemistry 20】 However, C 5~7 Selected from cycloalkyl, 5-7 member heterocycloalkyl, 5-7 member heteroaryl, and phenyl, each of which optionally contains one or more R 11 Replaced by, L 1 However, bond, C 1-2 Alkylene and C 1-2 Selected from haloalkylenes, R 1 However, one or more R 11c C, which is optionally substituted with 1~2 A compound, salt, or solvate according to any one of claims 1 to 8, which is alkyl.

10. R 7 However, halogen, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 Carbon rings, 3- to 10-membered heterocycles, -OR 12 , -SR 12 , -N(R 12 ) (Caution 13 ), -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)OR 15 , -N(R 14 ) S(O) 2 R 15 , -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -N(R 14 ) C(O)R 15 , -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon ring and the 3- to 10-membered heterocycle independently and selectively have one, two, or three R groups. 20 Replaced by, R 7b However, -CN, C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkynyl, C3-10 carbon ring, 3-10 membered heterocycle, -OR 12 , -SR 12 , -C(O)OR 12 , -OC(O)N(R 12 ) (Caution 13 ), -C(O)R 15 , -S(O)R 15 , -OC(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -C(O)C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , -S(O) 2 N(R) 12 ) (Caution 13 ), -S(=O)(=NH)N(R 12 ) (Caution 13 ), -CH 2 C(O)N(R) 12 ) (Caution 13 ), -CH 2 N(R) 14 ) C(O)R 15 ien-CH 2 S(O) 2 R 15 , and -CH 2 S(O) 2 N(R) 12 ) (Caution 13 ) are selected from each C 1~6 Alkyl, C 2~6 Alkenil, C 2~6 Alkinyl, C 3~10 The carbon ring and the 3- to 10-membered heterocycle independently and selectively have one, two, or three R groups. 20 A compound, salt, or solvate according to any one of claims 1 to 9, substituted with.

11. W 2 However, N, or C(R 2 A compound, salt, or solvate according to any one of claims 4 to 10.

12. W 3 However, N(R 3b ), and C (R 3 A compound, salt, or solvate according to any one of claims 4 to 11, selected from ).

13. W 4 However, N, C(R 4 A compound, salt, or solvate according to any one of claims 4 to 12, selected from ), and C(O).

14. W 5 However, N(R 5b ), and C (R 5 A compound, salt, or solvate according to any one of claims 4 to 13, selected from ).

15. W 7 However, N(R 7b ), and C (R 7 A compound, salt, or solvate according to any one of claims 4 to 14, selected from ).

16. W 8 However, N(R 8b ), O, S, and C (R 8 A compound, salt, or solvate according to any one of claims 6 to 15, selected from ).

17. A compound according to claim 1 having the structure of formula (I-A1) or (I-A2): 【Chemistry 21】 or a pharmaceutically acceptable salt or solvate thereof.

18. A compound according to claim 1, having the structure of formula (I-B1) or (I-B2): 【Chemistry 22】 or a pharmaceutically acceptable salt or solvate thereof.

19. A compound according to claim 1 having the structure of formula (I-C1), (I-C2), (I-C3), or (I-C4): 【Chemistry 23】 or a pharmaceutically acceptable salt or solvate thereof.

20. A compound according to claim 1 having the structure of formula (I-E1), (I-E2), (I-E3), or (I-E4): 【Chemistry 24】 or a pharmaceutically acceptable salt or solvate thereof.

21. R 1 However, non-substituted C 1~2 A compound, salt, or solvate according to any one of claims 1 to 20, wherein the compound is alkyl.

22. R 1 However, -CH 3 The compound, salt, or solvate according to claim 21.

23. R 3 However, hydrogen, halogen, -CN, -OR 12 , and one, two, or three R 20 C is optionally replaced by 1~6 A compound, salt, or solvate according to any one of claims 1 to 22, selected from alkyl groups.

24. R 3 However, one, two, or three R 20 C, which is optionally substituted with 1~6 The compound, salt, or solvate according to claim 23, wherein it is alkyl.

25. R 3 However, hydrogen, or -CH 3 The compound, salt, or solvate according to claim 23.

26. R 3b However, -CH 3 The compound, salt, or solvate according to any one of claims 1 to 22.

27. R 5 However, hydrogen, -OR 12 , and one, two, or three R 20 C is optionally replaced by 1~6 A compound, salt, or solvate according to any one of claims 1 to 26, selected from alkyl groups.

28. R 5 The compound, salt, or solvate according to claim 27, wherein the compound is hydrogen.

29. R 5b However, hydrogen and one, two, or three R 20 C is optionally replaced by 1~6 A compound, salt, or solvate according to any one of claims 1 to 28, selected from alkyl groups.

30. R 5b However, -CH 3 The compound, salt, or solvate according to claim 29.

31. R 6 However, hydrogen, -OR 12 , and one, two, or three R 20 C is optionally replaced by 1~6 Selected from alkyl groups, R 12 However, C 1~6 A compound, salt, or solvate according to any one of claims 1 to 30, selected from alkyl groups.

32. R 6 However, hydrogen, and -OCH 3 A compound, salt, or solvate according to claim 31, selected from the above.

33. R 7 However, C 1~6 Alkyl, C 3~10 Carbon ring, 3- to 10-membered heterocycle, -N(R) 12 ) (Caution 13 ), -C(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , and -SO 2 N(R) 12 ) (Caution 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 A compound, salt, or solvate according to any one of claims 1 to 32, substituted with.

34. R 7 However, C 1~6 Alkyl, C 3~10 Cycloalkyl, 3-10 member heterocycloalkyl, and -N(R 12 ) (Caution 13 ) is selected from C 1~6 Alkyl, C 3~10 Cycloalkyls and 3- to 10-membered heterocycloalkyls are optionally associated with one, two, or three R groups. 20 A compound, salt, or solvate according to claim 33, substituted with the compound, salt, or solvate of

35. R 7 However, one, two, or three R 20 The compound, salt, or solvate according to claim 33, wherein the compound is a 3- to 10-membered heterocycloalkyl group optionally substituted with the compound.

36. R 7 However, one, two, or three R 20 C, which is optionally substituted with 3~10 The compound, salt, or solvate according to claim 33, which is a cycloalkyl compound.

37. R 7 However, one R 20 C, which is optionally substituted with 3~4 The compound, salt, or solvate according to claim 33, which is a cycloalkyl compound.

38. R 7 However, a compound, salt, or solvate according to any one of claims 33 to 37, substituted with -CN.

39. R 7 but, 【Chemistry 25】 The compound, salt, or solvate according to claim 37.

40. R 7 However, one, two, or three R 20 C, which is optionally substituted with 1~6 The compound, salt, or solvate according to claim 33, wherein the compound is alkyl.

41. R 7 However, -N(R 12 ) (Caution 13 The compound, salt, or solvate according to claim 33.

42. R 7 but, 【Chemistry 26-1】 【Chemistry 26-2】 【Chemistry 26-3】 【Chemistry 26-4】 【Chemistry 26-5】 【Chemistry 26-6】 A compound, salt, or solvate according to any one of claims 1 to 32, selected from the above.

43. R 7 but, 【Chemistry 27】 A compound, salt, or solvate according to claim 42, selected from the above.

44. R 7 but, 【Chemistry 28】 A compound, salt, or solvate according to claim 43, selected from the above.

45. R 8 However, hydrogen, halogens, and one, two, or three R 20 C is optionally replaced by 1~6 A compound, salt, or solvate according to any one of claims 1 to 44, selected from alkyl groups.

46. R 8 The compound, salt, or solvate according to claim 45, wherein the compound is hydrogen. 【Request Item 47】 【Chemistry 29】 However, these are selected from phenyl and 5- to 7-membered heteroaryls, each of which is optionally selected from one or more R 11 A compound, salt, or solvate according to any one of claims 1 to 46, substituted with. 【Request Item 48】 【Chemistry 30】 However, selected from phenyl, pyridyl, and thiophenyl, each of which is optionally one or more R 11 A compound, salt, or solvate according to any one of claims 1 to 46, substituted with. 【Request Item 49】 【Chemistry 31】 but, 【Chemistry 32】 A compound, salt, or solvate according to any one of claims 1 to 46, selected from the above.

50. R 11 However, if present, fluorine and -CH exist independently in each occurrence. 3 A compound, salt, or solvate according to any one of claims 47 to 49, selected from among.

51. L 1 However, bonding, and C 1~3 A compound, salt, or solvate according to any one of claims 1 to 50, selected from haloalkylenes.

52. L 1 However, C 1~3 The compound, salt, or solvate according to claim 51, which is a haloalkylene.

53. L 1 However, -CF 2 -, -CF 2 CH 2 -, and -CF 2 CH 2 CH 2 - A compound, salt, or solvate according to claim 52, selected from -. 【Request Item 54】 【Chemistry 33】 However, the absence of phenyl, and a selection of 4- to 8-membered heterocycles are available, and the phenyl and 4- to 8-membered heterocycles are optionally available as one or more R 11a A compound, salt, or solvate according to any one of claims 1 to 53, substituted with. 【Request Item 55】 【Chemistry 34】 However, it is absent, selected from phenyl, azetidine, pyrrolidine, and piperidine, and the phenyl, azetidine, pyrrolidine, and piperidine are optionally one or more R 11a A compound, salt, or solvate according to claim 54, substituted with the compound, salt, or solvate of the claim. 【Request Item 56】 【Chemistry 35】 However, it is selected from azetidine, pyrrolidine, and piperidine, and each of them is optionally given one or more -CH 3 A substituted compound, salt, or solvate according to claim 54.

57. L 2 The compound, salt, or solvate according to any one of claims 1 to 56, wherein it, together with the bonded atom, forms a 16-36 membered macrocyclic ring.

58. L 2 The compound, salt, or solvate according to claim 57, wherein it, together with the bonded atom, forms a 16-24 membered macrocyclic ring.

59. L 2 However, C 6~15 Alkylene, C 6~15 Alkenylene, C 6~15 Selected from alkynylenes, 6-15 member heteroalkylenes, and 6-15 member heteroalkynylenes, each of which is optionally selected from one or more R 11b A compound, salt, or solvate according to any one of claims 1 to 58, substituted with.

60. L 2 However, C 5~10 Alkylene, C 5~10 Alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkylenes are selected, and each of them is optionally selected for one or more R 11b A compound, salt, or solvate according to any one of claims 1 to 59, substituted with.

61. The compound, salt, or solvate according to claim 59 or 60, wherein the alkenylene and heteroalkenylene contain one carbon-carbon double bond.

62. The compound, salt, or solvate according to claim 59 or 60, wherein the heteroalkylene and heteroalkenylene each contain at least one oxygen atom or a nitrogen atom.

63. R 11b However, in each appearance, halogen, oxo, and C appear independently. 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 A compound, salt, or solvate according to any one of claims 1 to 62, selected from alkyl)-OH and -OH.

64. R 11b However, in each occurrence, independently, -F, =O, -CH 3 ien-CH 2 F, -CHF 2 , -CF 3 ien-CH 2 CH 2 F, -CH 2 CHF 2 ien-CH 2 A compound, salt, or solvate according to claim 63, selected from OH and -OH.

65. R 3 However, hydrogen and -CH 3 Selected from, R 7 However, C 1~6 Alkyl, C 3~10 Carbon ring, 3- to 10-membered heterocycle, -N(R) 12 ) (Caution 13 ), -C(O)R 15 , -C(O)N(R 12 ) (Caution 13 ), -S(O) 2 R 15 , and -SO 2 N(R) 12 ) (Caution 13 ) is selected from C 1~6 Alkyl, C 3~10 Carbon rings and 3- to 10-membered heterocycles can optionally contain one, two, or three R groups. 20 Replaced by, R 8 The compound, salt, or solvate according to any one of claims 1 to 3 or 19, wherein the compound is hydrogen.

66. R 7 but, 【Transformation 36】 A compound, salt, or solvate according to claim 65, selected from the above.

67. R 1 However, -CH 3 And, 【Chemistry 37】 However, these are selected from phenyl and 5- to 7-membered heteroaryls, each of which is optionally selected from one or more R 11 Replaced by, L 1 However, bonding, and C 1~3 Selected from haloalkylenes, 【Transformation 38】 However, the absence of phenyl, and a selection of 4- to 8-membered heterocycles are available, and the phenyl and 4- to 8-membered heterocycles are optionally available as one or more R 11a Replaced by, L 2 However, C 5~10 Alkylene, C 5~10 Alkenylenes, 5-10 membered heteroalkylenes, and 5-10 membered heteroalkylenes are selected, and each of them is optionally selected for one or more R 11b A compound, salt, or solvate according to any one of claims 1 to 20, 65, or 66, substituted with.

68. R 11 However, if present, it is fluorine, R 11a However, if present, -CH 3 And, R 11b However, if present, each occurrence independently involves halogen, oxo, and C. 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 A compound, salt, or solvate according to claim 67, selected from alkyl)-OH and -OH. 【Request Item 69】 【Chemistry 39】 but, 【Chemistry 40】 The compound, salt, or solvate according to any one of claims 1 to 20 or 57 to 68. 【Request Item 70】 【Chemistry 41】 but, 【Chemistry 42】 Selected from, 【Chemistry 43】 However, it is selected from azetidine, pyrrolidine, and piperidine, and each of them is optionally given one or more -CH 3 Replaced by, L 1 However, C 1~3 It is a haloalkylene, L 2 However, one or more R 11b C, which is optionally substituted with 5~10 It is alkenylene, R 1 However, -CH 3 And, R 3 However, hydrogen, or -CH 3 And, R 7 but, 【Chemistry 44】 Selected from, R 8 However, it is hydrogen, R 11 However, fluorine and -CH 3 Selected from, R 11b However, halogen, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 A compound, salt, or solvate according to any one of claims 1 to 20, selected from alkyl)-OH and -OH. 【Request Item 71】 【Chemistry 45】 but, 【Chemistry 46】 Selected from, 【Chemistry 47】 However, it is selected from azetidine, pyrrolidine, and piperidine, and each of them is optionally given one or more -CH 3 Replaced by, L 1 However, C 1~3 It is a haloalkylene, L 2 However, one or more R 11b Selected from 5- to 10-membered heteroalkylenes that are optionally substituted, R 1 However, -CH 3 And, R 3 However, hydrogen, or -CH 3 And, R 7 but, 【Chemistry 48】 Selected from, R 8 However, it is hydrogen, R 11 However, fluorine and -CH 3 Selected from, R 11b However, halogen, oxo, C 1~6 Alkyl, C 1~6 Haloalkyl, (C 1~6 A compound, salt, or solvate according to any one of claims 1 to 20, selected from alkyl)-OH and -OH.

72. A compound selected from Table 1, or a pharmaceutically acceptable salt or solvate thereof.

73. A pharmaceutical composition comprising a compound according to any one of claims 1 to 72, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

74. A method for treating cancer in a subject requiring cancer treatment, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 72, or a pharmaceutically acceptable salt or solvate thereof.

75. The method according to claim 74, wherein the cancer is a solid tumor or a blood cancer.

76. The method according to claim 74, wherein the subject is administered together with an additional drug or therapy.

77. A method for reducing Ras signaling output, comprising contacting the SOS1 protein with an effective amount of a compound according to any one of claims 1 to 72, or a pharmaceutically acceptable salt or solvate thereof, thereby reducing the Ras signaling output.

78. The method according to claim 77, wherein the compound disrupts the interaction between the Ras protein and SOS1.

79. The method according to claim 78, wherein the Ras protein is wild-type K-Ras or mutant K-Ras.

80. A method for inhibiting cell proliferation, comprising administering an effective amount of a compound according to any one of claims 1 to 72, or a pharmaceutically acceptable salt thereof, or a solvate thereof, to cells expressing SOS1, thereby inhibiting the proliferation of said cells.

81. A method for reducing the Ras signaling output of cells, comprising contacting the cells with an effective amount of a compound according to any one of claims 1 to 72, or a pharmaceutically acceptable salt or solvate thereof, in combination with an additional agent, wherein the additional agent is a chemotherapeutic agent, a radiopharmaceutical, an immunomodulator, or one or more targets selected from: MEK, epidermal growth factor receptor (EGFR), FFFR1, FFFR2, FFFR3, FFFR4, mitotic kinase, topoisomerase, A LK, c-MET, ErbB2, AXL, NTRK1, RET, A-Raf, B-Raf, C-Raf, ERK, MDM2, mTOR, BET, IGF1 / 2, IGF1-R, CDK9, SHC, GAB, GRB, PI3 kinase, MAPK, SHIP1, SHIP2, SHP1, SHP2, SRC, JAK, PARP, BTK, FLT3, HDAC, VEGFR, PDGFR, LCK, Bcr-Abl, AKT, wild type KRas, KRas mutants (e.g., KrasG12C, KRas A method comprising inhibitors of variants of G12D, KRas G12S, KRas G12V, KRas G13D, KRas G13C, or KRas G13V), ROS1, CDK4 / 6, and one or more of their targets.

82. The method according to claim 81, wherein the additional agent is an inhibitor of one or more targets selected from MEK, epidermal growth factor receptor (EGFR), A-Raf, B-Raf, C-Raf, ErbB2, SHP2, wild-type KRas, KRas variants, and CDK4 / 6.

83. The method according to claim 81, wherein the additional agent is a chemotherapeutic agent, a radiopharmaceutical, or an immunomodulator.

84. An SOS1 protein conjugated with a compound according to any one of claims 1 to 72, or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the interaction between the SOS1 protein and the Ras protein is reduced compared to an SOS1 protein not conjugated with the compound.